BL_genes.md
... ...
@@ -1,776 +1,213 @@
1
-# BL genes
2
-
3
-## Origins of BL genes
4
-```mermaid
5 1
---
6
-config:
7
- sankey:
8
- showValues: false
9
- linkColor: target
10
- width: 800
11
- height: 1000
12
- nodeAlignment: right
2
+title: 'BL genes'
3
+bibliography: 'morinlab.bib'
4
+csl: 'NLM.csl'
5
+link-citations: true
13 6
---
14
-sankey-beta
15
-Grande 2019, BL Tier 1, 9
16
-Grande 2019, BL Tier 2, 4
17
-Richter 2012, BL Tier 1, 5
18
-Burkhardt 2022, BL Tier 2, 25
19
-Schmitz 2012, BL Tier 1, 3
20
-Schmitz 2012, BL Tier 2, 16
21
-Love 2012, BL Tier 1, 3
22
-Love 2012, BL Tier 2, 56
23
-Muppidi 2014, BL Tier 1, 1
24
-Muppidi 2014, BL Tier 2, 2
25
-Panea 2019, BL Tier 1, 4
26
-Panea 2019, BL Tier 2, 46
27
-Thomas 2023, BL Tier 1, 2
28
-Thomas 2023, BL Tier 2, 3
29
-BL, panel, 25
30
-panel, Burkhardt 2022, 25
31
-BL, WGS, 13
32
-WGS, Grande 2019, 13
33
-BL, RNA-seq/WGS/exome, 5
34
-RNA-seq/WGS/exome, Richter 2012, 5
35
-BL, exome, 59
36
-exome, Love 2012, 59
37
-BL, RNA-seq, 19
38
-RNA-seq, Schmitz 2012, 19
39
-BL, Sanger, 3
40
-Sanger, Muppidi 2014, 3
41
-BL, RNA-seq/exome, 50
42
-RNA-seq/exome, Panea 2019, 50
43
-BL, WGS, 5
44
-WGS, Thomas 2023, 5
45
-```
7
+
8
+## Origins of BL genes
9
+
10
+![](BL_sankey-1.svg)
11
+
46 12
## Tier 1 BL genes
47 13
48 14
### *29 total*
49 15
50
-| Gene | Tier | Relevant references |
51
-|:------------------:|:-------:|:---------------------------------------------------------------------------------------------------|
52
-| [ARID1A](ARID1A) | 1 | Rossi et al. 2012; Wienand et al. 2019; Zhang et al. 2013; Love et al. 2012; Krysiak et al. 2017 |
53
-| [BCL7A](BCL7A) | 1, aSHM | Krysiak et al. 2017; Arthur et al. 2018; Grande et al. 2019; Reichel et al. 2015 |
54
-| [BMP7](BMP7) | 1 | Panea et al. 2019 |
55
-| [CCND3](CCND3) | 1 | Desch et al. 2020; Richter et al. 2012; Jallades et al. 2017; Morin et al. 2011 |
56
-| [CHD8](CHD8) | 1 | Reddy et al. 2017; Grande et al. 2019 |
57
-| [DDX3X](DDX3X) | 1 | Schmitz et al. 2012, 2018; Mottok et al. 2019 |
58
-| [EIF4A1](EIF4A1) | 1 | Panea et al. 2019 |
59
-| [EPPK1](EPPK1) | 1 | Panea et al. 2019 |
60
-| [FBXO11](FBXO11) | 1 | Hübschmann et al. 2021; Parry et al. 2013; Richter et al. 2012 |
61
-| [FOXO1](FOXO1) | 1 | Schmitz et al. 2012; Morin et al. 2011; Duns et al. 2021 |
62
-| [GNA13](GNA13) | 1 | Reichel et al. 2015; Love et al. 2012; Morin et al. 2011 |
63
-| [GNAI2](GNAI2) | 1 | Grande et al. 2019; Morin et al. 2013 |
64
-| [HNRNPU](HNRNPU) | 1, aSHM | Panea et al. 2019; Reddy et al. 2017 |
65
-| [ID3](ID3) | 1 | Schmitz et al. 2012; Spina et al. 2016; Richter et al. 2012 |
66
-| [KMT2D](KMT2D) | 1 | Desch et al. 2020; Rossi et al. 2012; Morin et al. 2011; Beà et al. 2013; Grande et al. 2019 |
67
-| [MYC](MYC) | 1, aSHM | Johnston and Carroll 1992; L. Pasqualucci et al. 2001; Duns et al. 2021; Jallades et al. 2017 |
68
-| [P2RY8](P2RY8) | 1 | Muppidi et al. 2014; Lohr et al. 2012 |
69
-| [PHF6](PHF6) | 1 | Thomas et al. 2023; Reddy et al. 2017 |
70
-| [PTEN](PTEN) | 1 | Love et al. 2012 |
71
-| [RFX7](RFX7) | 1 | Grande et al. 2019 |
72
-| [RHOA](RHOA) | 1 | Richter et al. 2012 |
73
-| [SIN3A](SIN3A) | 1 | Grande et al. 2019; Rossi et al. 2012 |
74
-| [SMARCA4](SMARCA4) | 1 | Richter et al. 2012; Nadeu et al. 2020; Zhang et al. 2013; Krysiak et al. 2017 |
75
-| [TCF3](TCF3) | 1 | Schmitz et al. 2012 |
76
-| [TCL1A](TCL1A) | 1, aSHM | Grande et al. 2019 |
77
-| [TFAP4](TFAP4) | 1 | Grande et al. 2019 |
78
-| [TP53](TP53) | 1 | Rossi et al. 2012; Wilda et al. 2004; Tiacci et al. 2018; Beà et al. 2013; Morin et al. 2011 |
79
-| [USP7](USP7) | 1 | Grande et al. 2019 |
80
-| [WNK1](WNK1) | 1 | Hübschmann et al. 2021; Thomas et al. 2023; Jallades et al. 2017 |
16
+|Gene|Tier| Relevant references|
17
+|:-:|:-:|:-|
18
+|[ARID1A](ARID1A)|1|[@wienandGenomicAnalysesFlowsorted2019b; @loveGeneticLandscapeMutations2012; @zhangGeneticHeterogeneityDiffuse2013; @rossiCodingGenomeSplenic2012c; @krysiakRecurrentSomaticMutations2017b]|
19
+|[BCL7A](BCL7A)|1, aSHM|[@grandeGenomewideDiscoverySomatic2019; @reichelFlowSortingExome2015a; @krysiakRecurrentSomaticMutations2017b; @arthurGenomewideDiscoverySomatic2018]|
20
+|[BMP7](BMP7)|1|[@paneaWholeGenomeLandscape2019]|
21
+|[CCND3](CCND3)|1|[@deschGenotypingCirculatingTumor2020; @richterRecurrentMutationID32012a; @jalladesExomeSequencingIdentifies2017; @morinFrequentMutationHistonemodifying2011]|
22
+|[CHD8](CHD8)|1|[@grandeGenomewideDiscoverySomatic2019; @reddyGeneticFunctionalDrivers2017]|
23
+|[DDX3X](DDX3X)|1|[@mottokIntegrativeGenomicAnalysis2019b; @schmitzBurkittLymphomaPathogenesis2012; @schmitzGeneticsPathogenesisDiffuse2018a]|
24
+|[EIF4A1](EIF4A1)|1|[@paneaWholeGenomeLandscape2019]|
25
+|[EPPK1](EPPK1)|1|[@paneaWholeGenomeLandscape2019]|
26
+|[FBXO11](FBXO11)|1|[@parryWholeExomeSequencing2013; @hubschmannMutationalMechanismsShaping2021b; @richterRecurrentMutationID32012a]|
27
+|[FOXO1](FOXO1)|1|[@dunsCharacterizationDLBCLPMBL2021b; @morinFrequentMutationHistonemodifying2011; @schmitzBurkittLymphomaPathogenesis2012]|
28
+|[GNA13](GNA13)|1|[@morinFrequentMutationHistonemodifying2011; @reichelFlowSortingExome2015a; @loveGeneticLandscapeMutations2012]|
29
+|[GNAI2](GNAI2)|1|[@grandeGenomewideDiscoverySomatic2019; @morinMutationalStructuralAnalysis2013]|
30
+|[HNRNPU](HNRNPU)|1, aSHM|[@reddyGeneticFunctionalDrivers2017; @paneaWholeGenomeLandscape2019]|
31
+|[ID3](ID3)|1|[@schmitzBurkittLymphomaPathogenesis2012; @spinaGeneticsNodalMarginal2016b; @richterRecurrentMutationID32012a]|
32
+|[KMT2D](KMT2D)|1|[@morinFrequentMutationHistonemodifying2011; @rossiCodingGenomeSplenic2012c; @deschGenotypingCirculatingTumor2020; @grandeGenomewideDiscoverySomatic2019; @beaLandscapeSomaticMutations2013]|
33
+|[MYC](MYC)|1, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @jalladesExomeSequencingIdentifies2017; @johnstonCmycHypermutationBurkitt1992; @pasqualucciHypermutationMultipleProtooncogenes2001a]|
34
+|[P2RY8](P2RY8)|1|[@muppidiLossSignalingGa132014b; @lohrDiscoveryPrioritizationSomatic2012a]|
35
+|[PHF6](PHF6)|1|[@thomasGeneticSubgroupsInform2023; @reddyGeneticFunctionalDrivers2017]|
36
+|[PTEN](PTEN)|1|[@loveGeneticLandscapeMutations2012]|
37
+|[RFX7](RFX7)|1|[@grandeGenomewideDiscoverySomatic2019]|
38
+|[RHOA](RHOA)|1|[@richterRecurrentMutationID32012a]|
39
+|[SIN3A](SIN3A)|1|[@rossiCodingGenomeSplenic2012c; @grandeGenomewideDiscoverySomatic2019]|
40
+|[SMARCA4](SMARCA4)|1|[@krysiakRecurrentSomaticMutations2017b; @zhangGeneticHeterogeneityDiffuse2013; @nadeuGenomicEpigenomicInsights2020b; @richterRecurrentMutationID32012a]|
41
+|[TCF3](TCF3)|1|[@schmitzBurkittLymphomaPathogenesis2012]|
42
+|[TCL1A](TCL1A)|1, aSHM|[@grandeGenomewideDiscoverySomatic2019]|
43
+|[TFAP4](TFAP4)|1|[@grandeGenomewideDiscoverySomatic2019]|
44
+|[TP53](TP53)|1|[@rossiCodingGenomeSplenic2012c; @morinFrequentMutationHistonemodifying2011; @tiacciPervasiveMutationsJAKSTAT2018b; @beaLandscapeSomaticMutations2013; @wildaInactivationARFMDM2p53Pathway2004]|
45
+|[USP7](USP7)|1|[@grandeGenomewideDiscoverySomatic2019]|
46
+|[WNK1](WNK1)|1|[@hubschmannMutationalMechanismsShaping2021b; @thomasGeneticSubgroupsInform2023; @jalladesExomeSequencingIdentifies2017]|
81 47
82 48
## Tier 2 BL genes
83 49
84 50
### *157 total*
85 51
86
-| Gene | Tier | Relevant references |
87
-|:----------------------:|:-------:|:--------------------------------------------------------------------------------------------------------|
88
-| [ACAD9](ACAD9) | 2 | Love et al. 2012 |
89
-| [ACE](ACE) | 2 | Love et al. 2012 |
90
-| [ADAMTS5](ADAMTS5) | 2 | Burkhardt et al. 2022 |
91
-| [ADNP](ADNP) | 2 | Burkhardt et al. 2022 |
92
-| [AGO4](AGO4) | 2 | Burkhardt et al. 2022 |
93
-| [ALPK2](ALPK2) | 2 | Panea et al. 2019 |
94
-| [ARHGEF1](ARHGEF1) | 2 | Muppidi et al. 2014 |
95
-| [ATP2C2](ATP2C2) | 2 | Love et al. 2012 |
96
-| [BACH2](BACH2) | 2, aSHM | Grande et al. 2019 |
97
-| [BCL2](BCL2) | 2, aSHM | Sarkozy et al. 2021; Tanaka et al. 1992; Burkhardt et al. 2022; Morin et al. 2011 |
98
-| [BCL6](BCL6) | 2, aSHM | Love et al. 2012; Morin et al. 2011 |
99
-| [BRAF](BRAF) | 2 | Tiacci et al. 2011; Love et al. 2012 |
100
-| [BRD4](BRD4) | 2 | Love et al. 2012 |
101
-| [BTG1](BTG1) | 2, aSHM | Sarkozy et al. 2021; Burkhardt et al. 2022; Morin et al. 2011 |
102
-| [BTG2](BTG2) | 2, aSHM | Love et al. 2012; Morin et al. 2011 |
103
-| [C16orf48](C16orf48) | 2 | Schmitz et al. 2012 |
104
-| [C6orf27](C6orf27) | 2 | Love et al. 2012 |
105
-| [CAD](CAD) | 2 | Love et al. 2012 |
106
-| [CARD11](CARD11) | 2 | Wu et al. 2016; Panea et al. 2019; Morin et al. 2011; Yan et al. 2012; Lenz et al. 2008 |
107
-| [CARD4](CARD4) | 2 | Love et al. 2012 |
108
-| [CCNF](CCNF) | 2 | Abate et al. 2015 |
109
-| [CCT6B](CCT6B) | 2 | Love et al. 2012 |
110
-| [CD79A](CD79A) | 2 | Burkhardt et al. 2022; Rossi et al. 2012 |
111
-| [CD79B](CD79B) | 2 | Morin et al. 2011; Panea et al. 2019 |
112
-| [CD83](CD83) | 2, aSHM | Russler-Germain et al. 2023; Morin et al. 2013; Duns et al. 2021; Panea et al. 2019 |
113
-| [CDC73](CDC73) | 2 | Reddy et al. 2017; Love et al. 2012 |
114
-| [CDH17](CDH17) | 2 | Love et al. 2012 |
115
-| [CDKN2A](CDKN2A) | 2 | Morin et al. 2013; Spina et al. 2016; Grande et al. 2019 |
116
-| [CDKN2C](CDKN2C) | 2 | Thomas et al. 2023 |
117
-| [CHD4](CHD4) | 2 | Burkhardt et al. 2022 |
118
-| [COL4A2](COL4A2) | 2 | Love et al. 2012 |
119
-| [CPXM2](CPXM2) | 2 | Burkhardt et al. 2022 |
120
-| [CREBBP](CREBBP) | 2 | Parry et al. 2013; Love et al. 2012; Laura Pasqualucci, Dominguez-Sola, et al. 2011; Duns et al. 2021 |
121
-| [CTCF](CTCF) | 2 | Panea et al. 2019 |
122
-| [CXCR4](CXCR4) | 2, aSHM | Krysiak et al. 2017; Panea et al. 2019; Khodabakhshi et al. 2012 |
123
-| [CYB5D1](CYB5D1) | 2 | Love et al. 2012 |
124
-| [CYP4F22](CYP4F22) | 2 | Love et al. 2012 |
125
-| [DHCR7](DHCR7) | 2 | Schmitz et al. 2012 |
126
-| [DLGAP1](DLGAP1) | 2 | Love et al. 2012 |
127
-| [DNMT1](DNMT1) | 2 | Panea et al. 2019 |
128
-| [DTX1](DTX1) | 2, aSHM | Gomez et al. 2023; Panea et al. 2019; Schmitz et al. 2018; Rossi et al. 2012 |
129
-| [E2F2](E2F2) | 2 | Burkhardt et al. 2022 |
130
-| [EBF1](EBF1) | 2, aSHM | Reichel et al. 2015; Bohle et al. 2013; Thomas et al. 2023 |
131
-| [EDNRB](EDNRB) | 2 | Burkhardt et al. 2022 |
132
-| [EHD1](EHD1) | 2 | Thomas et al. 2023 |
133
-| [EIF2C4](EIF2C4) | 2 | Love et al. 2012 |
134
-| [ELP2](ELP2) | 2 | Schmitz et al. 2012 |
135
-| [EML2](EML2) | 2 | Love et al. 2012 |
136
-| [ENTPD3](ENTPD3) | 2 | Love et al. 2012 |
137
-| [EP300](EP300) | 2 | Panea et al. 2019; Rossi et al. 2012; Laura Pasqualucci, Dominguez-Sola, et al. 2011 |
138
-| [EPHB2](EPHB2) | 2 | Love et al. 2012 |
139
-| [ERAP1](ERAP1) | 2 | Burkhardt et al. 2022 |
140
-| [ETS1](ETS1) | 2, aSHM | Morin et al. 2011; Panea et al. 2019 |
141
-| [EXOSC6](EXOSC6) | 2 | Schmitz et al. 2012 |
142
-| [EZH2](EZH2) | 2 | Mottok et al. 2019; Love et al. 2012; Morin et al. 2010 |
143
-| [FAM129B](FAM129B) | 2 | Love et al. 2012 |
144
-| [FGFR3](FGFR3) | 2 | Love et al. 2012 |
145
-| [FLYWCH1](FLYWCH1) | 2 | Schmitz et al. 2012 |
146
-| [FTCD](FTCD) | 2 | Love et al. 2012 |
147
-| [FZD3](FZD3) | 2 | Panea et al. 2019 |
148
-| [GGTLA4](GGTLA4) | 2 | Love et al. 2012 |
149
-| [GRB2](GRB2) | 2 | Panea et al. 2019; Laura Pasqualucci, Trifonov, et al. 2011 |
150
-| [GRIK5](GRIK5) | 2 | Love et al. 2012 |
151
-| [GTSE1](GTSE1) | 2 | Schmitz et al. 2012 |
152
-| [HIST1H1C](HIST1H1C) | 2, aSHM | Panea et al. 2019; Morin et al. 2011 |
153
-| [HIST1H1E](HIST1H1E) | 2, aSHM | Morin et al. 2013; Reichel et al. 2015; Grande et al. 2019; Krysiak et al. 2017 |
154
-| [HIST1H2AG](HIST1H2AG) | 2, aSHM | Krysiak et al. 2017; Panea et al. 2019; Morin et al. 2013; Rossi et al. 2012 |
155
-| [HIST1H2AM](HIST1H2AM) | 2, aSHM | Krysiak et al. 2017; Panea et al. 2019 |
156
-| [HIST1H2BK](HIST1H2BK) | 2, aSHM | Rossi et al. 2012; Panea et al. 2019 |
157
-| [HIST1H3D](HIST1H3D) | 2, aSHM | Panea et al. 2019 |
158
-| [HIST1H3H](HIST1H3H) | 2, aSHM | Panea et al. 2019 |
159
-| [HIST1H3I](HIST1H3I) | 2, aSHM | Panea et al. 2019; Krysiak et al. 2017 |
160
-| [HIST1H3J](HIST1H3J) | 2, aSHM | Panea et al. 2019 |
161
-| [HIST1H4J](HIST1H4J) | 2, aSHM | Mottok et al. 2019; Panea et al. 2019 |
162
-| [HLA-A](HLA-A) | 2 | Desch et al. 2020 |
163
-| [HLA-B](HLA-B) | 2 | Wienand et al. 2019 |
164
-| [HLA-DMB](HLA-DMB) | 2 | |
165
-| [HLA-DQB1](HLA-DQB1) | 2 | Burkhardt et al. 2022 |
166
-| [ICK](ICK) | 2 | Love et al. 2012 |
167
-| [IGLL5](IGLL5) | 2, aSHM | Russler-Germain et al. 2023; Panea et al. 2019; Desch et al. 2020 |
168
-| [IKZF3](IKZF3) | 2, aSHM | Morin et al. 2013; Panea et al. 2019 |
169
-| [IRF8](IRF8) | 2, aSHM | Mottok et al. 2019; Morin et al. 2011; Panea et al. 2019 |
170
-| [ITPR3](ITPR3) | 2 | Tiacci et al. 2018; Love et al. 2012 |
171
-| [KANK2](KANK2) | 2 | Schmitz et al. 2012 |
172
-| [KCNK10](KCNK10) | 2 | Panea et al. 2019 |
173
-| [KIFC3](KIFC3) | 2 | Love et al. 2012 |
174
-| [KLHL26](KLHL26) | 2 | Burkhardt et al. 2022 |
175
-| [KLHL6](KLHL6) | 2, aSHM | Ganapathi et al. 2016; Panea et al. 2019; Morin et al. 2011 |
176
-| [KMT2C](KMT2C) | 2 | Zhang et al. 2013; Zhou et al. 2019; Sarkozy et al. 2021; Zhang et al. 2014 |
177
-| [LTB](LTB) | 2, aSHM | Panea et al. 2019; Chapuy et al. 2018; Desch et al. 2020 |
178
-| [MAP3K6](MAP3K6) | 2 | Love et al. 2012 |
179
-| [MCL1](MCL1) | 2 | Reddy et al. 2017; Duns et al. 2021; Panea et al. 2019 |
180
-| [MIR142](MIR142) | 2, aSHM | Grande et al. 2019; Kwanhian et al. 2012 |
181
-| [MKI67](MKI67) | 2 | Russler-Germain et al. 2023; Schmitz et al. 2012 |
182
-| [MME](MME) | 2 | Panea et al. 2019 |
183
-| [MTOR](MTOR) | 2 | Panea et al. 2019; Zhang et al. 2013 |
184
-| [MYH10](MYH10) | 2 | Love et al. 2012 |
185
-| [MYO18A](MYO18A) | 2 | Schmitz et al. 2012 |
186
-| [NBEAL1](NBEAL1) | 2 | Love et al. 2012 |
187
-| [NCOR2](NCOR2) | 2 | Spina et al. 2016; Sarkozy et al. 2021; Schmitz et al. 2012 |
188
-| [NOA1](NOA1) | 2 | Burkhardt et al. 2022 |
189
-| [NOTCH1](NOTCH1) | 2 | Love et al. 2012; Laura Pasqualucci, Trifonov, et al. 2011; Beà et al. 2013; Rossi et al. 2012 |
190
-| [NOTCH2](NOTCH2) | 2 | Rossi et al. 2012; Panea et al. 2019; Trøen et al. 2008; Beà et al. 2013 |
191
-| [NRXN2](NRXN2) | 2 | Love et al. 2012 |
192
-| [P2RY2](P2RY2) | 2 | Love et al. 2012 |
193
-| [PABPC4L](PABPC4L) | 2 | Panea et al. 2019 |
194
-| [PC](PC) | 2 | Love et al. 2012 |
195
-| [PCBP1](PCBP1) | 2 | Schmitz et al. 2012 |
196
-| [PCDHA11](PCDHA11) | 2 | Panea et al. 2019 |
197
-| [PDCD11](PDCD11) | 2 | Schmitz et al. 2012 |
198
-| [PDZRN3](PDZRN3) | 2 | Panea et al. 2019 |
199
-| [PIK3R1](PIK3R1) | 2 | Zhang et al. 2013; Panea et al. 2019 |
200
-| [PIM1](PIM1) | 2, aSHM | Burkhardt et al. 2022; Duns et al. 2021; L. Pasqualucci et al. 2001 |
201
-| [PLCG2](PLCG2) | 2 | Panea et al. 2019 |
202
-| [POLRMT](POLRMT) | 2 | Love et al. 2012 |
203
-| [POR](POR) | 2 | Love et al. 2012 |
204
-| [PPP6R2](PPP6R2) | 2 | Burkhardt et al. 2022 |
205
-| [PREX1](PREX1) | 2 | Burkhardt et al. 2022 |
206
-| [PRSS22](PRSS22) | 2 | Love et al. 2012 |
207
-| [PTPRN](PTPRN) | 2 | Love et al. 2012 |
208
-| [PXDNL](PXDNL) | 2 | Panea et al. 2019 |
209
-| [RAC2](RAC2) | 2 | Hübschmann et al. 2021; Panea et al. 2019 |
210
-| [RANBP6](RANBP6) | 2 | Love et al. 2012 |
211
-| [RBP3](RBP3) | 2 | Love et al. 2012 |
212
-| [RET](RET) | 2 | Love et al. 2012 |
213
-| [REV3L](REV3L) | 2 | Burkhardt et al. 2022 |
214
-| [RNF144B](RNF144B) | 2 | Panea et al. 2019 |
215
-| [RPL10](RPL10) | 2 | Burkhardt et al. 2022 |
216
-| [S1PR2](S1PR2) | 2, aSHM | Morin et al. 2011; Muppidi et al. 2014 |
217
-| [SAL3](SAL3) | 2 | Burkhardt et al. 2022 |
218
-| [SALL3](SALL3) | 2 | Love et al. 2012; Zhang et al. 2014 |
219
-| [SAPS2](SAPS2) | 2 | Love et al. 2012 |
220
-| [SBF1](SBF1) | 2 | Love et al. 2012 |
221
-| [SF3B1](SF3B1) | 2 | Love et al. 2012 |
222
-| [SHANK1](SHANK1) | 2 | Love et al. 2012 |
223
-| [SLC29A2](SLC29A2) | 2 | Love et al. 2012 |
224
-| [SNTB2](SNTB2) | 2 | Panea et al. 2019 |
225
-| [SP3](SP3) | 2 | Panea et al. 2019 |
226
-| [SYNCRIP](SYNCRIP) | 2 | Panea et al. 2019 |
227
-| [SYNGAP1](SYNGAP1) | 2 | Love et al. 2012 |
228
-| [TBC1D9B](TBC1D9B) | 2 | Love et al. 2012 |
229
-| [TET2](TET2) | 2 | Albuquerque et al. 2017; Panea et al. 2019 |
230
-| [TIGD6](TIGD6) | 2 | Love et al. 2012 |
231
-| [TOP2A](TOP2A) | 2 | Schmitz et al. 2012 |
232
-| [TPST2](TPST2) | 2 | Love et al. 2012 |
233
-| [TTN](TTN) | 2 | Burkhardt et al. 2022 |
234
-| [VWA7](VWA7) | 2 | Burkhardt et al. 2022 |
235
-| [WDR7](WDR7) | 2 | Panea et al. 2019 |
236
-| [WDR90](WDR90) | 2 | Schmitz et al. 2012 |
237
-| [WHAMM](WHAMM) | 2 | Schmitz et al. 2012 |
238
-| [WNK2](WNK2) | 2 | Panea et al. 2019 |
239
-| [YY1AP1](YY1AP1) | 2 | Schmitz et al. 2012 |
240
-| [ZAN](ZAN) | 2 | Burkhardt et al. 2022 |
241
-| [ZBTB7A](ZBTB7A) | 2 | Burkhardt et al. 2022; Reddy et al. 2017 |
242
-| [ZFP36L1](ZFP36L1) | 2, aSHM | Morin et al. 2011; Reichel et al. 2015; Panea et al. 2019 |
243
-| [ZNF229](ZNF229) | 2 | Love et al. 2012 |
244
-| [ZNF85](ZNF85) | 2 | Burkhardt et al. 2022 |
245
-
246
-# References
247
-
248
-<div id="refs" class="references csl-bib-body hanging-indent">
249
-
250
-<div id="ref-abateDistinctViralMutational2015a" class="csl-entry">
251
-
252
-Abate, F., M. Ambrosio, L. Mundo, M. Laginestra, F. Fuligni, M. Rossi,
253
-Sakellarios Zairis, et al. 2015. “Distinct Viral and Mutational Spectrum
254
-of Endemic Burkitt Lymphoma.” *PLoS Pathogens* 11.
255
-<https://doi.org/10.1371/journal.ppat.1005158>.
256
-
257
-</div>
258
-
259
-<div id="ref-albuquerqueEnhancingKnowledgeDiscovery2017a"
260
-class="csl-entry">
261
-
262
-Albuquerque, Marco A., Bruno M. Grande, Elie J. Ritch, Prasath
263
-Pararajalingam, Selin Jessa, Martin Krzywinski, Jasleen K. Grewal,
264
-Sohrab P. Shah, Paul C. Boutros, and Ryan D. Morin. 2017. “Enhancing
265
-Knowledge Discovery from Cancer Genomics Data with Galaxy.”
266
-*GigaScience* 6 5: 1–13. <https://doi.org/10.1093/gigascience/gix015>.
267
-
268
-</div>
269
-
270
-<div id="ref-arthurGenomewideDiscoverySomatic2018" class="csl-entry">
271
-
272
-Arthur, Sarah E., Aixiang Jiang, Bruno M. Grande, Miguel Alcaide, Razvan
273
-Cojocaru, Christopher K. Rushton, Anja Mottok, et al. 2018. “Genome-Wide
274
-Discovery of Somatic Regulatory Variants in Diffuse Large <span
275
-class="nocase">B-cell</span> Lymphoma.” *Nature Communications* 9 1:
276
-4001. <https://doi.org/10.1038/s41467-018-06354-3>.
277
-
278
-</div>
279
-
280
-<div id="ref-beaLandscapeSomaticMutations2013" class="csl-entry">
281
-
282
-Beà, Sílvia, Rafael Valdés-Mas, Alba Navarro, Itziar Salaverria, David
283
-Martín-Garcia, Pedro Jares, Eva Giné, et al. 2013. “Landscape of Somatic
284
-Mutations and Clonal Evolution in Mantle Cell Lymphoma.” *Proceedings of
285
-the National Academy of Sciences* 110 45: 18250–55.
286
-<https://doi.org/10.1073/pnas.1314608110>.
287
-
288
-</div>
289
-
290
-<div id="ref-bohleRoleEarlyBcell2013" class="csl-entry">
291
-
292
-Bohle, V., C. Döring, M.-L. Hansmann, and R. Küppers. 2013. “Role of
293
-Early <span class="nocase">B-cell</span> Factor 1 EBF1 in Hodgkin
294
-Lymphoma.” *Leukemia* 27 3: 671–79.
295
-<https://doi.org/10.1038/leu.2012.280>.
296
-
297
-</div>
298
-
299
-<div id="ref-burkhardtClinicalRelevanceMolecular2022b"
300
-class="csl-entry">
301
-
302
-Burkhardt, Birgit, Ulf Michgehl, Jonas Rohde, Tabea Erdmann, Philipp
303
-Berning, Katrin Reutter, Marius Rohde, et al. 2022. “Clinical Relevance
304
-of Molecular Characteristics in Burkitt Lymphoma Differs According to
305
-Age.” *Nature Communications* 13 1: 3881.
306
-<https://doi.org/10.1038/s41467-022-31355-8>.
307
-
308
-</div>
309
-
310
-<div id="ref-chapuyMolecularSubtypesDiffuse2018b" class="csl-entry">
311
-
312
-Chapuy, Bjoern, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Atanas
313
-Kamburov, Robert A. Redd, Mike S. Lawrence, et al. 2018. “Molecular
314
-Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct
315
-Pathogenic Mechanisms and Outcomes.” *Nature Medicine* 24 5: 679–90.
316
-<https://doi.org/10.1038/s41591-018-0016-8>.
317
-
318
-</div>
319
-
320
-<div id="ref-deschGenotypingCirculatingTumor2020" class="csl-entry">
321
-
322
-Desch, Ann-Kathrin, Kristin Hartung, Ante Botzen, Alexander Brobeil,
323
-Mathias Rummel, Lars Kurch, Thomas Georgi, et al. 2020. “Genotyping
324
-Circulating Tumor DNA of Pediatric Hodgkin Lymphoma.” *Leukemia* 34 1:
325
-151–66. <https://doi.org/10.1038/s41375-019-0541-6>.
326
-
327
-</div>
328
-
329
-<div id="ref-dunsCharacterizationDLBCLPMBL2021b" class="csl-entry">
330
-
331
-Duns, Gerben, Elena Viganò, Daisuke Ennishi, Clementine Sarkozy, Stacy
332
-S. Hung, Elizabeth Chavez, Katsuyoshi Takata, et al. 2021.
333
-“Characterization of DLBCL with a PMBL Gene Expression Signature.”
334
-*Blood* 138 2: 136–48. <https://doi.org/10.1182/blood.2020007683>.
335
-
336
-</div>
337
-
338
-<div id="ref-ganapathiGeneticLandscapeDural2016" class="csl-entry">
339
-
340
-Ganapathi, Karthik A., Vaidehi Jobanputra, Fabio Iwamoto, Preti Jain,
341
-Jinli Chen, Luciano Cascione, Odelia Nahum, et al. 2016. “The Genetic
342
-Landscape of Dural Marginal Zone Lymphomas.” *Oncotarget* 7 28:
343
-43052–61. <https://doi.org/10.18632/oncotarget.9678>.
344
-
345
-</div>
346
-
347
-<div id="ref-gomezUltraDeepSequencingReveals2023" class="csl-entry">
348
-
349
-Gomez, Felicia, Bryan Fisk, Joshua F. McMichael, Matthew Mosior,
350
-Jennifer A. Foltz, Zachary L. Skidmore, Eric J. Duncavage, et al. 2023.
351
-“Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical
352
-Hodgkin Lymphoma.” *Cancer Research Communications* 3 11: 2312–30.
353
-<https://doi.org/10.1158/2767-9764.CRC-23-0140>.
354
-
355
-</div>
356
-
357
-<div id="ref-grandeGenomewideDiscoverySomatic2019" class="csl-entry">
358
-
359
-Grande, Bruno M., Daniela S. Gerhard, Aixiang Jiang, Nicholas B. Griner,
360
-Jeremy S. Abramson, Thomas B. Alexander, Hilary Allen, et al. 2019.
361
-“Genome-Wide Discovery of Somatic Coding and Noncoding Mutations in
362
-Pediatric Endemic and Sporadic Burkitt Lymphoma.” *Blood* 133 12:
363
-1313–24. <https://doi.org/10.1182/blood-2018-09-871418>.
364
-
365
-</div>
366
-
367
-<div id="ref-hubschmannMutationalMechanismsShaping2021b"
368
-class="csl-entry">
369
-
370
-Hübschmann, Daniel, Kortine Kleinheinz, Rabea Wagener, Stephan H.
371
-Bernhart, Cristina López, Umut H. Toprak, Stephanie Sungalee, et al.
372
-2021. “Mutational Mechanisms Shaping the Coding and Noncoding Genome of
373
-Germinal Center Derived <span class="nocase">B-cell</span> Lymphomas.”
374
-*Leukemia* 35 7: 2002–16.
375
-<https://doi.org/10.1038/s41375-021-01251-z>.
376
-
377
-</div>
378
-
379
-<div id="ref-jalladesExomeSequencingIdentifies2017" class="csl-entry">
380
-
381
-Jallades, Laurent, Lucile Baseggio, Pierre Sujobert, Sarah Huet, Kaddour
382
-Chabane, Evelyne Callet-Bauchu, Aurélie Verney, et al. 2017. “Exome
383
-Sequencing Identifies Recurrent BCOR Alterations and the Absence of
384
-KLF2, TNFAIP3 and MYD88 Mutations in Splenic Diffuse Red Pulp Small
385
-<span class="nocase">B-cell</span> Lymphoma.” *Haematologica* 102 10:
386
-1758–66. <https://doi.org/10.3324/haematol.2016.160192>.
387
-
388
-</div>
389
-
390
-<div id="ref-johnstonCmycHypermutationBurkitt1992" class="csl-entry">
391
-
392
-Johnston, J. M., and W. L. Carroll. 1992. “C-Myc Hypermutation in
393
-Burkitt’s Lymphoma.” *Leukemia & Lymphoma* 8 6: 431–39.
394
-<https://doi.org/10.3109/10428199209051025>.
395
-
396
-</div>
397
-
398
-<div id="ref-khodabakhshiRecurrentTargetsAberrant2012"
399
-class="csl-entry">
400
-
401
-Khodabakhshi, Alireza Hadj, Ryan D. Morin, Anthony P. Fejes, Andrew J.
402
-Mungall, Karen L. Mungall, Madison Bolger-Munro, Nathalie A. Johnson, et
403
-al. 2012. “Recurrent Targets of Aberrant Somatic Hypermutation in
404
-Lymphoma.” *Oncotarget* 3 11: 1308–19.
405
-<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717795/>.
406
-
407
-</div>
408
-
409
-<div id="ref-krysiakRecurrentSomaticMutations2017b" class="csl-entry">
410
-
411
-Krysiak, Kilannin, Felicia Gomez, Brian S. White, Matthew Matlock,
412
-Christopher A. Miller, Lee Trani, Catrina C. Fronick, et al. 2017.
413
-“Recurrent Somatic Mutations Affecting <span
414
-class="nocase">B-cell</span> Receptor Signaling Pathway Genes in
415
-Follicular Lymphoma.” *Blood* 129 4: 473–83.
416
-<https://doi.org/10.1182/blood-2016-07-729954>.
417
-
418
-</div>
419
-
420
-<div id="ref-kwanhianMicroRNA142Mutated202012b" class="csl-entry">
421
-
422
-Kwanhian, Wiyada, Dido Lenze, Julia Alles, Natalie Motsch, Stephanie
423
-Barth, Celina Döll, Jochen Imig, et al. 2012. “MicroRNA-142 Is Mutated
424
-in about 20% of Diffuse Large <span class="nocase">B-cell</span>
425
-Lymphoma.” *Cancer Medicine* 1 2: 141–55.
426
-<https://doi.org/10.1002/cam4.29>.
427
-
428
-</div>
429
-
430
-<div id="ref-lenzOncogenicCARD11Mutations2008" class="csl-entry">
431
-
432
-Lenz, Georg, R Eric Davis, Vu N Ngo, Lloyd Lam, Thaddeus C George,
433
-George W Wright, Sandeep S Dave, et al. 2008. “Oncogenic CARD11
434
-Mutations in Human Diffuse Large B Cell Lymphoma.” *Science* 319 5870:
435
-1676–79.
436
-
437
-</div>
438
-
439
-<div id="ref-lohrDiscoveryPrioritizationSomatic2012a" class="csl-entry">
440
-
441
-Lohr, Jens G., Petar Stojanov, Michael S. Lawrence, Daniel Auclair,
442
-Bjoern Chapuy, Carrie Sougnez, Peter Cruz-Gordillo, et al. 2012.
443
-“Discovery and Prioritization of Somatic Mutations in Diffuse Large
444
-<span class="nocase">B-cell</span> Lymphoma DLBCL by Whole-Exome
445
-Sequencing.” *Proceedings of the National Academy of Sciences of the
446
-United States of America* 109 10: 3879–84.
447
-<https://doi.org/10.1073/pnas.1121343109>.
448
-
449
-</div>
450
-
451
-<div id="ref-loveGeneticLandscapeMutations2012" class="csl-entry">
452
-
453
-Love, Cassandra, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney
454
-Miles, Kristy L. Richards, et al. 2012. “The Genetic Landscape of
455
-Mutations in Burkitt Lymphoma.” *Nature Genetics* 44 12: 1321–25.
456
-<https://doi.org/10.1038/ng.2468>.
457
-
458
-</div>
459
-
460
-<div id="ref-morinSomaticMutationsAltering2010a" class="csl-entry">
461
-
462
-Morin, Ryan D., Nathalie A. Johnson, Tesa M. Severson, Andrew J.
463
-Mungall, Jianghong An, Rodrigo Goya, Jessica E. Paul, et al. 2010.
464
-“Somatic Mutations Altering EZH2 Tyr641 in Follicular and Diffuse
465
-Large <span class="nocase">B-cell</span> Lymphomas of Germinal-Center
466
-Origin.” *Nature Genetics* 42 2: 181–85.
467
-<https://doi.org/10.1038/ng.518>.
468
-
469
-</div>
470
-
471
-<div id="ref-morinFrequentMutationHistonemodifying2011"
472
-class="csl-entry">
473
-
474
-Morin, Ryan D., Maria Mendez-Lago, Andrew J. Mungall, Rodrigo Goya,
475
-Karen L. Mungall, Richard D. Corbett, Nathalie A. Johnson, et al. 2011.
476
-“Frequent Mutation of Histone-Modifying Genes in Non-Hodgkin Lymphoma.”
477
-*Nature* 476 7360: 298–303. <https://doi.org/10.1038/nature10351>.
478
-
479
-</div>
480
-
481
-<div id="ref-morinMutationalStructuralAnalysis2013" class="csl-entry">
482
-
483
-Morin, Ryan D., Karen Mungall, Erin Pleasance, Andrew J. Mungall,
484
-Rodrigo Goya, Ryan D. Huff, David W. Scott, et al. 2013. “Mutational and
485
-Structural Analysis of Diffuse Large <span class="nocase">B-cell</span>
486
-Lymphoma Using Whole-Genome Sequencing.” *Blood* 122 7: 1256–65.
487
-<https://doi.org/10.1182/blood-2013-02-483727>.
488
-
489
-</div>
490
-
491
-<div id="ref-mottokIntegrativeGenomicAnalysis2019b" class="csl-entry">
492
-
493
-Mottok, Anja, Stacy S. Hung, Elizabeth A. Chavez, Bruce Woolcock, Adèle
494
-Telenius, Lauren C. Chong, Barbara Meissner, et al. 2019. “Integrative
495
-Genomic Analysis Identifies Key Pathogenic Mechanisms in Primary
496
-Mediastinal Large <span class="nocase">B-cell</span> Lymphoma.” *Blood*
497
-134 10: 802–13. <https://doi.org/10.1182/blood.2019001126>.
498
-
499
-</div>
52
+|Gene|Tier| Relevant references|
53
+|:-:|:-:|:-|
54
+|[ACAD9](ACAD9)|2|[@loveGeneticLandscapeMutations2012]|
55
+|[ACE](ACE)|2|[@loveGeneticLandscapeMutations2012]|
56
+|[ADAMTS5](ADAMTS5)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
57
+|[ADNP](ADNP)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
58
+|[AGO4](AGO4)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
59
+|[ALPK2](ALPK2)|2|[@paneaWholeGenomeLandscape2019]|
60
+|[ARHGEF1](ARHGEF1)|2|[@muppidiLossSignalingGa132014b]|
61
+|[ATP2C2](ATP2C2)|2|[@loveGeneticLandscapeMutations2012]|
62
+|[BACH2](BACH2)|2, aSHM|[@grandeGenomewideDiscoverySomatic2019]|
63
+|[BCL2](BCL2)|2, aSHM|[@tanakaFrequentIncidenceSomatic1992; @burkhardtClinicalRelevanceMolecular2022b; @sarkozyMutationalLandscapeGray2021a; @morinFrequentMutationHistonemodifying2011]|
64
+|[BCL6](BCL6)|2, aSHM|[@morinFrequentMutationHistonemodifying2011; @loveGeneticLandscapeMutations2012]|
65
+|[BRAF](BRAF)|2|[@tiacciBRAFMutationsHairycell2011a; @loveGeneticLandscapeMutations2012]|
66
+|[BRD4](BRD4)|2|[@loveGeneticLandscapeMutations2012]|
67
+|[BTG1](BTG1)|2, aSHM|[@sarkozyMutationalLandscapeGray2021a; @morinFrequentMutationHistonemodifying2011; @burkhardtClinicalRelevanceMolecular2022b]|
68
+|[BTG2](BTG2)|2, aSHM|[@morinFrequentMutationHistonemodifying2011; @loveGeneticLandscapeMutations2012]|
69
+|[C16orf48](C16orf48)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
70
+|[C6orf27](C6orf27)|2|[@loveGeneticLandscapeMutations2012]|
71
+|[CAD](CAD)|2|[@loveGeneticLandscapeMutations2012]|
72
+|[CARD11](CARD11)|2|[@lenzOncogenicCARD11Mutations2008; @paneaWholeGenomeLandscape2019; @wuGeneticHeterogeneityPrimary2016; @morinFrequentMutationHistonemodifying2011; @yanBCRTLRSignaling2012a]|
73
+|[CARD4](CARD4)|2|[@loveGeneticLandscapeMutations2012]|
74
+|[CCNF](CCNF)|2|[@abateDistinctViralMutational2015a]|
75
+|[CCT6B](CCT6B)|2|[@loveGeneticLandscapeMutations2012]|
76
+|[CD79A](CD79A)|2|[@burkhardtClinicalRelevanceMolecular2022b; @rossiCodingGenomeSplenic2012c]|
77
+|[CD79B](CD79B)|2|[@morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019]|
78
+|[CD83](CD83)|2, aSHM|[@morinMutationalStructuralAnalysis2013; @russler-germainMutationsAssociatedProgression2023b; @dunsCharacterizationDLBCLPMBL2021b; @paneaWholeGenomeLandscape2019]|
79
+|[CDC73](CDC73)|2|[@reddyGeneticFunctionalDrivers2017; @loveGeneticLandscapeMutations2012]|
80
+|[CDH17](CDH17)|2|[@loveGeneticLandscapeMutations2012]|
81
+|[CDKN2A](CDKN2A)|2|[@grandeGenomewideDiscoverySomatic2019; @spinaGeneticsNodalMarginal2016b; @morinMutationalStructuralAnalysis2013]|
82
+|[CDKN2C](CDKN2C)|2|[@thomasGeneticSubgroupsInform2023]|
83
+|[CHD4](CHD4)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
84
+|[COL4A2](COL4A2)|2|[@loveGeneticLandscapeMutations2012]|
85
+|[CPXM2](CPXM2)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
86
+|[CREBBP](CREBBP)|2|[@pasqualucciInactivatingMutationsAcetyltransferase2011a; @loveGeneticLandscapeMutations2012; @parryWholeExomeSequencing2013; @dunsCharacterizationDLBCLPMBL2021b]|
87
+|[CTCF](CTCF)|2|[@paneaWholeGenomeLandscape2019]|
88
+|[CXCR4](CXCR4)|2, aSHM|[@khodabakhshiRecurrentTargetsAberrant2012; @krysiakRecurrentSomaticMutations2017b; @paneaWholeGenomeLandscape2019]|
89
+|[CYB5D1](CYB5D1)|2|[@loveGeneticLandscapeMutations2012]|
90
+|[CYP4F22](CYP4F22)|2|[@loveGeneticLandscapeMutations2012]|
91
+|[DHCR7](DHCR7)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
92
+|[DLGAP1](DLGAP1)|2|[@loveGeneticLandscapeMutations2012]|
93
+|[DNMT1](DNMT1)|2|[@paneaWholeGenomeLandscape2019]|
94
+|[DTX1](DTX1)|2, aSHM|[@gomezUltraDeepSequencingReveals2023; @schmitzGeneticsPathogenesisDiffuse2018a; @paneaWholeGenomeLandscape2019; @rossiCodingGenomeSplenic2012c]|
95
+|[E2F2](E2F2)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
96
+|[EBF1](EBF1)|2, aSHM|[@reichelFlowSortingExome2015a; @bohleRoleEarlyBcell2013; @thomasGeneticSubgroupsInform2023]|
97
+|[EDNRB](EDNRB)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
98
+|[EHD1](EHD1)|2|[@thomasGeneticSubgroupsInform2023]|
99
+|[EIF2C4](EIF2C4)|2|[@loveGeneticLandscapeMutations2012]|
100
+|[ELP2](ELP2)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
101
+|[EML2](EML2)|2|[@loveGeneticLandscapeMutations2012]|
102
+|[ENTPD3](ENTPD3)|2|[@loveGeneticLandscapeMutations2012]|
103
+|[EP300](EP300)|2|[@paneaWholeGenomeLandscape2019; @rossiCodingGenomeSplenic2012c; @pasqualucciInactivatingMutationsAcetyltransferase2011a]|
104
+|[EPHB2](EPHB2)|2|[@loveGeneticLandscapeMutations2012]|
105
+|[ERAP1](ERAP1)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
106
+|[ETS1](ETS1)|2, aSHM|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011]|
107
+|[EXOSC6](EXOSC6)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
108
+|[EZH2](EZH2)|2|[@mottokIntegrativeGenomicAnalysis2019b; @morinSomaticMutationsAltering2010a; @loveGeneticLandscapeMutations2012]|
109
+|[FAM129B](FAM129B)|2|[@loveGeneticLandscapeMutations2012]|
110
+|[FGFR3](FGFR3)|2|[@loveGeneticLandscapeMutations2012]|
111
+|[FLYWCH1](FLYWCH1)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
112
+|[FTCD](FTCD)|2|[@loveGeneticLandscapeMutations2012]|
113
+|[FZD3](FZD3)|2|[@paneaWholeGenomeLandscape2019]|
114
+|[GGTLA4](GGTLA4)|2|[@loveGeneticLandscapeMutations2012]|
115
+|[GRB2](GRB2)|2|[@paneaWholeGenomeLandscape2019; @pasqualucciAnalysisCodingGenome2011]|
116
+|[GRIK5](GRIK5)|2|[@loveGeneticLandscapeMutations2012]|
117
+|[GTSE1](GTSE1)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
118
+|[HIST1H1C](HIST1H1C)|2, aSHM|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011]|
119
+|[HIST1H1E](HIST1H1E)|2, aSHM|[@grandeGenomewideDiscoverySomatic2019; @reichelFlowSortingExome2015a; @morinMutationalStructuralAnalysis2013; @krysiakRecurrentSomaticMutations2017b]|
120
+|[HIST1H2AG](HIST1H2AG)|2, aSHM|[@morinMutationalStructuralAnalysis2013; @rossiCodingGenomeSplenic2012c; @krysiakRecurrentSomaticMutations2017b; @paneaWholeGenomeLandscape2019]|
121
+|[HIST1H2AM](HIST1H2AM)|2, aSHM|[@paneaWholeGenomeLandscape2019; @krysiakRecurrentSomaticMutations2017b]|
122
+|[HIST1H2BK](HIST1H2BK)|2, aSHM|[@rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019]|
123
+|[HIST1H3D](HIST1H3D)|2, aSHM|[@paneaWholeGenomeLandscape2019]|
124
+|[HIST1H3H](HIST1H3H)|2, aSHM|[@paneaWholeGenomeLandscape2019]|
125
+|[HIST1H3I](HIST1H3I)|2, aSHM|[@paneaWholeGenomeLandscape2019; @krysiakRecurrentSomaticMutations2017b]|
126
+|[HIST1H3J](HIST1H3J)|2, aSHM|[@paneaWholeGenomeLandscape2019]|
127
+|[HIST1H4J](HIST1H4J)|2, aSHM|[@mottokIntegrativeGenomicAnalysis2019b; @paneaWholeGenomeLandscape2019]|
128
+|[HLA-A](HLA-A)|2|[@deschGenotypingCirculatingTumor2020]|
129
+|[HLA-B](HLA-B)|2|[@wienandGenomicAnalysesFlowsorted2019b]|
130
+|[HLA-DMB](HLA-DMB)|2||
131
+|[HLA-DQB1](HLA-DQB1)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
132
+|[ICK](ICK)|2|[@loveGeneticLandscapeMutations2012]|
133
+|[IGLL5](IGLL5)|2, aSHM|[@deschGenotypingCirculatingTumor2020; @russler-germainMutationsAssociatedProgression2023b; @paneaWholeGenomeLandscape2019]|
134
+|[IKZF3](IKZF3)|2, aSHM|[@morinMutationalStructuralAnalysis2013; @paneaWholeGenomeLandscape2019]|
135
+|[IRF8](IRF8)|2, aSHM|[@mottokIntegrativeGenomicAnalysis2019b; @morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019]|
136
+|[ITPR3](ITPR3)|2|[@tiacciPervasiveMutationsJAKSTAT2018b; @loveGeneticLandscapeMutations2012]|
137
+|[KANK2](KANK2)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
138
+|[KCNK10](KCNK10)|2|[@paneaWholeGenomeLandscape2019]|
139
+|[KIFC3](KIFC3)|2|[@loveGeneticLandscapeMutations2012]|
140
+|[KLHL26](KLHL26)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
141
+|[KLHL6](KLHL6)|2, aSHM|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011; @ganapathiGeneticLandscapeDural2016]|
142
+|[KMT2C](KMT2C)|2|[@zhouSporadicEndemicBurkitt2019; @zhangGenomicLandscapeMantle2014; @zhangGeneticHeterogeneityDiffuse2013; @sarkozyMutationalLandscapeGray2021a]|
143
+|[LTB](LTB)|2, aSHM|[@deschGenotypingCirculatingTumor2020; @chapuyMolecularSubtypesDiffuse2018b; @paneaWholeGenomeLandscape2019]|
144
+|[MAP3K6](MAP3K6)|2|[@loveGeneticLandscapeMutations2012]|
145
+|[MCL1](MCL1)|2|[@reddyGeneticFunctionalDrivers2017; @dunsCharacterizationDLBCLPMBL2021b; @paneaWholeGenomeLandscape2019]|
146
+|[MIR142](MIR142)|2, aSHM|[@kwanhianMicroRNA142Mutated202012b; @grandeGenomewideDiscoverySomatic2019]|
147
+|[MKI67](MKI67)|2|[@schmitzBurkittLymphomaPathogenesis2012; @russler-germainMutationsAssociatedProgression2023b]|
148
+|[MME](MME)|2|[@paneaWholeGenomeLandscape2019]|
149
+|[MTOR](MTOR)|2|[@paneaWholeGenomeLandscape2019; @zhangGeneticHeterogeneityDiffuse2013]|
150
+|[MYH10](MYH10)|2|[@loveGeneticLandscapeMutations2012]|
151
+|[MYO18A](MYO18A)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
152
+|[NBEAL1](NBEAL1)|2|[@loveGeneticLandscapeMutations2012]|
153
+|[NCOR2](NCOR2)|2|[@sarkozyMutationalLandscapeGray2021a; @spinaGeneticsNodalMarginal2016b; @schmitzBurkittLymphomaPathogenesis2012]|
154
+|[NOA1](NOA1)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
155
+|[NOTCH1](NOTCH1)|2|[@rossiCodingGenomeSplenic2012c; @pasqualucciAnalysisCodingGenome2011; @beaLandscapeSomaticMutations2013; @loveGeneticLandscapeMutations2012]|
156
+|[NOTCH2](NOTCH2)|2|[@troenNOTCH2MutationsMarginal2008; @rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019; @beaLandscapeSomaticMutations2013]|
157
+|[NRXN2](NRXN2)|2|[@loveGeneticLandscapeMutations2012]|
158
+|[P2RY2](P2RY2)|2|[@loveGeneticLandscapeMutations2012]|
159
+|[PABPC4L](PABPC4L)|2|[@paneaWholeGenomeLandscape2019]|
160
+|[PC](PC)|2|[@loveGeneticLandscapeMutations2012]|
161
+|[PCBP1](PCBP1)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
162
+|[PCDHA11](PCDHA11)|2|[@paneaWholeGenomeLandscape2019]|
163
+|[PDCD11](PDCD11)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
164
+|[PDZRN3](PDZRN3)|2|[@paneaWholeGenomeLandscape2019]|
165
+|[PIK3R1](PIK3R1)|2|[@paneaWholeGenomeLandscape2019; @zhangGeneticHeterogeneityDiffuse2013]|
166
+|[PIM1](PIM1)|2, aSHM|[@pasqualucciHypermutationMultipleProtooncogenes2001a; @dunsCharacterizationDLBCLPMBL2021b; @burkhardtClinicalRelevanceMolecular2022b]|
167
+|[PLCG2](PLCG2)|2|[@paneaWholeGenomeLandscape2019]|
168
+|[POLRMT](POLRMT)|2|[@loveGeneticLandscapeMutations2012]|
169
+|[POR](POR)|2|[@loveGeneticLandscapeMutations2012]|
170
+|[PPP6R2](PPP6R2)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
171
+|[PREX1](PREX1)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
172
+|[PRSS22](PRSS22)|2|[@loveGeneticLandscapeMutations2012]|
173
+|[PTPRN](PTPRN)|2|[@loveGeneticLandscapeMutations2012]|
174
+|[PXDNL](PXDNL)|2|[@paneaWholeGenomeLandscape2019]|
175
+|[RAC2](RAC2)|2|[@hubschmannMutationalMechanismsShaping2021b; @paneaWholeGenomeLandscape2019]|
176
+|[RANBP6](RANBP6)|2|[@loveGeneticLandscapeMutations2012]|
177
+|[RBP3](RBP3)|2|[@loveGeneticLandscapeMutations2012]|
178
+|[RET](RET)|2|[@loveGeneticLandscapeMutations2012]|
179
+|[REV3L](REV3L)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
180
+|[RNF144B](RNF144B)|2|[@paneaWholeGenomeLandscape2019]|
181
+|[RPL10](RPL10)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
182
+|[S1PR2](S1PR2)|2, aSHM|[@morinFrequentMutationHistonemodifying2011; @muppidiLossSignalingGa132014b]|
183
+|[SAL3](SAL3)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
184
+|[SALL3](SALL3)|2|[@loveGeneticLandscapeMutations2012; @zhangGenomicLandscapeMantle2014]|
185
+|[SAPS2](SAPS2)|2|[@loveGeneticLandscapeMutations2012]|
186
+|[SBF1](SBF1)|2|[@loveGeneticLandscapeMutations2012]|
187
+|[SF3B1](SF3B1)|2|[@loveGeneticLandscapeMutations2012]|
188
+|[SHANK1](SHANK1)|2|[@loveGeneticLandscapeMutations2012]|
189
+|[SLC29A2](SLC29A2)|2|[@loveGeneticLandscapeMutations2012]|
190
+|[SNTB2](SNTB2)|2|[@paneaWholeGenomeLandscape2019]|
191
+|[SP3](SP3)|2|[@paneaWholeGenomeLandscape2019]|
192
+|[SYNCRIP](SYNCRIP)|2|[@paneaWholeGenomeLandscape2019]|
193
+|[SYNGAP1](SYNGAP1)|2|[@loveGeneticLandscapeMutations2012]|
194
+|[TBC1D9B](TBC1D9B)|2|[@loveGeneticLandscapeMutations2012]|
195
+|[TET2](TET2)|2|[@paneaWholeGenomeLandscape2019; @albuquerqueEnhancingKnowledgeDiscovery2017a]|
196
+|[TIGD6](TIGD6)|2|[@loveGeneticLandscapeMutations2012]|
197
+|[TOP2A](TOP2A)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
198
+|[TPST2](TPST2)|2|[@loveGeneticLandscapeMutations2012]|
199
+|[TTN](TTN)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
200
+|[VWA7](VWA7)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
201
+|[WDR7](WDR7)|2|[@paneaWholeGenomeLandscape2019]|
202
+|[WDR90](WDR90)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
203
+|[WHAMM](WHAMM)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
204
+|[WNK2](WNK2)|2|[@paneaWholeGenomeLandscape2019]|
205
+|[YY1AP1](YY1AP1)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
206
+|[ZAN](ZAN)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
207
+|[ZBTB7A](ZBTB7A)|2|[@burkhardtClinicalRelevanceMolecular2022b; @reddyGeneticFunctionalDrivers2017]|
208
+|[ZFP36L1](ZFP36L1)|2, aSHM|[@morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019; @reichelFlowSortingExome2015a]|
209
+|[ZNF229](ZNF229)|2|[@loveGeneticLandscapeMutations2012]|
210
+|[ZNF85](ZNF85)|2|[@burkhardtClinicalRelevanceMolecular2022b]|
500 211
501
-<div id="ref-muppidiLossSignalingGa132014b" class="csl-entry">
502 212
503
-Muppidi, J., R. Schmitz, Jesse A. Green, Jesse A. Green, Wenming Xiao,
504
-Adrien B. Larsen, S. Braun, et al. 2014. “Loss of Signaling via Gα13 in
505
-Germinal Center B Cell-Derived Lymphoma.” *Nature* 516: 254–58.
506
-<https://doi.org/10.1038/nature13765>.
507
-
508
-</div>
509
-
510
-<div id="ref-nadeuGenomicEpigenomicInsights2020b" class="csl-entry">
511
-
512
-Nadeu, F., D. Martín-García, G. Clot, A. Díaz-Navarro, M. Duran-Ferrer,
513
-A. Navarro, Roser Vilarrasa-Blasi, et al. 2020. “Genomic and Epigenomic
514
-Insights into the Origin, Pathogenesis and Clinical Behavior of Mantle
515
-Cell Lymphoma Subtypes.” *Blood*.
516
-<https://doi.org/10.1182/blood.2020005289>.
517
-
518
-</div>
519
-
520
-<div id="ref-paneaWholeGenomeLandscape2019" class="csl-entry">
521
-
522
-Panea, R., C. Love, Jennifer R. Shingleton, Anupama Reddy, J. Bailey, A.
523
-Moormann, J. Otieno, et al. 2019. “The Whole Genome Landscape of Burkitt
524
-Lymphoma Subtypes.” *Blood*. <https://doi.org/10.1182/blood.2019001880>.
525
-
526
-</div>
527
-
528
-<div id="ref-parryWholeExomeSequencing2013" class="csl-entry">
529
-
530
-Parry, Marina, Matthew J. J. Rose-Zerilli, Jane Gibson, Sarah Ennis,
531
-Renata Walewska, Jade Forster, Helen Parker, et al. 2013. “Whole Exome
532
-Sequencing Identifies Novel Recurrently Mutated Genes in Patients with
533
-Splenic Marginal Zone Lymphoma.” *PloS One* 8 12: e83244.
534
-<https://doi.org/10.1371/journal.pone.0083244>.
535
-
536
-</div>
537
-
538
-<div id="ref-pasqualucciInactivatingMutationsAcetyltransferase2011a"
539
-class="csl-entry">
540
-
541
-Pasqualucci, Laura, David Dominguez-Sola, Annalisa Chiarenza, Giulia
542
-Fabbri, Adina Grunn, Vladimir Trifonov, Lawryn H. Kasper, et al. 2011.
543
-“Inactivating Mutations of Acetyltransferase Genes in <span
544
-class="nocase">B-cell</span> Lymphoma.” *Nature* 471 7337: 189–95.
545
-<https://doi.org/10.1038/nature09730>.
546
-
547
-</div>
548
-
549
-<div id="ref-pasqualucciAnalysisCodingGenome2011" class="csl-entry">
550
-
551
-Pasqualucci, Laura, Vladimir Trifonov, Giulia Fabbri, Jing Ma, Davide
552
-Rossi, Annalisa Chiarenza, Victoria A. Wells, et al. 2011. “Analysis of
553
-the Coding Genome of Diffuse Large <span class="nocase">B-cell</span>
554
-Lymphoma.” *Nature Genetics* 43 9: 830–37.
555
-<https://doi.org/10.1038/ng.892>.
556
-
557
-</div>
558
-
559
-<div id="ref-pasqualucciHypermutationMultipleProtooncogenes2001a"
560
-class="csl-entry">
561
-
562
-Pasqualucci, L., P. Neumeister, T. Goossens, G. Nanjangud, R. S.
563
-Chaganti, R. Küppers, and R. Dalla-Favera. 2001. “Hypermutation of
564
-Multiple Proto-Oncogenes in <span class="nocase">B-cell</span> Diffuse
565
-Large-Cell Lymphomas.” *Nature* 412 6844: 341–46.
566
-<https://doi.org/10.1038/35085588>.
567
-
568
-</div>
569
-
570
-<div id="ref-reddyGeneticFunctionalDrivers2017" class="csl-entry">
571
-
572
-Reddy, Anupama, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt,
573
-Cassandra L Love, Alexander Waldrop, Sirpa Leppa, et al. 2017. “Genetic
574
-and Functional Drivers of Diffuse Large B Cell Lymphoma.” *Cell* 171
575
-2: 481–494.e15.
576
-
577
-</div>
578
-
579
-<div id="ref-reichelFlowSortingExome2015a" class="csl-entry">
580
-
581
-Reichel, Jonathan, Amy Chadburn, Paul G. Rubinstein, Lisa Giulino-Roth,
582
-Wayne Tam, Yifang Liu, Rafael Gaiolla, et al. 2015. “Flow Sorting and
583
-Exome Sequencing Reveal the Oncogenome of Primary Hodgkin and
584
-Reed-Sternberg Cells.” *Blood* 125 7: 1061–72.
585
-<https://doi.org/10.1182/blood-2014-11-610436>.
586
-
587
-</div>
588
-
589
-<div id="ref-richterRecurrentMutationID32012a" class="csl-entry">
590
-
591
-Richter, Julia, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen
592
-Leich, Birgit Burkhardt, Maciej Rosolowski, et al. 2012. “Recurrent
593
-Mutation of the ID3 Gene in Burkitt Lymphoma Identified by Integrated
594
-Genome, Exome and Transcriptome Sequencing.” *Nature Genetics* 44 12:
595
-1316–20. <https://doi.org/10.1038/ng.2469>.
596
-
597
-</div>
598
-
599
-<div id="ref-rossiCodingGenomeSplenic2012c" class="csl-entry">
600
-
601
-Rossi, Davide, Vladimir Trifonov, Marco Fangazio, Alessio Bruscaggin,
602
-Silvia Rasi, Valeria Spina, Sara Monti, et al. 2012. “The Coding Genome
603
-of Splenic Marginal Zone Lymphoma: Activation of NOTCH2 and Other
604
-Pathways Regulating Marginal Zone Development.” *The Journal of
605
-Experimental Medicine* 209 9: 1537–51.
606
-<https://doi.org/10.1084/jem.20120904>.
607
-
608
-</div>
609
-
610
-<div id="ref-russler-germainMutationsAssociatedProgression2023b"
611
-class="csl-entry">
612
-
613
-Russler-Germain, David A., Kilannin Krysiak, Cody A. Ramirez, Matthew
614
-Mosior, Marcus P. Watkins, Felicia Gomez, Zachary L. Skidmore, et al.
615
-2023. “Mutations Associated with Progression in Follicular Lymphoma
616
-Predict Inferior Outcomes at Diagnosis: Alliance A151303.” *Blood
617
-Advances* 7: 5524–39.
618
-<https://doi.org/10.1182/bloodadvances.2023010779>.
619
-
620
-</div>
621
-
622
-<div id="ref-sarkozyMutationalLandscapeGray2021a" class="csl-entry">
623
-
624
-Sarkozy, Clémentine, Stacy S. Hung, Elizabeth A. Chavez, Gerben Duns,
625
-Katsuyoshi Takata, Lauren C. Chong, Tomohiro Aoki, et al. 2021.
626
-“Mutational Landscape of Gray Zone Lymphoma.” *Blood* 137 13: 1765–76.
627
-<https://doi.org/10.1182/blood.2020007507>.
628
-
629
-</div>
630
-
631
-<div id="ref-schmitzGeneticsPathogenesisDiffuse2018a" class="csl-entry">
632
-
633
-Schmitz, Roland, George W. Wright, Da Wei Huang, Calvin A. Johnson,
634
-James D. Phelan, James Q. Wang, Sandrine Roulland, et al. 2018.
635
-“Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.” *The New
636
-England Journal of Medicine* 378 15: 1396–1407.
637
-<https://doi.org/10.1056/NEJMoa1801445>.
638
-
639
-</div>
640
-
641
-<div id="ref-schmitzBurkittLymphomaPathogenesis2012" class="csl-entry">
642
-
643
-Schmitz, Roland, Ryan M. Young, Michele Ceribelli, Sameer Jhavar,
644
-Wenming Xiao, Meili Zhang, George Wright, et al. 2012. “Burkitt Lymphoma
645
-Pathogenesis and Therapeutic Targets from Structural and Functional
646
-Genomics.” *Nature* 490 7418: 116–20.
647
-<https://doi.org/10.1038/nature11378>.
648
-
649
-</div>
650
-
651
-<div id="ref-spinaGeneticsNodalMarginal2016b" class="csl-entry">
652
-
653
-Spina, Valeria, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano
654
-Cascione, Alessio Bruscaggin, Elisa Spaccarotella, et al. 2016. “The
655
-Genetics of Nodal Marginal Zone Lymphoma.” *Blood* 128 10: 1362–73.
656
-<https://doi.org/10.1182/blood-2016-02-696757>.
657
-
658
-</div>
659
-
660
-<div id="ref-tanakaFrequentIncidenceSomatic1992" class="csl-entry">
661
-
662
-Tanaka, S., D. C. Louie, J. A. Kant, and J. C. Reed. 1992. “Frequent
663
-Incidence of Somatic Mutations in Translocated BCL2 Oncogenes of
664
-Non-Hodgkin’s Lymphomas.” *Blood* 79 1: 229–37.
665
-
666
-</div>
667
-
668
-<div id="ref-thomasGeneticSubgroupsInform2023" class="csl-entry">
669
-
670
-Thomas, Nicole, Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton,
671
-Jeremy S. Abramson, Richard F. Ambinder, Stefan Barta, et al. 2023.
672
-“Genetic Subgroups Inform on Pathobiology in Adult and Pediatric Burkitt
673
-Lymphoma.” *Blood* 141 8: 904–16.
674
-<https://doi.org/10.1182/blood.2022016534>.
675
-
676
-</div>
677
-
678
-<div id="ref-tiacciPervasiveMutationsJAKSTAT2018b" class="csl-entry">
679
-
680
-Tiacci, Enrico, Erik Ladewig, Gianluca Schiavoni, Alex Penson,
681
-Elisabetta Fortini, Valentina Pettirossi, Yuchun Wang, et al. 2018.
682
-“Pervasive Mutations of JAK-STAT Pathway Genes in Classical Hodgkin
683
-Lymphoma.” *Blood* 131 22: 2454–65.
684
-<https://doi.org/10.1182/blood-2017-11-814913>.
685
-
686
-</div>
687
-
688
-<div id="ref-tiacciBRAFMutationsHairycell2011a" class="csl-entry">
689
-
690
-Tiacci, Enrico, Vladimir Trifonov, Gianluca Schiavoni, Antony Holmes,
691
-Wolfgang Kern, Maria Paola Martelli, Alessandra Pucciarini, et al. 2011.
692
-“BRAF Mutations in Hairy-Cell Leukemia.” *The New England Journal of
693
-Medicine* 364 24: 2305–15. <https://doi.org/10.1056/NEJMoa1014209>.
694
-
695
-</div>
696
-
697
-<div id="ref-troenNOTCH2MutationsMarginal2008" class="csl-entry">
698
-
699
-Trøen, Gunhild, Iwona Wlodarska, Abdirashid Warsame, Silvia Hernández
700
-Llodrà, Christiane De Wolf-Peeters, and Jan Delabie. 2008. “NOTCH2
701
-Mutations in Marginal Zone Lymphoma.” *Haematologica* 93 7: 1107–9.
702
-<https://doi.org/10.3324/haematol.11635>.
703
-
704
-</div>
705
-
706
-<div id="ref-wienandGenomicAnalysesFlowsorted2019b" class="csl-entry">
707
-
708
-Wienand, Kirsty, Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, David
709
-Wu, Jaegil Kim, Atanas Kamburov, et al. 2019. “Genomic Analyses of
710
-Flow-Sorted Hodgkin Reed-Sternberg Cells Reveal Complementary Mechanisms
711
-of Immune Evasion.” *Blood Advances* 3 23: 4065–80.
712
-<https://doi.org/10.1182/bloodadvances.2019001012>.
713
-
714
-</div>
715
-
716
-<div id="ref-wildaInactivationARFMDM2p53Pathway2004" class="csl-entry">
717
-
718
-Wilda, M., J. Bruch, L. Harder, D. Rawer, A. Reiter, A. Borkhardt, and
719
-W. Woessmann. 2004. “Inactivation of the <span
720
-class="nocase">ARF-MDM-2-p53</span> Pathway in Sporadic Burkitt’s
721
-Lymphoma in Children.” *Leukemia* 18 3: 584–88.
722
-<https://doi.org/10.1038/sj.leu.2403254>.
723
-
724
-</div>
725
-
726
-<div id="ref-wuGeneticHeterogeneityPrimary2016" class="csl-entry">
727
-
728
-Wu, Chenglin, Noel Fcc de Miranda, Longyun Chen, Agata M. Wasik, Larry
729
-Mansouri, Wojciech Jurczak, Krystyna Galazka, et al. 2016. “Genetic
730
-Heterogeneity in Primary and Relapsed Mantle Cell Lymphomas: Impact of
731
-Recurrent CARD11 Mutations.” *Oncotarget* 7 25: 38180–90.
732
-<https://doi.org/10.18632/oncotarget.9500>.
733
-
734
-</div>
735
-
736
-<div id="ref-yanBCRTLRSignaling2012a" class="csl-entry">
737
-
738
-Yan, Qingguo, Yuanxue Huang, A. James Watkins, Sylvia Kocialkowski,
739
-Naiyan Zeng, Rifat A. Hamoudi, Peter G. Isaacson, Laurence de Leval,
740
-Andrew Wotherspoon, and Ming-Qing Du. 2012. “BCR and TLR Signaling
741
-Pathways Are Recurrently Targeted by Genetic Changes in Splenic Marginal
742
-Zone Lymphomas.” *Haematologica* 97 4: 595–98.
743
-<https://doi.org/10.3324/haematol.2011.054080>.
744
-
745
-</div>
746
-
747
-<div id="ref-zhangGeneticHeterogeneityDiffuse2013" class="csl-entry">
748
-
749
-Zhang, Jenny, Vladimir Grubor, Cassandra L Love, Anjishnu Banerjee,
750
-Kristy L Richards, Piotr A Mieczkowski, Cherie Dunphy, et al. 2013.
751
-“Genetic Heterogeneity of Diffuse Large <span
752
-class="nocase">B-cell</span> Lymphoma.” January.
753
-
754
-</div>
755
-
756
-<div id="ref-zhangGenomicLandscapeMantle2014" class="csl-entry">
757
-
758
-Zhang, Jenny, Dereje Jima, Andrea B. Moffitt, Qingquan Liu, Magdalena
759
-Czader, Eric D. Hsi, Yuri Fedoriw, et al. 2014. “The Genomic Landscape
760
-of Mantle Cell Lymphoma Is Related to the Epigenetically Determined
761
-Chromatin State of Normal B Cells.” *Blood* 123 19: 2988–96.
762
-<https://doi.org/10.1182/blood-2013-07-517177>.
763
-
764
-</div>
765
-
766
-<div id="ref-zhouSporadicEndemicBurkitt2019" class="csl-entry">
767
-
768
-Zhou, Peixun, Alex E. Blain, Alexander M. Newman, Masood Zaka, George
769
-Chagaluka, Filbert R. Adlar, Ugonna T. Offor, et al. 2019. “Sporadic and
770
-Endemic Burkitt Lymphoma Have Frequent FOXO1 Mutations but Distinct
771
-Hotspots in the AKT Recognition Motif.” *Blood Advances* 3 14:
772
-2118–27. <https://doi.org/10.1182/bloodadvances.2018029546>.
773
-
774
-</div>
775
-
776
-</div>
213
+# References
DLBCL_genes.md
... ...
@@ -1,1220 +1,353 @@
1
-# DLBCL genes
1
+---
2
+title: 'DLBCL genes'
3
+bibliography: 'morinlab.bib'
4
+csl: 'NLM.csl'
5
+link-citations: true
6
+---
2 7
3 8
## Origins of DLBCL genes
4 9
5
-```mermaid
6
----
7
-config:
8
- sankey:
9
- showValues: false
10
- linkColor: target
11
- width: 800
12
- height: 1000
13
- nodeAlignment: right
14
----
15
-sankey-beta
16
-Morin 2013, DLBCL Tier 1, 11
17
-Morin 2013, DLBCL Tier 2, 29
18
-Morin 2016, DLBCL Tier 1, 2
19
-Mareschal 2016, DLBCL Tier 1, 2
20
-Arthur 2018, DLBCL Tier 1, 8
21
-Arthur 2018, DLBCL Tier 2, 12
22
-Pasqualucci 2001, DLBCL Tier 1, 2
23
-Pasqualucci 2001, DLBCL Tier 2, 2
24
-Albuquerque 2017, DLBCL Tier 1, 3
25
-Lohr 2012, DLBCL Tier 1, 3
26
-Lohr 2012, DLBCL Tier 2, 1
27
-Schmitz 2018, DLBCL Tier 1, 7
28
-Schmitz 2018, DLBCL Tier 2, 9
29
-Zhang 2013, DLBCL Tier 1, 11
30
-Zhang 2013, DLBCL Tier 2, 8
31
-Morin 2011, DLBCL Tier 1, 24
32
-Morin 2011, DLBCL Tier 2, 1
33
-Reddy 2017, DLBCL Tier 1, 7
34
-Reddy 2017, DLBCL Tier 2, 53
35
-Pasqualucci 2011, DLBCL Tier 1, 3
36
-Pasqualucci 2011, DLBCL Tier 2, 4
37
-Chapuy 2018, DLBCL Tier 1, 2
38
-Chapuy 2018, DLBCL Tier 2, 17
39
-Pasqualucci 2011, DLBCL Tier 1, 2
40
-Hubschmann 2021, DLBCL Tier 1, 3
41
-Hubschmann 2021, DLBCL Tier 2, 20
42
-Pararajalingam 2020, DLBCL Tier 2, 2
43
-DLBCL, Sanger, 4
44
-Sanger, Pasqualucci 2001, 4
45
-DLBCL, exome, 2
46
-exome, Mareschal 2016, 2
47
-DLBCL, WGS, 20
48
-WGS, Arthur 2018, 20
49
-DLBCL, exome, 2
50
-exome, Morin 2016, 2
51
-DLBCL, WGS, 40
52
-WGS, Morin 2013, 40
53
-DLBCL, exome, 3
54
-exome, Albuquerque 2017, 3
55
-DLBCL, exome, 4
56
-exome, Lohr 2012, 4
57
-DLBCL, exome, 60
58
-exome, Reddy 2017, 60
59
-DLBCL, exome, 16
60
-exome, Schmitz 2018, 16
61
-DLBCL, exome, 19
62
-exome, Zhang 2013, 19
63
-DLBCL, RNA-seq/WGS, 25
64
-RNA-seq/WGS, Morin 2011, 25
65
-DLBCL, exome, 2
66
-exome, Pasqualucci 2011, 2
67
-DLBCL, WGS/exome, 2
68
-WGS/exome, Pararajalingam 2020, 2
69
-DLBCL, WGS, 23
70
-WGS, Hubschmann 2021, 23
71
-DLBCL, exome, 19
72
-exome, Chapuy 2018, 19
73
-DLBCL, exome, 7
74
-exome, Pasqualucci 2011, 7
75
-```
10
+![](DLBCL_sankey-1.svg)
76 11
77 12
## Tier 1 DLBCL genes
78 13
79 14
### *128 total*
80 15
81
-| Gene | Tier | Relevant references |
82
-|:----------------------:|:------------:|:--------------------------------------------------------------------------------------------------------|
83
-| [ACTB](ACTB) | 1, aSHM | Wienand et al. 2019; Lohr et al. 2012 |
84
-| [ACTG1](ACTG1) | 1, aSHM | Spina et al. 2016; Desch et al. 2020; Hübschmann et al. 2021 |
85
-| [ARID1A](ARID1A) | 1 | Rossi et al. 2012; Wienand et al. 2019; Love et al. 2012; Zhang et al. 2013; Krysiak et al. 2017 |
86
-| [ATM](ATM) | 1 | Braggio et al. 2012; Beà et al. 2013; Reddy et al. 2017 |
87
-| [B2M](B2M) | 1 | Pararajalingam et al. 2020; Reichel et al. 2015; Morin et al. 2011 |
88
-| [BCL10](BCL10) | 1 | Morin et al. 2011; Russler-Germain et al. 2023; Spina et al. 2016 |
89
-| [BCL2](BCL2) | 1, aSHM | Sarkozy et al. 2021; Tanaka et al. 1992; Burkhardt et al. 2022; Morin et al. 2011 |
90
-| [BCL6](BCL6) | 1, aSHM | Morin et al. 2011; Love et al. 2012 |
91
-| [BCL7A](BCL7A) | 1, aSHM | Reichel et al. 2015; Krysiak et al. 2017; Arthur et al. 2018; Grande et al. 2019 |
92
-| [BIRC6](BIRC6) | 1 | Reddy et al. 2017; Sarkozy et al. 2021 |
93
-| [BRAF](BRAF) | 1 | Love et al. 2012; Tiacci et al. 2011 |
94
-| [BTG1](BTG1) | 1, aSHM | Morin et al. 2011; Burkhardt et al. 2022; Sarkozy et al. 2021 |
95
-| [BTG2](BTG2) | 1, aSHM | Morin et al. 2011; Love et al. 2012 |
96
-| [BTK](BTK) | 1 | Krysiak et al. 2017; Albuquerque et al. 2017 |
97
-| [CARD11](CARD11) | 1 | Wu et al. 2016; Panea et al. 2019; Lenz et al. 2008; Yan et al. 2012; Morin et al. 2011 |
98
-| [CCND3](CCND3) | 1 | Jallades et al. 2017; Richter et al. 2012; Desch et al. 2020; Morin et al. 2011 |
99
-| [CD58](CD58) | 1 | Morin et al. 2011; Schneider et al. 2015 |
100
-| [CD70](CD70) | 1 | Russler-Germain et al. 2023; Morin et al. 2011 |
101
-| [CD79B](CD79B) | 1 | Morin et al. 2011; Panea et al. 2019 |
102
-| [CD83](CD83) | 1, aSHM | Russler-Germain et al. 2023; Morin et al. 2013; Duns et al. 2021; Panea et al. 2019 |
103
-| [CDKN2A](CDKN2A) | 1 | Grande et al. 2019; Spina et al. 2016; Morin et al. 2013 |
104
-| [CIITA](CIITA) | 1, aSHM | Mottok et al. 2015; Morin et al. 2011 |
105
-| [CREBBP](CREBBP) | 1 | Duns et al. 2021; Laura Pasqualucci, Dominguez-Sola, et al. 2011; Love et al. 2012; Parry et al. 2013 |
106
-| [CXCR4](CXCR4) | 1, aSHM | Khodabakhshi et al. 2012; Panea et al. 2019; Krysiak et al. 2017 |
107
-| [CXCR5](CXCR5) | 1 | Schmitz et al. 2018; Mottok et al. 2019 |
108
-| [DDX3X](DDX3X) | 1 | Schmitz et al. 2012, 2018; Mottok et al. 2019 |
109
-| [DTX1](DTX1) | 1, aSHM | Panea et al. 2019; Gomez et al. 2023; Schmitz et al. 2018; Rossi et al. 2012 |
110
-| [DUSP2](DUSP2) | 1, aSHM | Duns et al. 2021; Morin et al. 2013 |
111
-| [EBF1](EBF1) | 1, aSHM | Reichel et al. 2015; Bohle et al. 2013; Thomas et al. 2023 |
112
-| [EEF1A1](EEF1A1) | 1 | Hübschmann et al. 2021; Reichel et al. 2015 |
113
-| [EP300](EP300) | 1 | Rossi et al. 2012; Panea et al. 2019; Laura Pasqualucci, Dominguez-Sola, et al. 2011 |
114
-| [ETS1](ETS1) | 1, aSHM | Panea et al. 2019; Morin et al. 2011 |
115
-| [ETV6](ETV6) | 1, aSHM | Arthur et al. 2018 |
116
-| [EZH2](EZH2) | 1 | Morin et al. 2010; Mottok et al. 2019; Love et al. 2012 |
117
-| [FAS](FAS) | 1 | Scholl et al. 2007; Spina et al. 2016 |
118
-| [FBXO11](FBXO11) | 1 | Richter et al. 2012; Hübschmann et al. 2021; Parry et al. 2013 |
119
-| [FBXW7](FBXW7) | 1 | Zhang et al. 2013 |
120
-| [FOXO1](FOXO1) | 1 | Schmitz et al. 2012; Morin et al. 2011; Duns et al. 2021 |
121
-| [GNA13](GNA13) | 1 | Love et al. 2012; Morin et al. 2011; Reichel et al. 2015 |
122
-| [GNAI2](GNAI2) | 1 | Grande et al. 2019; Morin et al. 2013 |
123
-| [GRB2](GRB2) | 1 | Panea et al. 2019; Laura Pasqualucci, Trifonov, et al. 2011 |
124
-| [GRHPR](GRHPR) | 1, aSHM | Arthur et al. 2018 |
125
-| [HIST1H1B](HIST1H1B) | 1, aSHM | Krysiak et al. 2017; Sarkozy et al. 2021; Chapuy et al. 2018 |
126
-| [HIST1H1C](HIST1H1C) | 1, aSHM | Morin et al. 2011; Panea et al. 2019 |
127
-| [HIST1H1D](HIST1H1D) | 1, aSHM | Krysiak et al. 2017; Jallades et al. 2017; Morin et al. 2013 |
128
-| [HIST1H1E](HIST1H1E) | 1, aSHM | Morin et al. 2013; Reichel et al. 2015; Grande et al. 2019; Krysiak et al. 2017 |
129
-| [HIST1H2AC](HIST1H2AC) | 1, aSHM | Krysiak et al. 2017; Morin et al. 2013 |
130
-| [HIST1H2AM](HIST1H2AM) | 1, aSHM | Panea et al. 2019; Krysiak et al. 2017 |
131
-| [HIST1H2BC](HIST1H2BC) | 1, aSHM | Krysiak et al. 2017; Mottok et al. 2019; Reddy et al. 2017 |
132
-| [HIST1H2BK](HIST1H2BK) | 1, aSHM | Panea et al. 2019; Rossi et al. 2012 |
133
-| [HIST1H3B](HIST1H3B) | 1, aSHM | Zhang et al. 2013; Reichel et al. 2015 |
134
-| [HIST2H2BE](HIST2H2BE) | 1, aSHM | Schmitz et al. 2018 |
135
-| [HLA-A](HLA-A) | 1 | Desch et al. 2020 |
136
-| [HLA-B](HLA-B) | 1 | Wienand et al. 2019 |
137
-| [HLA-C](HLA-C) | 1 | Gomez et al. 2023 |
138
-| [HLA-DMB](HLA-DMB) | 1 | |
139
-| [HNRNPU](HNRNPU) | 1, aSHM | Panea et al. 2019; Reddy et al. 2017 |
140
-| [HVCN1](HVCN1) | 1 | Krysiak et al. 2017 |
141
-| [IKZF3](IKZF3) | 1 | Morin et al. 2013; Panea et al. 2019 |
142
-| [IL4R](IL4R) | 1, aSHM | Duns et al. 2021; Viganò et al. 2018 |
143
-| [IRF4](IRF4) | 1, aSHM | Mottok et al. 2019; Morin et al. 2011 |
144
-| [IRF8](IRF8) | 1, aSHM | Panea et al. 2019; Morin et al. 2011; Mottok et al. 2019 |
145
-| [ITPKB](ITPKB) | 1, aSHM | Schmitz et al. 2018; Reichel et al. 2015 |
146
-| [KLF2](KLF2) | 1, aSHM | Desch et al. 2020; Jallades et al. 2017; Laura Pasqualucci, Trifonov, et al. 2011 |
147
-| [KLHL14](KLHL14) | 1 | Zhang et al. 2013 |
148
-| [KLHL6](KLHL6) | 1, aSHM | Panea et al. 2019; Ganapathi et al. 2016; Morin et al. 2011 |
149
-| [KMT2C](KMT2C) | 1 | Zhang et al. 2014; Sarkozy et al. 2021; Zhou et al. 2019; Zhang et al. 2013 |
150
-| [KMT2D](KMT2D) | 1 | Desch et al. 2020; Rossi et al. 2012; Grande et al. 2019; Morin et al. 2011; Beà et al. 2013 |
151
-| [KRAS](KRAS) | 1 | Lohr et al. 2012 |
152
-| [LCOR](LCOR) | 1 | Arthur et al. 2018 |
153
-| [LTB](LTB) | 1, aSHM | Desch et al. 2020; Chapuy et al. 2018; Panea et al. 2019 |
154
-| [MEF2B](MEF2B) | 1, aSHM | Beà et al. 2013; Morin et al. 2011 |
155
-| [MEF2C](MEF2C) | 1, aSHM | Arthur et al. 2018 |
156
-| [MGA](MGA) | 1 | Jallades et al. 2017; Zhang et al. 2013 |
157
-| [MPEG1](MPEG1) | 1 | Morin et al. 2013 |
158
-| [MS4A1](MS4A1) | 1, aSHM | Rushton et al. 2020; Mottok et al. 2019 |
159
-| [MTOR](MTOR) | 1 | Zhang et al. 2013; Panea et al. 2019 |
160
-| [MYC](MYC) | 1, aSHM | L. Pasqualucci et al. 2001; Jallades et al. 2017; Duns et al. 2021; Johnston and Carroll 1992 |
161
-| [MYD88](MYD88) | 1 | Yan et al. 2012; Ngo et al. 2011 |
162
-| [NFKBIA](NFKBIA) | 1 | Lake et al. 2009; Wienand et al. 2019; Russler-Germain et al. 2023 |
163
-| [NFKBIE](NFKBIE) | 1 | Morin et al. 2016; Pararajalingam et al. 2020; Mansouri et al. 2016 |
164
-| [NFKBIZ](NFKBIZ) | 1, noncoding | Morin et al. 2016 |
165
-| [NOL9](NOL9) | 1, aSHM | Spina et al. 2016; Schmitz et al. 2018 |
166
-| [NOTCH1](NOTCH1) | 1 | Beà et al. 2013; Laura Pasqualucci, Trifonov, et al. 2011; Love et al. 2012; Rossi et al. 2012 |
167
-| [NOTCH2](NOTCH2) | 1 | Rossi et al. 2012; Panea et al. 2019; Beà et al. 2013; Trøen et al. 2008 |
168
-| [OSBPL10](OSBPL10) | 1, aSHM | Arthur et al. 2018 |
169
-| [P2RY8](P2RY8) | 1 | Muppidi et al. 2014; Lohr et al. 2012 |
170
-| [PIM1](PIM1) | 1, aSHM | L. Pasqualucci et al. 2001; Duns et al. 2021; Burkhardt et al. 2022 |
171
-| [PIM2](PIM2) | 1, aSHM | Arthur et al. 2018; Reichel et al. 2015 |
172
-| [POU2AF1](POU2AF1) | 1, aSHM | Krysiak et al. 2017 |
173
-| [POU2F2](POU2F2) | 1 | Krysiak et al. 2017; Zhang et al. 2013 |
174
-| [PRDM1](PRDM1) | 1 | Laura Pasqualucci et al. 2006 |
175
-| [PTEN](PTEN) | 1 | Love et al. 2012 |
176
-| [PTPRD](PTPRD) | 1 | Spina et al. 2016 |
177
-| [RB1](RB1) | 1 | Zhang et al. 2014; Morin et al. 2013 |
178
-| [RFX7](RFX7) | 1 | Grande et al. 2019 |
179
-| [RHOA](RHOA) | 1 | Richter et al. 2012 |
180
-| [RRAGC](RRAGC) | 1 | Okosun et al. 2016 |
181
-| [S1PR2](S1PR2) | 1, aSHM | Morin et al. 2011; Muppidi et al. 2014 |
182
-| [SETD1B](SETD1B) | 1 | Reddy et al. 2017 |
183
-| [SF3B1](SF3B1) | 1 | Love et al. 2012 |
184
-| [SGK1](SGK1) | 1, aSHM | Duns et al. 2021; Morin et al. 2011 |
185
-| [SIN3A](SIN3A) | 1 | Grande et al. 2019; Rossi et al. 2012 |
186
-| [SMARCA4](SMARCA4) | 1 | Zhang et al. 2013; Nadeu et al. 2020; Krysiak et al. 2017; Richter et al. 2012 |
187
-| [SOCS1](SOCS1) | 1, aSHM | Weniger et al. 2006; Morin et al. 2011 |
188
-| [SPEN](SPEN) | 1 | Sarkozy et al. 2021; Rossi et al. 2012 |
189
-| [STAT3](STAT3) | 1 | Ohgami et al. 2014 |
190
-| [STAT6](STAT6) | 1 | Yildiz et al. 2015; Ritz et al. 2009 |
191
-| [TAF1](TAF1) | 1 | Spina et al. 2016; Morin et al. 2013 |
192
-| [TBL1XR1](TBL1XR1) | 1 | Rossi et al. 2012; Mareschal et al. 2016 |
193
-| [TET2](TET2) | 1 | Albuquerque et al. 2017; Panea et al. 2019 |
194
-| [TMEM30A](TMEM30A) | 1 | Morin et al. 2011 |
195
-| [TMSB4X](TMSB4X) | 1, aSHM | Albuquerque et al. 2017 |
196
-| [TNFAIP3](TNFAIP3) | 1 | Schmitz et al. 2009; Rossi et al. 2011; Compagno et al. 2009 |
197
-| [TNFRSF14](TNFRSF14) | 1 | Cheung et al. 2010; Spina et al. 2016 |
198
-| [TOX](TOX) | 1 | Reddy et al. 2017 |
199
-| [TP53](TP53) | 1 | Wilda et al. 2004; Rossi et al. 2012; Tiacci et al. 2018; Beà et al. 2013; Morin et al. 2011 |
200
-| [TRRAP](TRRAP) | 1 | Rossi et al. 2012; Parry et al. 2013 |
201
-| [UBE2A](UBE2A) | 1 | Reddy et al. 2017; Reichel et al. 2015 |
202
-| [UNC5C](UNC5C) | 1 | |
203
-| [USP7](USP7) | 1 | Grande et al. 2019 |
204
-| [VPS13B](VPS13B) | 1 | |
205
-| [WEE1](WEE1) | 1 | Schmitz et al. 2018; Reichel et al. 2015 |
206
-| [XPO1](XPO1) | 1 | Jardin et al. 2016; Mareschal et al. 2016 |
207
-| [ZC3H12A](ZC3H12A) | 1 | Arthur et al. 2018 |
208
-| [ZFP36L1](ZFP36L1) | 1, aSHM | Morin et al. 2011; Reichel et al. 2015; Panea et al. 2019 |
209
-| [ZNF292](ZNF292) | 1 | Zhang et al. 2013 |
210
-| [ZNF608](ZNF608) | 1, aSHM | Zhang et al. 2013; Krysiak et al. 2017 |
16
+|Gene|Tier| Relevant references|
17
+|:-:|:-:|:-|
18
+|[ACTB](ACTB)|1, aSHM|[@lohrDiscoveryPrioritizationSomatic2012a; @wienandGenomicAnalysesFlowsorted2019b]|
19
+|[ACTG1](ACTG1)|1, aSHM|[@deschGenotypingCirculatingTumor2020; @spinaGeneticsNodalMarginal2016b; @hubschmannMutationalMechanismsShaping2021b]|
20
+|[ARID1A](ARID1A)|1|[@zhangGeneticHeterogeneityDiffuse2013; @rossiCodingGenomeSplenic2012c; @krysiakRecurrentSomaticMutations2017b; @wienandGenomicAnalysesFlowsorted2019b; @loveGeneticLandscapeMutations2012]|
21
+|[ATM](ATM)|1|[@beaLandscapeSomaticMutations2013; @braggioGenomicAnalysisMarginal2012; @reddyGeneticFunctionalDrivers2017]|
22
+|[B2M](B2M)|1|[@morinFrequentMutationHistonemodifying2011; @reichelFlowSortingExome2015a; @pararajalingamCodingNoncodingDrivers2020]|
23
+|[BCL10](BCL10)|1|[@russler-germainMutationsAssociatedProgression2023b; @morinFrequentMutationHistonemodifying2011; @spinaGeneticsNodalMarginal2016b]|
24
+|[BCL2](BCL2)|1, aSHM|[@sarkozyMutationalLandscapeGray2021a; @morinFrequentMutationHistonemodifying2011; @tanakaFrequentIncidenceSomatic1992; @burkhardtClinicalRelevanceMolecular2022b]|
25
+|[BCL6](BCL6)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @loveGeneticLandscapeMutations2012]|
26
+|[BCL7A](BCL7A)|1, aSHM|[@arthurGenomewideDiscoverySomatic2018; @krysiakRecurrentSomaticMutations2017b; @reichelFlowSortingExome2015a; @grandeGenomewideDiscoverySomatic2019]|
27
+|[BIRC6](BIRC6)|1|[@sarkozyMutationalLandscapeGray2021a; @reddyGeneticFunctionalDrivers2017]|
28
+|[BRAF](BRAF)|1|[@loveGeneticLandscapeMutations2012; @tiacciBRAFMutationsHairycell2011a]|
29
+|[BTG1](BTG1)|1, aSHM|[@burkhardtClinicalRelevanceMolecular2022b; @morinFrequentMutationHistonemodifying2011; @sarkozyMutationalLandscapeGray2021a]|
30
+|[BTG2](BTG2)|1, aSHM|[@loveGeneticLandscapeMutations2012; @morinFrequentMutationHistonemodifying2011]|
31
+|[BTK](BTK)|1|[@krysiakRecurrentSomaticMutations2017b; @albuquerqueEnhancingKnowledgeDiscovery2017a]|
32
+|[CARD11](CARD11)|1|[@morinFrequentMutationHistonemodifying2011; @wuGeneticHeterogeneityPrimary2016; @paneaWholeGenomeLandscape2019; @lenzOncogenicCARD11Mutations2008; @yanBCRTLRSignaling2012a]|
33
+|[CCND3](CCND3)|1|[@jalladesExomeSequencingIdentifies2017; @morinFrequentMutationHistonemodifying2011; @richterRecurrentMutationID32012a; @deschGenotypingCirculatingTumor2020]|
34
+|[CD58](CD58)|1|[@morinFrequentMutationHistonemodifying2011; @schneiderAlterationsCD58Gene2015a]|
35
+|[CD70](CD70)|1|[@russler-germainMutationsAssociatedProgression2023b; @morinFrequentMutationHistonemodifying2011]|
36
+|[CD79B](CD79B)|1|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011]|
37
+|[CD83](CD83)|1, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @paneaWholeGenomeLandscape2019; @russler-germainMutationsAssociatedProgression2023b; @morinMutationalStructuralAnalysis2013]|
38
+|[CDKN2A](CDKN2A)|1|[@morinMutationalStructuralAnalysis2013; @spinaGeneticsNodalMarginal2016b; @grandeGenomewideDiscoverySomatic2019]|
39
+|[CIITA](CIITA)|1, aSHM|[@mottokGenomicAlterationsCIITA2015b; @morinFrequentMutationHistonemodifying2011]|
40
+|[CREBBP](CREBBP)|1|[@dunsCharacterizationDLBCLPMBL2021b; @parryWholeExomeSequencing2013; @loveGeneticLandscapeMutations2012; @pasqualucciInactivatingMutationsAcetyltransferase2011a]|
41
+|[CXCR4](CXCR4)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b; @paneaWholeGenomeLandscape2019; @khodabakhshiRecurrentTargetsAberrant2012]|
42
+|[CXCR5](CXCR5)|1|[@schmitzGeneticsPathogenesisDiffuse2018a; @mottokIntegrativeGenomicAnalysis2019b]|
43
+|[DDX3X](DDX3X)|1|[@schmitzBurkittLymphomaPathogenesis2012; @schmitzGeneticsPathogenesisDiffuse2018a; @mottokIntegrativeGenomicAnalysis2019b]|
44
+|[DTX1](DTX1)|1, aSHM|[@schmitzGeneticsPathogenesisDiffuse2018a; @gomezUltraDeepSequencingReveals2023; @rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019]|
45
+|[DUSP2](DUSP2)|1, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @morinMutationalStructuralAnalysis2013]|
46
+|[EBF1](EBF1)|1, aSHM|[@reichelFlowSortingExome2015a; @bohleRoleEarlyBcell2013; @thomasGeneticSubgroupsInform2023]|
47
+|[EEF1A1](EEF1A1)|1|[@hubschmannMutationalMechanismsShaping2021b; @reichelFlowSortingExome2015a]|
48
+|[EP300](EP300)|1|[@rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019; @pasqualucciInactivatingMutationsAcetyltransferase2011a]|
49
+|[ETS1](ETS1)|1, aSHM|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011]|
50
+|[ETV6](ETV6)|1, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
51
+|[EZH2](EZH2)|1|[@loveGeneticLandscapeMutations2012; @morinSomaticMutationsAltering2010a; @mottokIntegrativeGenomicAnalysis2019b]|
52
+|[FAS](FAS)|1|[@spinaGeneticsNodalMarginal2016b; @schollMutationsRegionFAS2007]|
53
+|[FBXO11](FBXO11)|1|[@parryWholeExomeSequencing2013; @hubschmannMutationalMechanismsShaping2021b; @richterRecurrentMutationID32012a]|
54
+|[FBXW7](FBXW7)|1|[@zhangGeneticHeterogeneityDiffuse2013]|
55
+|[FOXO1](FOXO1)|1|[@schmitzBurkittLymphomaPathogenesis2012; @dunsCharacterizationDLBCLPMBL2021b; @morinFrequentMutationHistonemodifying2011]|
56
+|[GNA13](GNA13)|1|[@morinFrequentMutationHistonemodifying2011; @loveGeneticLandscapeMutations2012; @reichelFlowSortingExome2015a]|
57
+|[GNAI2](GNAI2)|1|[@morinMutationalStructuralAnalysis2013; @grandeGenomewideDiscoverySomatic2019]|
58
+|[GRB2](GRB2)|1|[@paneaWholeGenomeLandscape2019; @pasqualucciAnalysisCodingGenome2011]|
59
+|[GRHPR](GRHPR)|1, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
60
+|[HIST1H1B](HIST1H1B)|1, aSHM|[@chapuyMolecularSubtypesDiffuse2018b; @sarkozyMutationalLandscapeGray2021a; @krysiakRecurrentSomaticMutations2017b]|
61
+|[HIST1H1C](HIST1H1C)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019]|
62
+|[HIST1H1D](HIST1H1D)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b; @jalladesExomeSequencingIdentifies2017; @morinMutationalStructuralAnalysis2013]|
63
+|[HIST1H1E](HIST1H1E)|1, aSHM|[@grandeGenomewideDiscoverySomatic2019; @morinMutationalStructuralAnalysis2013; @reichelFlowSortingExome2015a; @krysiakRecurrentSomaticMutations2017b]|
64
+|[HIST1H2AC](HIST1H2AC)|1, aSHM|[@morinMutationalStructuralAnalysis2013; @krysiakRecurrentSomaticMutations2017b]|
65
+|[HIST1H2AM](HIST1H2AM)|1, aSHM|[@paneaWholeGenomeLandscape2019; @krysiakRecurrentSomaticMutations2017b]|
66
+|[HIST1H2BC](HIST1H2BC)|1, aSHM|[@mottokIntegrativeGenomicAnalysis2019b; @reddyGeneticFunctionalDrivers2017; @krysiakRecurrentSomaticMutations2017b]|
67
+|[HIST1H2BK](HIST1H2BK)|1, aSHM|[@rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019]|
68
+|[HIST1H3B](HIST1H3B)|1, aSHM|[@reichelFlowSortingExome2015a; @zhangGeneticHeterogeneityDiffuse2013]|
69
+|[HIST2H2BE](HIST2H2BE)|1, aSHM|[@schmitzGeneticsPathogenesisDiffuse2018a]|
70
+|[HLA-A](HLA-A)|1|[@deschGenotypingCirculatingTumor2020]|
71
+|[HLA-B](HLA-B)|1|[@wienandGenomicAnalysesFlowsorted2019b]|
72
+|[HLA-C](HLA-C)|1|[@gomezUltraDeepSequencingReveals2023]|
73
+|[HLA-DMB](HLA-DMB)|1||
74
+|[HNRNPU](HNRNPU)|1, aSHM|[@reddyGeneticFunctionalDrivers2017; @paneaWholeGenomeLandscape2019]|
75
+|[HVCN1](HVCN1)|1|[@krysiakRecurrentSomaticMutations2017b]|
76
+|[IKZF3](IKZF3)|1|[@morinMutationalStructuralAnalysis2013; @paneaWholeGenomeLandscape2019]|
77
+|[IL4R](IL4R)|1, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @viganoSomaticIL4RMutations2018b]|
78
+|[IRF4](IRF4)|1, aSHM|[@mottokIntegrativeGenomicAnalysis2019b; @morinFrequentMutationHistonemodifying2011]|
79
+|[IRF8](IRF8)|1, aSHM|[@paneaWholeGenomeLandscape2019; @mottokIntegrativeGenomicAnalysis2019b; @morinFrequentMutationHistonemodifying2011]|
80
+|[ITPKB](ITPKB)|1, aSHM|[@schmitzGeneticsPathogenesisDiffuse2018a; @reichelFlowSortingExome2015a]|
81
+|[KLF2](KLF2)|1, aSHM|[@jalladesExomeSequencingIdentifies2017; @deschGenotypingCirculatingTumor2020; @pasqualucciAnalysisCodingGenome2011]|
82
+|[KLHL14](KLHL14)|1|[@zhangGeneticHeterogeneityDiffuse2013]|
83
+|[KLHL6](KLHL6)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019; @ganapathiGeneticLandscapeDural2016]|
84
+|[KMT2C](KMT2C)|1|[@zhangGeneticHeterogeneityDiffuse2013; @sarkozyMutationalLandscapeGray2021a; @zhangGenomicLandscapeMantle2014; @zhouSporadicEndemicBurkitt2019]|
85
+|[KMT2D](KMT2D)|1|[@grandeGenomewideDiscoverySomatic2019; @beaLandscapeSomaticMutations2013; @deschGenotypingCirculatingTumor2020; @rossiCodingGenomeSplenic2012c; @morinFrequentMutationHistonemodifying2011]|
86
+|[KRAS](KRAS)|1|[@lohrDiscoveryPrioritizationSomatic2012a]|
87
+|[LCOR](LCOR)|1|[@arthurGenomewideDiscoverySomatic2018]|
88
+|[LTB](LTB)|1, aSHM|[@paneaWholeGenomeLandscape2019; @chapuyMolecularSubtypesDiffuse2018b; @deschGenotypingCirculatingTumor2020]|
89
+|[MEF2B](MEF2B)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @beaLandscapeSomaticMutations2013]|
90
+|[MEF2C](MEF2C)|1, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
91
+|[MGA](MGA)|1|[@jalladesExomeSequencingIdentifies2017; @zhangGeneticHeterogeneityDiffuse2013]|
92
+|[MPEG1](MPEG1)|1|[@morinMutationalStructuralAnalysis2013]|
93
+|[MS4A1](MS4A1)|1, aSHM|[@mottokIntegrativeGenomicAnalysis2019b; @rushtonGeneticEvolutionaryPatterns2020]|
94
+|[MTOR](MTOR)|1|[@paneaWholeGenomeLandscape2019; @zhangGeneticHeterogeneityDiffuse2013]|
95
+|[MYC](MYC)|1, aSHM|[@jalladesExomeSequencingIdentifies2017; @johnstonCmycHypermutationBurkitt1992; @dunsCharacterizationDLBCLPMBL2021b; @pasqualucciHypermutationMultipleProtooncogenes2001a]|
96
+|[MYD88](MYD88)|1|[@ngoOncogenicallyActiveMYD882011a; @yanBCRTLRSignaling2012a]|
97
+|[NFKBIA](NFKBIA)|1|[@wienandGenomicAnalysesFlowsorted2019b; @lakeMutationsNFKBIAEncoding2009; @russler-germainMutationsAssociatedProgression2023b]|
98
+|[NFKBIE](NFKBIE)|1|[@mansouriFrequentNFKBIEDeletions2016; @morinGeneticLandscapesRelapsed2016; @pararajalingamCodingNoncodingDrivers2020]|
99
+|[NFKBIZ](NFKBIZ)|1, noncoding|[@morinGeneticLandscapesRelapsed2016]|
100
+|[NOL9](NOL9)|1, aSHM|[@spinaGeneticsNodalMarginal2016b; @schmitzGeneticsPathogenesisDiffuse2018a]|
101
+|[NOTCH1](NOTCH1)|1|[@rossiCodingGenomeSplenic2012c; @loveGeneticLandscapeMutations2012; @beaLandscapeSomaticMutations2013; @pasqualucciAnalysisCodingGenome2011]|
102
+|[NOTCH2](NOTCH2)|1|[@troenNOTCH2MutationsMarginal2008; @rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019; @beaLandscapeSomaticMutations2013]|
103
+|[OSBPL10](OSBPL10)|1, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
104
+|[P2RY8](P2RY8)|1|[@lohrDiscoveryPrioritizationSomatic2012a; @muppidiLossSignalingGa132014b]|
105
+|[PIM1](PIM1)|1, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @pasqualucciHypermutationMultipleProtooncogenes2001a; @burkhardtClinicalRelevanceMolecular2022b]|
106
+|[PIM2](PIM2)|1, aSHM|[@arthurGenomewideDiscoverySomatic2018; @reichelFlowSortingExome2015a]|
107
+|[POU2AF1](POU2AF1)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b]|
108
+|[POU2F2](POU2F2)|1|[@zhangGeneticHeterogeneityDiffuse2013; @krysiakRecurrentSomaticMutations2017b]|
109
+|[PRDM1](PRDM1)|1|[@pasqualucciInactivationPRDM1BLIMP12006a]|
110
+|[PTEN](PTEN)|1|[@loveGeneticLandscapeMutations2012]|
111
+|[PTPRD](PTPRD)|1|[@spinaGeneticsNodalMarginal2016b]|
112
+|[RB1](RB1)|1|[@zhangGenomicLandscapeMantle2014; @morinMutationalStructuralAnalysis2013]|
113
+|[RFX7](RFX7)|1|[@grandeGenomewideDiscoverySomatic2019]|
114
+|[RHOA](RHOA)|1|[@richterRecurrentMutationID32012a]|
115
+|[RRAGC](RRAGC)|1|[@okosunRecurrentMTORC1activatingRRAGC2016a]|
116
+|[S1PR2](S1PR2)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @muppidiLossSignalingGa132014b]|
117
+|[SETD1B](SETD1B)|1|[@reddyGeneticFunctionalDrivers2017]|
118
+|[SF3B1](SF3B1)|1|[@loveGeneticLandscapeMutations2012]|
119
+|[SGK1](SGK1)|1, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @morinFrequentMutationHistonemodifying2011]|
120
+|[SIN3A](SIN3A)|1|[@grandeGenomewideDiscoverySomatic2019; @rossiCodingGenomeSplenic2012c]|
121
+|[SMARCA4](SMARCA4)|1|[@zhangGeneticHeterogeneityDiffuse2013; @krysiakRecurrentSomaticMutations2017b; @nadeuGenomicEpigenomicInsights2020b; @richterRecurrentMutationID32012a]|
122
+|[SOCS1](SOCS1)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @wenigerMutationsTumorSuppressor2006a]|
123
+|[SPEN](SPEN)|1|[@rossiCodingGenomeSplenic2012c; @sarkozyMutationalLandscapeGray2021a]|
124
+|[STAT3](STAT3)|1|[@ohgamiSTAT3MutationsAre2014]|
125
+|[STAT6](STAT6)|1|[@yildizActivatingSTAT6Mutations2015c; @ritzRecurrentMutationsSTAT62009a]|
126
+|[TAF1](TAF1)|1|[@spinaGeneticsNodalMarginal2016b; @morinMutationalStructuralAnalysis2013]|
127
+|[TBL1XR1](TBL1XR1)|1|[@rossiCodingGenomeSplenic2012c; @mareschalWholeExomeSequencing2016]|
128
+|[TET2](TET2)|1|[@paneaWholeGenomeLandscape2019; @albuquerqueEnhancingKnowledgeDiscovery2017a]|
129
+|[TMEM30A](TMEM30A)|1|[@morinFrequentMutationHistonemodifying2011]|
130
+|[TMSB4X](TMSB4X)|1, aSHM|[@albuquerqueEnhancingKnowledgeDiscovery2017a]|
131
+|[TNFAIP3](TNFAIP3)|1|[@compagnoMutationsMultipleGenes2009a; @rossiAlterationBIRC3Multiple2011a; @schmitzTNFAIP3A20Tumor2009a]|
132
+|[TNFRSF14](TNFRSF14)|1|[@cheungAcquiredTNFRSF14Mutations2010a; @spinaGeneticsNodalMarginal2016b]|
133
+|[TOX](TOX)|1|[@reddyGeneticFunctionalDrivers2017]|
134
+|[TP53](TP53)|1|[@wildaInactivationARFMDM2p53Pathway2004; @beaLandscapeSomaticMutations2013; @tiacciPervasiveMutationsJAKSTAT2018b; @morinFrequentMutationHistonemodifying2011; @rossiCodingGenomeSplenic2012c]|
135
+|[TRRAP](TRRAP)|1|[@rossiCodingGenomeSplenic2012c; @parryWholeExomeSequencing2013]|
136
+|[UBE2A](UBE2A)|1|[@reichelFlowSortingExome2015a; @reddyGeneticFunctionalDrivers2017]|
137
+|[UNC5C](UNC5C)|1||
138
+|[USP7](USP7)|1|[@grandeGenomewideDiscoverySomatic2019]|
139
+|[VPS13B](VPS13B)|1||
140
+|[WEE1](WEE1)|1|[@reichelFlowSortingExome2015a; @schmitzGeneticsPathogenesisDiffuse2018a]|
141
+|[XPO1](XPO1)|1|[@mareschalWholeExomeSequencing2016; @jardinRecurrentMutationsExportin2016a]|
142
+|[ZC3H12A](ZC3H12A)|1|[@arthurGenomewideDiscoverySomatic2018]|
143
+|[ZFP36L1](ZFP36L1)|1, aSHM|[@reichelFlowSortingExome2015a; @paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011]|
144
+|[ZNF292](ZNF292)|1|[@zhangGeneticHeterogeneityDiffuse2013]|
145
+|[ZNF608](ZNF608)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b; @zhangGeneticHeterogeneityDiffuse2013]|
211 146
212 147
## Tier 2 DLBCL genes
213 148
214 149
### *198 total*
215 150
216
-| Gene | Tier | Relevant references |
217
-|:----------------------:|:------------:|:--------------------------------------------------------------------------------|
218
-| [ABI3BP](ABI3BP) | 2 | Morin et al. 2013 |
219
-| [ADAMTS1](ADAMTS1) | 2 | Hübschmann et al. 2021 |
220
-| [AICDA](AICDA) | 2, aSHM | Arthur et al. 2018 |
221
-| [ANKRD12](ANKRD12) | 2 | Hübschmann et al. 2021 |
222
-| [ANKRD17](ANKRD17) | 2 | Reddy et al. 2017 |
223
-| [ARID1B](ARID1B) | 2 | Reddy et al. 2017 |
224
-| [ARID5B](ARID5B) | 2 | Reddy et al. 2017; Gomez et al. 2023 |
225
-| [ATR](ATR) | 2 | Reddy et al. 2017 |
226
-| [BCL11A](BCL11A) | 2, aSHM | |
227
-| [BCOR](BCOR) | 2 | Nadeu et al. 2020; Jallades et al. 2017 |
228
-| [BCR](BCR) | 2, aSHM | |
229
-| [BIRC3](BIRC3) | 2, aSHM | Duns et al. 2021; Rossi et al. 2011; Arthur et al. 2018; Beà et al. 2013 |
230
-| [BLK](BLK) | 2, aSHM | |
231
-| [BRINP3](BRINP3) | 2 | Reddy et al. 2017 |
232
-| [BTBD3](BTBD3) | 2 | Reddy et al. 2017 |
233
-| [CADPS2](CADPS2) | 2 | Hübschmann et al. 2021 |
234
-| [CASP8](CASP8) | 2 | Reddy et al. 2017 |
235
-| [CBLB](CBLB) | 2 | Reddy et al. 2017 |
236
-| [CCL4](CCL4) | 2 | Chapuy et al. 2018 |
237
-| [CD22](CD22) | 2 | Reddy et al. 2017 |
238
-| [CD274](CD274) | 2 | Morin et al. 2011 |
239
-| [CD36](CD36) | 2 | Laura Pasqualucci, Trifonov, et al. 2011 |
240
-| [CD44](CD44) | 2, aSHM | Arthur et al. 2018 |
241
-| [CD74](CD74) | 2, aSHM | Arthur et al. 2018 |
242
-| [CDC73](CDC73) | 2 | Reddy et al. 2017; Love et al. 2012 |
243
-| [CDH9](CDH9) | 2 | Morin et al. 2013 |
244
-| [CHD1](CHD1) | 2 | Reddy et al. 2017 |
245
-| [CHD8](CHD8) | 2 | Grande et al. 2019; Reddy et al. 2017 |
246
-| [CHST2](CHST2) | 2 | Reddy et al. 2017 |
247
-| [CNOT2](CNOT2) | 2 | Hübschmann et al. 2021 |
248
-| [CNTNAP5](CNTNAP5) | 2 | Morin et al. 2013 |
249
-| [COQ7](COQ7) | 2 | Chapuy et al. 2018 |
250
-| [CRIP1](CRIP1) | 2 | Chapuy et al. 2018 |
251
-| [DAZAP1](DAZAP1) | 2 | Pararajalingam et al. 2020 |
252
-| [DCAF6](DCAF6) | 2 | Reddy et al. 2017 |
253
-| [DDX10](DDX10) | 2 | Reddy et al. 2017 |
254
-| [DHX16](DHX16) | 2 | Hübschmann et al. 2021 |
255
-| [DICER1](DICER1) | 2 | Reddy et al. 2017 |
256
-| [DNAH5](DNAH5) | 2 | Morin et al. 2013; Jallades et al. 2017 |
257
-| [DNM2](DNM2) | 2 | Hübschmann et al. 2021 |
258
-| [DNMT3A](DNMT3A) | 2 | Reddy et al. 2017 |
259
-| [DOCK1](DOCK1) | 2 | Chapuy et al. 2018 |
260
-| [DSG4](DSG4) | 2 | Morin et al. 2013 |
261
-| [EIF2AK3](EIF2AK3) | 2, aSHM | |
262
-| [EZR](EZR) | 2, aSHM | Desch et al. 2020 |
263
-| [FAM102A](FAM102A) | 2, aSHM | |
264
-| [FAM38B](FAM38B) | 2 | Morin et al. 2013 |
265
-| [FANK1](FANK1) | 2, aSHM | |
266
-| [FAT4](FAT4) | 2 | Parry et al. 2013; Morin et al. 2013; Zhang et al. 2014 |
267
-| [FCRL3](FCRL3) | 2, aSHM | |
268
-| [FNBP1](FNBP1) | 2, aSHM | |
269
-| [FNDC1](FNDC1) | 2 | Morin et al. 2013 |
270
-| [FOXC1](FOXC1) | 2 | Schmitz et al. 2018 |
271
-| [FOXP1](FOXP1) | 2, aSHM | Reddy et al. 2017 |
272
-| [FUBP1](FUBP1) | 2 | Reddy et al. 2017 |
273
-| [FUT5](FUT5) | 2 | Chapuy et al. 2018 |
274
-| [GABRA2](GABRA2) | 2 | Chapuy et al. 2018 |
275
-| [GAK](GAK) | 2 | Hübschmann et al. 2021 |
276
-| [GNAS](GNAS) | 2 | Reddy et al. 2017 |
277
-| [GOLGA5](GOLGA5) | 2 | Reddy et al. 2017 |
278
-| [GPC5](GPC5) | 2 | Schmitz et al. 2018 |
279
-| [GSG2](GSG2) | 2 | Schmitz et al. 2018 |
280
-| [HDAC7](HDAC7) | 2 | Morin et al. 2013 |
281
-| [HIST1H2AG](HIST1H2AG) | 2, aSHM | Morin et al. 2013; Rossi et al. 2012; Panea et al. 2019; Krysiak et al. 2017 |
282
-| [HLA-DMA](HLA-DMA) | 2 | |
283
-| [HLA-DQA1](HLA-DQA1) | 2 | Hübschmann et al. 2021 |
284
-| [HNF1B](HNF1B) | 2 | Laura Pasqualucci, Trifonov, et al. 2011 |
285
-| [HNRNPD](HNRNPD) | 2 | |
286
-| [HNRNPH1](HNRNPH1) | 2, noncoding | Pararajalingam et al. 2020 |
287
-| [HRAS](HRAS) | 2 | Jallades et al. 2017; Reddy et al. 2017 |
288
-| [ID3](ID3) | 2 | Richter et al. 2012; Spina et al. 2016; Schmitz et al. 2012 |
289
-| [IER2](IER2) | 2 | Morin et al. 2013 |
290
-| [IFNGR1](IFNGR1) | 2 | Morin et al. 2013 |
291
-| [IGLL5](IGLL5) | 2, aSHM | Russler-Germain et al. 2023; Desch et al. 2020; Panea et al. 2019 |
292
-| [IKBKB](IKBKB) | 2 | Reddy et al. 2017; Rossi et al. 2011; Wienand et al. 2019 |
293
-| [IKBKE](IKBKE) | 2 | Hübschmann et al. 2021 |
294
-| [IL16](IL16) | 2 | |
295
-| [IL6](IL6) | 2 | Chapuy et al. 2018 |
296
-| [INO80](INO80) | 2 | Zhang et al. 2013 |
297
-| [IRAG2](IRAG2) | 2, aSHM | |
298
-| [IRF1](IRF1) | 2, aSHM | Hübschmann et al. 2021 |
299
-| [JAK1](JAK1) | 2 | Zhang et al. 2013; Mottok et al. 2019 |
300
-| [JAK3](JAK3) | 2 | Zhang et al. 2013 |
301
-| [JUNB](JUNB) | 2 | Reddy et al. 2017; Mottok et al. 2019 |
302
-| [KCMF1](KCMF1) | 2 | Reddy et al. 2017 |
303
-| [KLHL21](KLHL21) | 2 | Schmitz et al. 2018 |
304
-| [LAMA5](LAMA5) | 2 | Schmitz et al. 2018 |
305
-| [LAPTM5](LAPTM5) | 2, aSHM | Hübschmann et al. 2021 |
306
-| [LIN54](LIN54) | 2 | Reddy et al. 2017 |
307
-| [LPP](LPP) | 2, aSHM | Arthur et al. 2018 |
308
-| [LRP12](LRP12) | 2 | Hübschmann et al. 2021 |
309
-| [LRRN3](LRRN3) | 2 | Sarkozy et al. 2021; Morin et al. 2013 |
310
-| [LYN](LYN) | 2 | Chapuy et al. 2018 |
311
-| [MAGT1](MAGT1) | 2 | Reddy et al. 2017 |
312
-| [MALAT1](MALAT1) | 2, aSHM | Arthur et al. 2018 |
313
-| [MAP2K1](MAP2K1) | 2 | Shin et al. 2015; Louissaint et al. 2016 |
314
-| [MAP4K4](MAP4K4) | 2 | Reddy et al. 2017 |
315
-| [MARK1](MARK1) | 2 | Reddy et al. 2017 |
316
-| [MCL1](MCL1) | 2 | Panea et al. 2019; Reddy et al. 2017; Duns et al. 2021 |
317
-| [MECOM](MECOM) | 2 | Reddy et al. 2017 |
318
-| [MET](MET) | 2 | Reddy et al. 2017 |
319
-| [MIR142](MIR142) | 2, aSHM | Grande et al. 2019; Kwanhian et al. 2012 |
320
-| [MIR155HG](MIR155HG) | 2, aSHM | |
321
-| [MPDZ](MPDZ) | 2 | Reichel et al. 2015; Morin et al. 2013 |
322
-| [MSH2](MSH2) | 2 | Reddy et al. 2017 |
323
-| [MSH6](MSH6) | 2 | Reddy et al. 2017 |
324
-| [MYB](MYB) | 2 | Reddy et al. 2017; Desch et al. 2020 |
325
-| [MYBPC2](MYBPC2) | 2 | Schmitz et al. 2018 |
326
-| [MYO1E](MYO1E) | 2, aSHM | |
327
-| [MYOM2](MYOM2) | 2 | Laura Pasqualucci, Trifonov, et al. 2011 |
328
-| [N2RF2](N2RF2) | 2 | Hübschmann et al. 2021 |
329
-| [NANOG](NANOG) | 2 | Chapuy et al. 2018 |
330
-| [NAV1](NAV1) | 2 | Chapuy et al. 2018 |
331
-| [NCOA3](NCOA3) | 2, aSHM | |
332
-| [NCOR1](NCOR1) | 2 | Reddy et al. 2017 |
333
-| [NCOR2](NCOR2) | 2 | Schmitz et al. 2012; Spina et al. 2016; Sarkozy et al. 2021 |
334
-| [NEAT1](NEAT1) | 2, aSHM | Arthur et al. 2018 |
335
-| [NF1](NF1) | 2 | Reddy et al. 2017 |
336
-| [NFKB1](NFKB1) | 2 | |
337
-| [NFKB2](NFKB2) | 2 | Reddy et al. 2017; Mottok et al. 2019 |
338
-| [NLRC5](NLRC5) | 2 | |
339
-| [NLRP5](NLRP5) | 2 | Morin et al. 2013 |
340
-| [NLRP8](NLRP8) | 2 | Chapuy et al. 2018 |
341
-| [ODZ3](ODZ3) | 2 | Morin et al. 2013 |
342
-| [P2RX5](P2RX5) | 2, aSHM | Morin et al. 2013 |
343
-| [PAPOLG](PAPOLG) | 2 | Schmitz et al. 2018 |
344
-| [PASK](PASK) | 2 | Morin et al. 2013 |
345
-| [PAX5](PAX5) | 2, aSHM | L. Pasqualucci et al. 2001 |
346
-| [PCBP1](PCBP1) | 2 | Schmitz et al. 2012 |
347
-| [PCDHB11](PCDHB11) | 2 | Morin et al. 2013 |
348
-| [PCLO](PCLO) | 2 | Lohr et al. 2012 |
349
-| [PDE4DIP](PDE4DIP) | 2 | Chapuy et al. 2018 |
350
-| [PDS5B](PDS5B) | 2 | Hübschmann et al. 2021; Morin et al. 2013 |
351
-| [PHF6](PHF6) | 2 | Reddy et al. 2017; Thomas et al. 2023 |
352
-| [PIK3CD](PIK3CD) | 2 | Reddy et al. 2017 |
353
-| [PIK3R1](PIK3R1) | 2 | Zhang et al. 2013; Panea et al. 2019 |
354
-| [PKD1](PKD1) | 2 | Morin et al. 2013 |
355
-| [PNPO](PNPO) | 2 | Hübschmann et al. 2021 |
356
-| [POGZ](POGZ) | 2 | Morin et al. 2013 |
357
-| [PPP1R9B](PPP1R9B) | 2 | |
358
-| [PRKCB](PRKCB) | 2 | Morin et al. 2013 |
359
-| [PRKDC](PRKDC) | 2 | Hübschmann et al. 2021; Schmitz et al. 2018 |
360
-| [PRPS1](PRPS1) | 2 | Chapuy et al. 2018 |
361
-| [PTMA](PTMA) | 2, aSHM | |
362
-| [PTPN1](PTPN1) | 2, aSHM | Gunawardana et al. 2014 |
363
-| [PTPN23](PTPN23) | 2 | Morin et al. 2013 |
364
-| [PTPN6](PTPN6) | 2 | Reddy et al. 2017 |
365
-| [PTPRK](PTPRK) | 2 | Reddy et al. 2017 |
366
-| [RAC2](RAC2) | 2 | Hübschmann et al. 2021; Panea et al. 2019 |
367
-| [RAD9A](RAD9A) | 2 | Chapuy et al. 2018 |
368
-| [RARA](RARA) | 2 | Reddy et al. 2017 |
369
-| [RCC](RCC) | 2, aSHM | |
370
-| [RFTN1](RFTN1) | 2, aSHM | Duns et al. 2021; Arthur et al. 2018 |
371
-| [RFXAP](RFXAP) | 2 | |
372
-| [RHEX](RHEX) | 2, aSHM | |
373
-| [RHOH](RHOH) | 2, aSHM | L. Pasqualucci et al. 2001 |
374
-| [RUBCNL](RUBCNL) | 2, aSHM | |
375
-| [RUNX1](RUNX1) | 2 | Reddy et al. 2017 |
376
-| [SAMD9L](SAMD9L) | 2 | Morin et al. 2013 |
377
-| [SARM1](SARM1) | 2 | Morin et al. 2013 |
378
-| [SEL1L3](SEL1L3) | 2, aSHM | |
379
-| [SEPTIN9](SEPTIN9) | 2, aSHM | |
380
-| [SERPINA9](SERPINA9) | 2, aSHM | Arthur et al. 2018 |
381
-| [SETD2](SETD2) | 2 | Zhang et al. 2013 |
382
-| [SETD5](SETD5) | 2 | Reddy et al. 2017; Tiacci et al. 2018 |
383
-| [SIAH2](SIAH2) | 2 | Reichel et al. 2015; Hübschmann et al. 2021 |
384
-| [SLC34A2](SLC34A2) | 2 | Hübschmann et al. 2021 |
385
-| [SMEK1](SMEK1) | 2 | Chapuy et al. 2018 |
386
-| [SRRM2](SRRM2) | 2 | Russler-Germain et al. 2023; Morin et al. 2013 |
387
-| [ST6GAL1](ST6GAL1) | 2, aSHM | Arthur et al. 2018 |
388
-| [STAT5B](STAT5B) | 2 | Zhang et al. 2013; Tiacci et al. 2018 |
389
-| [SYK](SYK) | 2 | Reddy et al. 2017 |
390
-| [SYPL1](SYPL1) | 2 | Morin et al. 2013 |
391
-| [TAP1](TAP1) | 2 | Schmitz et al. 2018 |
392
-| [TBC1D4](TBC1D4) | 2, aSHM | Arthur et al. 2018 |
393
-| [TCL1A](TCL1A) | 2, aSHM | Grande et al. 2019 |
394
-| [TGFBR2](TGFBR2) | 2 | Reddy et al. 2017 |
395
-| [TIPARP](TIPARP) | 2 | Reddy et al. 2017 |
396
-| [TLR2](TLR2) | 2 | Chapuy et al. 2018; Beà et al. 2013 |
397
-| [TRAF3](TRAF3) | 2 | Rossi et al. 2011; Otto et al. 2012; Laura Pasqualucci, Trifonov, et al. 2011 |
398
-| [TRAF6](TRAF6) | 2 | Hübschmann et al. 2021 |
399
-| [TRIP12](TRIP12) | 2 | |
400
-| [UBE2J1](UBE2J1) | 2, aSHM | |
401
-| [UBR5](UBR5) | 2 | Pararajalingam et al. 2020; Zhang et al. 2013 |
402
-| [UNC5B](UNC5B) | 2 | Hübschmann et al. 2021 |
403
-| [UNC5D](UNC5D) | 2 | |
404
-| [WAC](WAC) | 2 | Rossi et al. 2012; Reddy et al. 2017 |
405
-| [WDFY3](WDFY3) | 2 | Morin et al. 2013 |
406
-| [WNK1](WNK1) | 2 | Hübschmann et al. 2021; Thomas et al. 2023; Jallades et al. 2017 |
407
-| [XBP1](XBP1) | 2, aSHM | |
408
-| [YY1](YY1) | 2 | Reddy et al. 2017 |
409
-| [ZBTB7A](ZBTB7A) | 2 | Burkhardt et al. 2022; Reddy et al. 2017 |
410
-| [ZCCHC7](ZCCHC7) | 2, aSHM | Arthur et al. 2018 |
411
-| [ZEB2](ZEB2) | 2 | Zhang et al. 2013 |
412
-| [ZFAT](ZFAT) | 2 | Reddy et al. 2017 |
413
-| [ZFX](ZFX) | 2 | Reddy et al. 2017 |
414
-| [ZNF217](ZNF217) | 2 | Hübschmann et al. 2021; Reichel et al. 2015 |
415
-| [ZNF423](ZNF423) | 2 | Chapuy et al. 2018 |
416
-
417
-# References
418
-
419
-<div id="refs" class="references csl-bib-body hanging-indent">
420
-
421
-<div id="ref-albuquerqueEnhancingKnowledgeDiscovery2017a"
422
-class="csl-entry">
423
-
424
-Albuquerque, Marco A., Bruno M. Grande, Elie J. Ritch, Prasath
425
-Pararajalingam, Selin Jessa, Martin Krzywinski, Jasleen K. Grewal,
426
-Sohrab P. Shah, Paul C. Boutros, and Ryan D. Morin. 2017. “Enhancing
427
-Knowledge Discovery from Cancer Genomics Data with Galaxy.”
428
-*GigaScience* 6 5: 1–13. <a href=https://doi.org/10.1093/gigascience/gix015>https://doi.org/10.1093/gigascience/gix015</a>.
429
-
430
-</div>
431
-
432
-<div id="ref-arthurGenomewideDiscoverySomatic2018" class="csl-entry">
433
-
434
-Arthur, Sarah E., Aixiang Jiang, Bruno M. Grande, Miguel Alcaide, Razvan
435
-Cojocaru, Christopher K. Rushton, Anja Mottok, et al. 2018. “Genome-Wide
436
-Discovery of Somatic Regulatory Variants in Diffuse Large <span
437
-class="nocase">B-cell</span> Lymphoma.” *Nature Communications* 9 1:
438
-4001. <https://doi.org/10.1038/s41467-018-06354-3>.
439
-
440
-</div>
441
-
442
-<div id="ref-beaLandscapeSomaticMutations2013" class="csl-entry">
443
-
444
-Beà, Sílvia, Rafael Valdés-Mas, Alba Navarro, Itziar Salaverria, David
445
-Martín-Garcia, Pedro Jares, Eva Giné, et al. 2013. “Landscape of Somatic
446
-Mutations and Clonal Evolution in Mantle Cell Lymphoma.” *Proceedings of
447
-the National Academy of Sciences* 110 45: 18250–55.
448
-<https://doi.org/10.1073/pnas.1314608110>.
449
-
450
-</div>
451
-
452
-<div id="ref-bohleRoleEarlyBcell2013" class="csl-entry">
453
-
454
-Bohle, V., C. Döring, M.-L. Hansmann, and R. Küppers. 2013. “Role of
455
-Early <span class="nocase">B-cell</span> Factor 1 EBF1 in Hodgkin
456
-Lymphoma.” *Leukemia* 27 3: 671–79.
457
-<https://doi.org/10.1038/leu.2012.280>.
458
-
459
-</div>
460
-
461
-<div id="ref-braggioGenomicAnalysisMarginal2012" class="csl-entry">
462
-
463
-Braggio, Esteban, Ahmet Dogan, Jonathan J. Keats, Wee J. Chng, Gaofeng
464
-Huang, Julie M. Matthews, Matthew J. Maurer, et al. 2012. “Genomic
465
-Analysis of Marginal Zone and Lymphoplasmacytic Lymphomas Identified
466
-Common and Disease-Specific Abnormalities.” *Modern Pathology: An
467
-Official Journal of the United States and Canadian Academy of Pathology,
468
-Inc* 25 5: 651–60. <https://doi.org/10.1038/modpathol.2011.213>.
469
-
470
-</div>
471
-
472
-<div id="ref-burkhardtClinicalRelevanceMolecular2022b"
473
-class="csl-entry">
474
-
475
-Burkhardt, Birgit, Ulf Michgehl, Jonas Rohde, Tabea Erdmann, Philipp
476
-Berning, Katrin Reutter, Marius Rohde, et al. 2022. “Clinical Relevance
477
-of Molecular Characteristics in Burkitt Lymphoma Differs According to
478
-Age.” *Nature Communications* 13 1: 3881.
479
-<https://doi.org/10.1038/s41467-022-31355-8>.
480
-
481
-</div>
482
-
483
-<div id="ref-chapuyMolecularSubtypesDiffuse2018b" class="csl-entry">
484
-
485
-Chapuy, Bjoern, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Atanas
486
-Kamburov, Robert A. Redd, Mike S. Lawrence, et al. 2018. “Molecular
487
-Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct
488
-Pathogenic Mechanisms and Outcomes.” *Nature Medicine* 24 5: 679–90.
489
-<https://doi.org/10.1038/s41591-018-0016-8>.
490
-
491
-</div>
492
-
493
-<div id="ref-cheungAcquiredTNFRSF14Mutations2010a" class="csl-entry">
494
-
495
-Cheung, K.-John J., Nathalie A. Johnson, Joslynn G. Affleck, Tesa
496
-Severson, Christian Steidl, Susana Ben-Neriah, Jacqueline Schein, et al.
497
-2010. “Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated
498
-with Worse Prognosis.” *Cancer Research* 70 22: 9166–74.
499
-<https://doi.org/10.1158/0008-5472.CAN-10-2460>.
500
-
501
-</div>
502
-
503
-<div id="ref-compagnoMutationsMultipleGenes2009a" class="csl-entry">
504
-
505
-Compagno, Mara, Wei Keat Lim, Adina Grunn, Subhadra V. Nandula, Manisha
506
-Brahmachary, Qiong Shen, Francesco Bertoni, et al. 2009. “Mutations of
507
-Multiple Genes Cause Deregulation of <span
508
-class="nocase">NF-kappaB</span> in Diffuse Large <span
509
-class="nocase">B-cell</span> Lymphoma.” *Nature* 459 7247: 717–21.
510
-<https://doi.org/10.1038/nature07968>.
511
-
512
-</div>
513
-
514
-<div id="ref-deschGenotypingCirculatingTumor2020" class="csl-entry">
515
-
516
-Desch, Ann-Kathrin, Kristin Hartung, Ante Botzen, Alexander Brobeil,
517
-Mathias Rummel, Lars Kurch, Thomas Georgi, et al. 2020. “Genotyping
518
-Circulating Tumor DNA of Pediatric Hodgkin Lymphoma.” *Leukemia* 34 1:
519
-151–66. <https://doi.org/10.1038/s41375-019-0541-6>.
520
-
521
-</div>
522
-
523
-<div id="ref-dunsCharacterizationDLBCLPMBL2021b" class="csl-entry">
524
-
525
-Duns, Gerben, Elena Viganò, Daisuke Ennishi, Clementine Sarkozy, Stacy
526
-S. Hung, Elizabeth Chavez, Katsuyoshi Takata, et al. 2021.
527
-“Characterization of DLBCL with a PMBL Gene Expression Signature.”
528
-*Blood* 138 2: 136–48. <https://doi.org/10.1182/blood.2020007683>.
529
-
530
-</div>
531
-
532
-<div id="ref-ganapathiGeneticLandscapeDural2016" class="csl-entry">
533
-
534
-Ganapathi, Karthik A., Vaidehi Jobanputra, Fabio Iwamoto, Preti Jain,
535
-Jinli Chen, Luciano Cascione, Odelia Nahum, et al. 2016. “The Genetic
536
-Landscape of Dural Marginal Zone Lymphomas.” *Oncotarget* 7 28:
537
-43052–61. <https://doi.org/10.18632/oncotarget.9678>.
538
-
539
-</div>
540
-
541
-<div id="ref-gomezUltraDeepSequencingReveals2023" class="csl-entry">
542
-
543
-Gomez, Felicia, Bryan Fisk, Joshua F. McMichael, Matthew Mosior,
544
-Jennifer A. Foltz, Zachary L. Skidmore, Eric J. Duncavage, et al. 2023.
545
-“Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical
546
-Hodgkin Lymphoma.” *Cancer Research Communications* 3 11: 2312–30.
547
-<https://doi.org/10.1158/2767-9764.CRC-23-0140>.
548
-
549
-</div>
550
-
551
-<div id="ref-grandeGenomewideDiscoverySomatic2019" class="csl-entry">
552
-
553
-Grande, Bruno M., Daniela S. Gerhard, Aixiang Jiang, Nicholas B. Griner,
554
-Jeremy S. Abramson, Thomas B. Alexander, Hilary Allen, et al. 2019.
555
-“Genome-Wide Discovery of Somatic Coding and Noncoding Mutations in
556
-Pediatric Endemic and Sporadic Burkitt Lymphoma.” *Blood* 133 12:
557
-1313–24. <https://doi.org/10.1182/blood-2018-09-871418>.
558
-
559
-</div>
560
-
561
-<div id="ref-gunawardanaRecurrentSomaticMutations2014c"
562
-class="csl-entry">
563
-
564
-Gunawardana, Jay, Fong Chun Chan, Adèle Telenius, Bruce Woolcock, Robert
565
-Kridel, King L. Tan, Susana Ben-Neriah, et al. 2014. “Recurrent Somatic
566
-Mutations of PTPN1 in Primary Mediastinal B Cell Lymphoma and Hodgkin
567
-Lymphoma.” *Nature Genetics* 46 4: 329–35.
568
-<https://doi.org/10.1038/ng.2900>.
569
-
570
-</div>
571
-
572
-<div id="ref-hubschmannMutationalMechanismsShaping2021b"
573
-class="csl-entry">
574
-
575
-Hübschmann, Daniel, Kortine Kleinheinz, Rabea Wagener, Stephan H.
576
-Bernhart, Cristina López, Umut H. Toprak, Stephanie Sungalee, et al.
577
-2021. “Mutational Mechanisms Shaping the Coding and Noncoding Genome of
578
-Germinal Center Derived <span class="nocase">B-cell</span> Lymphomas.”
579
-*Leukemia* 35 7: 2002–16.
580
-<https://doi.org/10.1038/s41375-021-01251-z>.
581
-
582
-</div>
583
-
584
-<div id="ref-jalladesExomeSequencingIdentifies2017" class="csl-entry">
585
-
586
-Jallades, Laurent, Lucile Baseggio, Pierre Sujobert, Sarah Huet, Kaddour
587
-Chabane, Evelyne Callet-Bauchu, Aurélie Verney, et al. 2017. “Exome
588
-Sequencing Identifies Recurrent BCOR Alterations and the Absence of
589
-KLF2, TNFAIP3 and MYD88 Mutations in Splenic Diffuse Red Pulp Small
590
-<span class="nocase">B-cell</span> Lymphoma.” *Haematologica* 102 10:
591
-1758–66. <https://doi.org/10.3324/haematol.2016.160192>.
592
-
593
-</div>
594
-
595
-<div id="ref-jardinRecurrentMutationsExportin2016a" class="csl-entry">
596
-
597
-Jardin, Fabrice, Anais Pujals, Laura Pelletier, Elodie Bohers, Vincent
598
-Camus, Sylvain Mareschal, Sydney Dubois, et al. 2016. “Recurrent
599
-Mutations of the Exportin 1 Gene XPO1 and Their Impact on Selective
600
-Inhibitor of Nuclear Export Compounds Sensitivity in Primary Mediastinal
601
-<span class="nocase">B-cell</span> Lymphoma.” *American Journal of
602
-Hematology* 91 9: 923–30. <https://doi.org/10.1002/ajh.24451>.
603
-
604
-</div>
605
-
606
-<div id="ref-johnstonCmycHypermutationBurkitt1992" class="csl-entry">
607
-
608
-Johnston, J. M., and W. L. Carroll. 1992. “C-Myc Hypermutation in
609
-Burkitt’s Lymphoma.” *Leukemia & Lymphoma* 8 6: 431–39.
610
-<https://doi.org/10.3109/10428199209051025>.
611
-
612
-</div>
613
-
614
-<div id="ref-khodabakhshiRecurrentTargetsAberrant2012"
615
-class="csl-entry">
616
-
617
-Khodabakhshi, Alireza Hadj, Ryan D. Morin, Anthony P. Fejes, Andrew J.
618
-Mungall, Karen L. Mungall, Madison Bolger-Munro, Nathalie A. Johnson, et
619
-al. 2012. “Recurrent Targets of Aberrant Somatic Hypermutation in
620
-Lymphoma.” *Oncotarget* 3 11: 1308–19.
621
-<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717795/>.
622
-
623
-</div>
624
-
625
-<div id="ref-krysiakRecurrentSomaticMutations2017b" class="csl-entry">
626
-
627
-Krysiak, Kilannin, Felicia Gomez, Brian S. White, Matthew Matlock,
628
-Christopher A. Miller, Lee Trani, Catrina C. Fronick, et al. 2017.
629
-“Recurrent Somatic Mutations Affecting <span
630
-class="nocase">B-cell</span> Receptor Signaling Pathway Genes in
631
-Follicular Lymphoma.” *Blood* 129 4: 473–83.
632
-<https://doi.org/10.1182/blood-2016-07-729954>.
633
-
634
-</div>
635
-
636
-<div id="ref-kwanhianMicroRNA142Mutated202012b" class="csl-entry">
637
-
638
-Kwanhian, Wiyada, Dido Lenze, Julia Alles, Natalie Motsch, Stephanie
639
-Barth, Celina Döll, Jochen Imig, et al. 2012. “MicroRNA-142 Is Mutated
640
-in about 20% of Diffuse Large <span class="nocase">B-cell</span>
641
-Lymphoma.” *Cancer Medicine* 1 2: 141–55.
642
-<https://doi.org/10.1002/cam4.29>.
643
-
644
-</div>
645
-
646
-<div id="ref-lakeMutationsNFKBIAEncoding2009" class="csl-entry">
647
-
648
-Lake, Annette, Lesley A. Shield, Pablo Cordano, Daniel T. Y. Chui, Julie
649
-Osborne, Shauna Crae, Katherine S. Wilson, et al. 2009. “Mutations of
650
-NFKBIA, Encoding IkappaB Alpha, Are a Recurrent Finding in Classical
651
-Hodgkin Lymphoma but Are Not a Unifying Feature of Non-<span
652
-class="nocase">EBV-associated</span> Cases.” *International Journal of
653
-Cancer* 125 6: 1334–42. <https://doi.org/10.1002/ijc.24502>.
654
-
655
-</div>
656
-
657
-<div id="ref-lenzOncogenicCARD11Mutations2008" class="csl-entry">
658
-
659
-Lenz, Georg, R Eric Davis, Vu N Ngo, Lloyd Lam, Thaddeus C George,
660
-George W Wright, Sandeep S Dave, et al. 2008. “Oncogenic CARD11
661
-Mutations in Human Diffuse Large B Cell Lymphoma.” *Science* 319 5870:
662
-1676–79.
663
-
664
-</div>
665
-
666
-<div id="ref-lohrDiscoveryPrioritizationSomatic2012a" class="csl-entry">
667
-
668
-Lohr, Jens G., Petar Stojanov, Michael S. Lawrence, Daniel Auclair,
669
-Bjoern Chapuy, Carrie Sougnez, Peter Cruz-Gordillo, et al. 2012.
670
-“Discovery and Prioritization of Somatic Mutations in Diffuse Large
671
-<span class="nocase">B-cell</span> Lymphoma DLBCL by Whole-Exome
672
-Sequencing.” *Proceedings of the National Academy of Sciences of the
673
-United States of America* 109 10: 3879–84.
674
-<https://doi.org/10.1073/pnas.1121343109>.
675
-
676
-</div>
677
-
678
-<div id="ref-louissaintPediatrictypeNodalFollicular2016a"
679
-class="csl-entry">
680
-
681
-Louissaint, Abner, Kristian T. Schafernak, Julia T. Geyer, Alexandra E.
682
-Kovach, Mahmoud Ghandi, Dita Gratzinger, Christine G. Roth, et al. 2016.
683
-“Pediatric-Type Nodal Follicular Lymphoma: A Biologically Distinct
684
-Lymphoma with Frequent MAPK Pathway Mutations.” *Blood* 128 8:
685
-1093–1100. <https://doi.org/10.1182/blood-2015-12-682591>.
686
-
687
-</div>
688
-
689
-<div id="ref-loveGeneticLandscapeMutations2012" class="csl-entry">
690
-
691
-Love, Cassandra, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney
692
-Miles, Kristy L. Richards, et al. 2012. “The Genetic Landscape of
693
-Mutations in Burkitt Lymphoma.” *Nature Genetics* 44 12: 1321–25.
694
-<https://doi.org/10.1038/ng.2468>.
695
-
696
-</div>
697
-
698
-<div id="ref-mansouriFrequentNFKBIEDeletions2016" class="csl-entry">
699
-
700
-Mansouri, Larry, Daniel Noerenberg, Emma Young, Elena Mylonas, Maysaa
701
-Abdulla, Mareike Frick, Fazila Asmar, et al. 2016. “Frequent NFKBIE
702
-Deletions Are Associated with Poor Outcome in Primary Mediastinal <span
703
-class="nocase">B-cell</span> Lymphoma.” *Blood* 128 23: 2666–70.
704
-<https://doi.org/10.1182/blood-2016-03-704528>.
705
-
706
-</div>
707
-
708
-<div id="ref-mareschalWholeExomeSequencing2016" class="csl-entry">
709
-
710
-Mareschal, Sylvain, Sydney Dubois, Pierre-Julien Viailly, Philippe
711
-Bertrand, Elodie Bohers, Catherine Maingonnat, Jean-Philippe Jaïs, et
712
-al. 2016. “Whole Exome Sequencing of Relapsed/Refractory Patients
713
-Expands the Repertoire of Somatic Mutations in Diffuse Large <span
714
-class="nocase">B-cell</span> Lymphoma.” *Genes, Chromosomes & Cancer* 55
715
-3: 251–67. <https://doi.org/10.1002/gcc.22328>.
716
-
717
-</div>
718
-
719
-<div id="ref-morinGeneticLandscapesRelapsed2016" class="csl-entry">
720
-
721
-Morin, Ryan D., Sarit Assouline, Miguel Alcaide, Arezoo Mohajeri,
722
-Rebecca L. Johnston, Lauren Chong, Jasleen Grewal, et al. 2016. “Genetic
723
-Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.”
724
-*Clinical Cancer Research: An Official Journal of the American
725
-Association for Cancer Research* 22 9: 2290–300.
726
-<https://doi.org/10.1158/1078-0432.CCR-15-2123>.
727
-
728
-</div>
729
-
730
-<div id="ref-morinSomaticMutationsAltering2010a" class="csl-entry">
731
-
732
-Morin, Ryan D., Nathalie A. Johnson, Tesa M. Severson, Andrew J.
733
-Mungall, Jianghong An, Rodrigo Goya, Jessica E. Paul, et al. 2010.
734
-“Somatic Mutations Altering EZH2 Tyr641 in Follicular and Diffuse
735
-Large <span class="nocase">B-cell</span> Lymphomas of Germinal-Center
736
-Origin.” *Nature Genetics* 42 2: 181–85.
737
-<https://doi.org/10.1038/ng.518>.
738
-
739
-</div>
740
-
741
-<div id="ref-morinFrequentMutationHistonemodifying2011"
742
-class="csl-entry">
743
-
744
-Morin, Ryan D., Maria Mendez-Lago, Andrew J. Mungall, Rodrigo Goya,
745
-Karen L. Mungall, Richard D. Corbett, Nathalie A. Johnson, et al. 2011.
746
-“Frequent Mutation of Histone-Modifying Genes in Non-Hodgkin Lymphoma.”
747
-*Nature* 476 7360: 298–303. <https://doi.org/10.1038/nature10351>.
748
-
749
-</div>
750
-
751
-<div id="ref-morinMutationalStructuralAnalysis2013" class="csl-entry">
752
-
753
-Morin, Ryan D., Karen Mungall, Erin Pleasance, Andrew J. Mungall,
754
-Rodrigo Goya, Ryan D. Huff, David W. Scott, et al. 2013. “Mutational and
755
-Structural Analysis of Diffuse Large <span class="nocase">B-cell</span>
756
-Lymphoma Using Whole-Genome Sequencing.” *Blood* 122 7: 1256–65.
757
-<https://doi.org/10.1182/blood-2013-02-483727>.
758
-
759
-</div>
760
-
761
-<div id="ref-mottokIntegrativeGenomicAnalysis2019b" class="csl-entry">
762
-
763
-Mottok, Anja, Stacy S. Hung, Elizabeth A. Chavez, Bruce Woolcock, Adèle
764
-Telenius, Lauren C. Chong, Barbara Meissner, et al. 2019. “Integrative
765
-Genomic Analysis Identifies Key Pathogenic Mechanisms in Primary
766
-Mediastinal Large <span class="nocase">B-cell</span> Lymphoma.” *Blood*
767
-134 10: 802–13. <https://doi.org/10.1182/blood.2019001126>.
768
-
769
-</div>
770
-
771
-<div id="ref-mottokGenomicAlterationsCIITA2015b" class="csl-entry">
772
-
773
-Mottok, Anja, Bruce Woolcock, Fong Chun Chan, King Mong Tong, Lauren
774
-Chong, Pedro Farinha, Adèle Telenius, et al. 2015. “Genomic Alterations
775
-in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and
776
-Are Associated with Diminished MHC Class II Expression.” *Cell Reports*
777
-13 7: 1418–31. <https://doi.org/10.1016/j.celrep.2015.10.008>.
778
-
779
-</div>
780
-
781
-<div id="ref-muppidiLossSignalingGa132014b" class="csl-entry">
782
-
783
-Muppidi, J., R. Schmitz, Jesse A. Green, Jesse A. Green, Wenming Xiao,
784
-Adrien B. Larsen, S. Braun, et al. 2014. “Loss of Signaling via Gα13 in
785
-Germinal Center B Cell-Derived Lymphoma.” *Nature* 516: 254–58.
786
-<https://doi.org/10.1038/nature13765>.
787
-
788
-</div>
789
-
790
-<div id="ref-nadeuGenomicEpigenomicInsights2020b" class="csl-entry">
791
-
792
-Nadeu, F., D. Martín-García, G. Clot, A. Díaz-Navarro, M. Duran-Ferrer,
793
-A. Navarro, Roser Vilarrasa-Blasi, et al. 2020. “Genomic and Epigenomic
794
-Insights into the Origin, Pathogenesis and Clinical Behavior of Mantle
795
-Cell Lymphoma Subtypes.” *Blood*.
796
-<https://doi.org/10.1182/blood.2020005289>.
797
-
798
-</div>
799
-
800
-<div id="ref-ngoOncogenicallyActiveMYD882011a" class="csl-entry">
801
-
802
-Ngo, Vu N., Ryan M. Young, Roland Schmitz, Sameer Jhavar, Wenming Xiao,
803
-Kian-Huat Lim, Holger Kohlhammer, et al. 2011. “Oncogenically Active
804
-MYD88 Mutations in Human Lymphoma.” *Nature* 470 7332: 115–19.
805
-<https://doi.org/10.1038/nature09671>.
806
-
807
-</div>
808
-
809
-<div id="ref-ohgamiSTAT3MutationsAre2014" class="csl-entry">
151
+|Gene|Tier| Relevant references|
152
+|:-:|:-:|:-|
153
+|[ABI3BP](ABI3BP)|2|[@morinMutationalStructuralAnalysis2013]|
154
+|[ADAMTS1](ADAMTS1)|2|[@hubschmannMutationalMechanismsShaping2021b]|
155
+|[AICDA](AICDA)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
156
+|[ANKRD12](ANKRD12)|2|[@hubschmannMutationalMechanismsShaping2021b]|
157
+|[ANKRD17](ANKRD17)|2|[@reddyGeneticFunctionalDrivers2017]|
158
+|[ARID1B](ARID1B)|2|[@reddyGeneticFunctionalDrivers2017]|
159
+|[ARID5B](ARID5B)|2|[@gomezUltraDeepSequencingReveals2023; @reddyGeneticFunctionalDrivers2017]|
160
+|[ATR](ATR)|2|[@reddyGeneticFunctionalDrivers2017]|
161
+|[BCL11A](BCL11A)|2, aSHM||
162
+|[BCOR](BCOR)|2|[@nadeuGenomicEpigenomicInsights2020b; @jalladesExomeSequencingIdentifies2017]|
163
+|[BCR](BCR)|2, aSHM||
164
+|[BIRC3](BIRC3)|2, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @arthurGenomewideDiscoverySomatic2018; @beaLandscapeSomaticMutations2013; @rossiAlterationBIRC3Multiple2011a]|
165
+|[BLK](BLK)|2, aSHM||
166
+|[BRINP3](BRINP3)|2|[@reddyGeneticFunctionalDrivers2017]|
167
+|[BTBD3](BTBD3)|2|[@reddyGeneticFunctionalDrivers2017]|
168
+|[CADPS2](CADPS2)|2|[@hubschmannMutationalMechanismsShaping2021b]|
169
+|[CASP8](CASP8)|2|[@reddyGeneticFunctionalDrivers2017]|
170
+|[CBLB](CBLB)|2|[@reddyGeneticFunctionalDrivers2017]|
171
+|[CCL4](CCL4)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
172
+|[CD22](CD22)|2|[@reddyGeneticFunctionalDrivers2017]|
173
+|[CD274](CD274)|2|[@morinFrequentMutationHistonemodifying2011]|
174
+|[CD36](CD36)|2|[@pasqualucciAnalysisCodingGenome2011]|
175
+|[CD44](CD44)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
176
+|[CD74](CD74)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
177
+|[CDC73](CDC73)|2|[@reddyGeneticFunctionalDrivers2017; @loveGeneticLandscapeMutations2012]|
178
+|[CDH9](CDH9)|2|[@morinMutationalStructuralAnalysis2013]|
179
+|[CHD1](CHD1)|2|[@reddyGeneticFunctionalDrivers2017]|
180
+|[CHD8](CHD8)|2|[@reddyGeneticFunctionalDrivers2017; @grandeGenomewideDiscoverySomatic2019]|
181
+|[CHST2](CHST2)|2|[@reddyGeneticFunctionalDrivers2017]|
182
+|[CNOT2](CNOT2)|2|[@hubschmannMutationalMechanismsShaping2021b]|
183
+|[CNTNAP5](CNTNAP5)|2|[@morinMutationalStructuralAnalysis2013]|
184
+|[COQ7](COQ7)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
185
+|[CRIP1](CRIP1)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
186
+|[DAZAP1](DAZAP1)|2|[@pararajalingamCodingNoncodingDrivers2020]|
187
+|[DCAF6](DCAF6)|2|[@reddyGeneticFunctionalDrivers2017]|
188
+|[DDX10](DDX10)|2|[@reddyGeneticFunctionalDrivers2017]|
189
+|[DHX16](DHX16)|2|[@hubschmannMutationalMechanismsShaping2021b]|
190
+|[DICER1](DICER1)|2|[@reddyGeneticFunctionalDrivers2017]|
191
+|[DNAH5](DNAH5)|2|[@jalladesExomeSequencingIdentifies2017; @morinMutationalStructuralAnalysis2013]|
192
+|[DNM2](DNM2)|2|[@hubschmannMutationalMechanismsShaping2021b]|
193
+|[DNMT3A](DNMT3A)|2|[@reddyGeneticFunctionalDrivers2017]|
194
+|[DOCK1](DOCK1)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
195
+|[DSG4](DSG4)|2|[@morinMutationalStructuralAnalysis2013]|
196
+|[EIF2AK3](EIF2AK3)|2, aSHM||
197
+|[EZR](EZR)|2, aSHM|[@deschGenotypingCirculatingTumor2020]|
198
+|[FAM102A](FAM102A)|2, aSHM||
199
+|[FAM38B](FAM38B)|2|[@morinMutationalStructuralAnalysis2013]|
200
+|[FANK1](FANK1)|2, aSHM||
201
+|[FAT4](FAT4)|2|[@zhangGenomicLandscapeMantle2014; @morinMutationalStructuralAnalysis2013; @parryWholeExomeSequencing2013]|
202
+|[FCRL3](FCRL3)|2, aSHM||
203
+|[FNBP1](FNBP1)|2, aSHM||
204
+|[FNDC1](FNDC1)|2|[@morinMutationalStructuralAnalysis2013]|
205
+|[FOXC1](FOXC1)|2|[@schmitzGeneticsPathogenesisDiffuse2018a]|
206
+|[FOXP1](FOXP1)|2, aSHM|[@reddyGeneticFunctionalDrivers2017]|
207
+|[FUBP1](FUBP1)|2|[@reddyGeneticFunctionalDrivers2017]|
208
+|[FUT5](FUT5)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
209
+|[GABRA2](GABRA2)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
210
+|[GAK](GAK)|2|[@hubschmannMutationalMechanismsShaping2021b]|
211
+|[GNAS](GNAS)|2|[@reddyGeneticFunctionalDrivers2017]|
212
+|[GOLGA5](GOLGA5)|2|[@reddyGeneticFunctionalDrivers2017]|
213
+|[GPC5](GPC5)|2|[@schmitzGeneticsPathogenesisDiffuse2018a]|
214
+|[GSG2](GSG2)|2|[@schmitzGeneticsPathogenesisDiffuse2018a]|
215
+|[HDAC7](HDAC7)|2|[@morinMutationalStructuralAnalysis2013]|
216
+|[HIST1H2AG](HIST1H2AG)|2, aSHM|[@morinMutationalStructuralAnalysis2013; @paneaWholeGenomeLandscape2019; @krysiakRecurrentSomaticMutations2017b; @rossiCodingGenomeSplenic2012c]|
217
+|[HLA-DMA](HLA-DMA)|2||
218
+|[HLA-DQA1](HLA-DQA1)|2|[@hubschmannMutationalMechanismsShaping2021b]|
219
+|[HNF1B](HNF1B)|2|[@pasqualucciAnalysisCodingGenome2011]|
220
+|[HNRNPD](HNRNPD)|2||
221
+|[HNRNPH1](HNRNPH1)|2, noncoding|[@pararajalingamCodingNoncodingDrivers2020]|
222
+|[HRAS](HRAS)|2|[@jalladesExomeSequencingIdentifies2017; @reddyGeneticFunctionalDrivers2017]|
223
+|[ID3](ID3)|2|[@spinaGeneticsNodalMarginal2016b; @richterRecurrentMutationID32012a; @schmitzBurkittLymphomaPathogenesis2012]|
224
+|[IER2](IER2)|2|[@morinMutationalStructuralAnalysis2013]|
225
+|[IFNGR1](IFNGR1)|2|[@morinMutationalStructuralAnalysis2013]|
226
+|[IGLL5](IGLL5)|2, aSHM|[@deschGenotypingCirculatingTumor2020; @russler-germainMutationsAssociatedProgression2023b; @paneaWholeGenomeLandscape2019]|
227
+|[IKBKB](IKBKB)|2|[@reddyGeneticFunctionalDrivers2017; @rossiAlterationBIRC3Multiple2011a; @wienandGenomicAnalysesFlowsorted2019b]|
228
+|[IKBKE](IKBKE)|2|[@hubschmannMutationalMechanismsShaping2021b]|
229
+|[IL16](IL16)|2||
230
+|[IL6](IL6)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
231
+|[INO80](INO80)|2|[@zhangGeneticHeterogeneityDiffuse2013]|
232
+|[IRAG2](IRAG2)|2, aSHM||
233
+|[IRF1](IRF1)|2, aSHM|[@hubschmannMutationalMechanismsShaping2021b]|
234
+|[JAK1](JAK1)|2|[@mottokIntegrativeGenomicAnalysis2019b; @zhangGeneticHeterogeneityDiffuse2013]|
235
+|[JAK3](JAK3)|2|[@zhangGeneticHeterogeneityDiffuse2013]|
236
+|[JUNB](JUNB)|2|[@reddyGeneticFunctionalDrivers2017; @mottokIntegrativeGenomicAnalysis2019b]|
237
+|[KCMF1](KCMF1)|2|[@reddyGeneticFunctionalDrivers2017]|
238
+|[KLHL21](KLHL21)|2|[@schmitzGeneticsPathogenesisDiffuse2018a]|
239
+|[LAMA5](LAMA5)|2|[@schmitzGeneticsPathogenesisDiffuse2018a]|
240
+|[LAPTM5](LAPTM5)|2, aSHM|[@hubschmannMutationalMechanismsShaping2021b]|
241
+|[LIN54](LIN54)|2|[@reddyGeneticFunctionalDrivers2017]|
242
+|[LPP](LPP)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
243
+|[LRP12](LRP12)|2|[@hubschmannMutationalMechanismsShaping2021b]|
244
+|[LRRN3](LRRN3)|2|[@sarkozyMutationalLandscapeGray2021a; @morinMutationalStructuralAnalysis2013]|
245
+|[LYN](LYN)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
246
+|[MAGT1](MAGT1)|2|[@reddyGeneticFunctionalDrivers2017]|
247
+|[MALAT1](MALAT1)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
248
+|[MAP2K1](MAP2K1)|2|[@louissaintPediatrictypeNodalFollicular2016a; @shinBRAFV600EMAP2K12015]|
249
+|[MAP4K4](MAP4K4)|2|[@reddyGeneticFunctionalDrivers2017]|
250
+|[MARK1](MARK1)|2|[@reddyGeneticFunctionalDrivers2017]|
251
+|[MCL1](MCL1)|2|[@paneaWholeGenomeLandscape2019; @dunsCharacterizationDLBCLPMBL2021b; @reddyGeneticFunctionalDrivers2017]|
252
+|[MECOM](MECOM)|2|[@reddyGeneticFunctionalDrivers2017]|
253
+|[MET](MET)|2|[@reddyGeneticFunctionalDrivers2017]|
254
+|[MIR142](MIR142)|2, aSHM|[@grandeGenomewideDiscoverySomatic2019; @kwanhianMicroRNA142Mutated202012b]|
255
+|[MIR155HG](MIR155HG)|2, aSHM||
256
+|[MPDZ](MPDZ)|2|[@morinMutationalStructuralAnalysis2013; @reichelFlowSortingExome2015a]|
257
+|[MSH2](MSH2)|2|[@reddyGeneticFunctionalDrivers2017]|
258
+|[MSH6](MSH6)|2|[@reddyGeneticFunctionalDrivers2017]|
259
+|[MYB](MYB)|2|[@reddyGeneticFunctionalDrivers2017; @deschGenotypingCirculatingTumor2020]|
260
+|[MYBPC2](MYBPC2)|2|[@schmitzGeneticsPathogenesisDiffuse2018a]|
261
+|[MYO1E](MYO1E)|2, aSHM||
262
+|[MYOM2](MYOM2)|2|[@pasqualucciAnalysisCodingGenome2011]|
263
+|[N2RF2](N2RF2)|2|[@hubschmannMutationalMechanismsShaping2021b]|
264
+|[NANOG](NANOG)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
265
+|[NAV1](NAV1)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
266
+|[NCOA3](NCOA3)|2, aSHM||
267
+|[NCOR1](NCOR1)|2|[@reddyGeneticFunctionalDrivers2017]|
268
+|[NCOR2](NCOR2)|2|[@schmitzBurkittLymphomaPathogenesis2012; @spinaGeneticsNodalMarginal2016b; @sarkozyMutationalLandscapeGray2021a]|
269
+|[NEAT1](NEAT1)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
270
+|[NF1](NF1)|2|[@reddyGeneticFunctionalDrivers2017]|
271
+|[NFKB1](NFKB1)|2||
272
+|[NFKB2](NFKB2)|2|[@mottokIntegrativeGenomicAnalysis2019b; @reddyGeneticFunctionalDrivers2017]|
273
+|[NLRC5](NLRC5)|2||
274
+|[NLRP5](NLRP5)|2|[@morinMutationalStructuralAnalysis2013]|
275
+|[NLRP8](NLRP8)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
276
+|[ODZ3](ODZ3)|2|[@morinMutationalStructuralAnalysis2013]|
277
+|[P2RX5](P2RX5)|2, aSHM|[@morinMutationalStructuralAnalysis2013]|
278
+|[PAPOLG](PAPOLG)|2|[@schmitzGeneticsPathogenesisDiffuse2018a]|
279
+|[PASK](PASK)|2|[@morinMutationalStructuralAnalysis2013]|
280
+|[PAX5](PAX5)|2, aSHM|[@pasqualucciHypermutationMultipleProtooncogenes2001a]|
281
+|[PCBP1](PCBP1)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
282
+|[PCDHB11](PCDHB11)|2|[@morinMutationalStructuralAnalysis2013]|
283
+|[PCLO](PCLO)|2|[@lohrDiscoveryPrioritizationSomatic2012a]|
284
+|[PDE4DIP](PDE4DIP)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
285
+|[PDS5B](PDS5B)|2|[@hubschmannMutationalMechanismsShaping2021b; @morinMutationalStructuralAnalysis2013]|
286
+|[PHF6](PHF6)|2|[@reddyGeneticFunctionalDrivers2017; @thomasGeneticSubgroupsInform2023]|
287
+|[PIK3CD](PIK3CD)|2|[@reddyGeneticFunctionalDrivers2017]|
288
+|[PIK3R1](PIK3R1)|2|[@zhangGeneticHeterogeneityDiffuse2013; @paneaWholeGenomeLandscape2019]|
289
+|[PKD1](PKD1)|2|[@morinMutationalStructuralAnalysis2013]|
290
+|[PNPO](PNPO)|2|[@hubschmannMutationalMechanismsShaping2021b]|
291
+|[POGZ](POGZ)|2|[@morinMutationalStructuralAnalysis2013]|
292
+|[PPP1R9B](PPP1R9B)|2||
293
+|[PRKCB](PRKCB)|2|[@morinMutationalStructuralAnalysis2013]|
294
+|[PRKDC](PRKDC)|2|[@schmitzGeneticsPathogenesisDiffuse2018a; @hubschmannMutationalMechanismsShaping2021b]|
295
+|[PRPS1](PRPS1)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
296
+|[PTMA](PTMA)|2, aSHM||
297
+|[PTPN1](PTPN1)|2, aSHM|[@gunawardanaRecurrentSomaticMutations2014c]|
298
+|[PTPN23](PTPN23)|2|[@morinMutationalStructuralAnalysis2013]|
299
+|[PTPN6](PTPN6)|2|[@reddyGeneticFunctionalDrivers2017]|
300
+|[PTPRK](PTPRK)|2|[@reddyGeneticFunctionalDrivers2017]|
301
+|[RAC2](RAC2)|2|[@paneaWholeGenomeLandscape2019; @hubschmannMutationalMechanismsShaping2021b]|
302
+|[RAD9A](RAD9A)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
303
+|[RARA](RARA)|2|[@reddyGeneticFunctionalDrivers2017]|
304
+|[RCC](RCC)|2, aSHM||
305
+|[RFTN1](RFTN1)|2, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @arthurGenomewideDiscoverySomatic2018]|
306
+|[RFXAP](RFXAP)|2||
307
+|[RHEX](RHEX)|2, aSHM||
308
+|[RHOH](RHOH)|2, aSHM|[@pasqualucciHypermutationMultipleProtooncogenes2001a]|
309
+|[RUBCNL](RUBCNL)|2, aSHM||
310
+|[RUNX1](RUNX1)|2|[@reddyGeneticFunctionalDrivers2017]|
311
+|[SAMD9L](SAMD9L)|2|[@morinMutationalStructuralAnalysis2013]|
312
+|[SARM1](SARM1)|2|[@morinMutationalStructuralAnalysis2013]|
313
+|[SEL1L3](SEL1L3)|2, aSHM||
314
+|[SEPTIN9](SEPTIN9)|2, aSHM||
315
+|[SERPINA9](SERPINA9)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
316
+|[SETD2](SETD2)|2|[@zhangGeneticHeterogeneityDiffuse2013]|
317
+|[SETD5](SETD5)|2|[@reddyGeneticFunctionalDrivers2017; @tiacciPervasiveMutationsJAKSTAT2018b]|
318
+|[SIAH2](SIAH2)|2|[@hubschmannMutationalMechanismsShaping2021b; @reichelFlowSortingExome2015a]|
319
+|[SLC34A2](SLC34A2)|2|[@hubschmannMutationalMechanismsShaping2021b]|
320
+|[SMEK1](SMEK1)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
321
+|[SRRM2](SRRM2)|2|[@morinMutationalStructuralAnalysis2013; @russler-germainMutationsAssociatedProgression2023b]|
322
+|[ST6GAL1](ST6GAL1)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
323
+|[STAT5B](STAT5B)|2|[@zhangGeneticHeterogeneityDiffuse2013; @tiacciPervasiveMutationsJAKSTAT2018b]|
324
+|[SYK](SYK)|2|[@reddyGeneticFunctionalDrivers2017]|
325
+|[SYPL1](SYPL1)|2|[@morinMutationalStructuralAnalysis2013]|
326
+|[TAP1](TAP1)|2|[@schmitzGeneticsPathogenesisDiffuse2018a]|
327
+|[TBC1D4](TBC1D4)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
328
+|[TCL1A](TCL1A)|2, aSHM|[@grandeGenomewideDiscoverySomatic2019]|
329
+|[TGFBR2](TGFBR2)|2|[@reddyGeneticFunctionalDrivers2017]|
330
+|[TIPARP](TIPARP)|2|[@reddyGeneticFunctionalDrivers2017]|
331
+|[TLR2](TLR2)|2|[@beaLandscapeSomaticMutations2013; @chapuyMolecularSubtypesDiffuse2018b]|
332
+|[TRAF3](TRAF3)|2|[@pasqualucciAnalysisCodingGenome2011; @rossiAlterationBIRC3Multiple2011a; @ottoGeneticLesionsTRAF32012a]|
333
+|[TRAF6](TRAF6)|2|[@hubschmannMutationalMechanismsShaping2021b]|
334
+|[TRIP12](TRIP12)|2||
335
+|[UBE2J1](UBE2J1)|2, aSHM||
336
+|[UBR5](UBR5)|2|[@pararajalingamCodingNoncodingDrivers2020; @zhangGeneticHeterogeneityDiffuse2013]|
337
+|[UNC5B](UNC5B)|2|[@hubschmannMutationalMechanismsShaping2021b]|
338
+|[UNC5D](UNC5D)|2||
339
+|[WAC](WAC)|2|[@reddyGeneticFunctionalDrivers2017; @rossiCodingGenomeSplenic2012c]|
340
+|[WDFY3](WDFY3)|2|[@morinMutationalStructuralAnalysis2013]|
341
+|[WNK1](WNK1)|2|[@thomasGeneticSubgroupsInform2023; @jalladesExomeSequencingIdentifies2017; @hubschmannMutationalMechanismsShaping2021b]|
342
+|[XBP1](XBP1)|2, aSHM||
343
+|[YY1](YY1)|2|[@reddyGeneticFunctionalDrivers2017]|
344
+|[ZBTB7A](ZBTB7A)|2|[@reddyGeneticFunctionalDrivers2017; @burkhardtClinicalRelevanceMolecular2022b]|
345
+|[ZCCHC7](ZCCHC7)|2, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
346
+|[ZEB2](ZEB2)|2|[@zhangGeneticHeterogeneityDiffuse2013]|
347
+|[ZFAT](ZFAT)|2|[@reddyGeneticFunctionalDrivers2017]|
348
+|[ZFX](ZFX)|2|[@reddyGeneticFunctionalDrivers2017]|
349
+|[ZNF217](ZNF217)|2|[@reichelFlowSortingExome2015a; @hubschmannMutationalMechanismsShaping2021b]|
350
+|[ZNF423](ZNF423)|2|[@chapuyMolecularSubtypesDiffuse2018b]|
810 351
811
-Ohgami, Robert S., Lisa Ma, Ahmad Monabati, James L. Zehnder, and Daniel
812
-A. Arber. 2014. “STAT3 Mutations Are Present in Aggressive <span
813
-class="nocase">B-cell</span> Lymphomas Including a Subset of Diffuse
814
-Large <span class="nocase">B-cell</span> Lymphomas with CD30
815
-Expression.” *Haematologica* 99 7: e105–107.
816
-<https://doi.org/10.3324/haematol.2013.101543>.
817 352
818
-</div>
819
-
820
-<div id="ref-okosunRecurrentMTORC1activatingRRAGC2016a"
821
-class="csl-entry">
822
-
823
-Okosun, Jessica, Rachel L. Wolfson, Jun Wang, Shamzah Araf, Lucy
824
-Wilkins, Brian M. Castellano, Leire Escudero-Ibarz, et al. 2016.
825
-“Recurrent <span class="nocase">mTORC1-activating RRAGC</span> Mutations
826
-in Follicular Lymphoma.” *Nature Genetics* 48 2: 183–88.
827
-<https://doi.org/10.1038/ng.3473>.
828
-
829
-</div>
830
-
831
-<div id="ref-ottoGeneticLesionsTRAF32012a" class="csl-entry">
832
-
833
-Otto, Claudia, Maciej Giefing, Anne Massow, Inga Vater, Stefan Gesk,
834
-Matthias Schlesner, Julia Richter, et al. 2012. “Genetic Lesions of the
835
-TRAF3 and MAP3K14 Genes in Classical Hodgkin Lymphoma.” *British Journal
836
-of Haematology* 157 6: 702–8.
837
-<https://doi.org/10.1111/j.1365-2141.2012.09113.x>.
838
-
839
-</div>
840
-
841
-<div id="ref-paneaWholeGenomeLandscape2019" class="csl-entry">
842
-
843
-Panea, R., C. Love, Jennifer R. Shingleton, Anupama Reddy, J. Bailey, A.
844
-Moormann, J. Otieno, et al. 2019. “The Whole Genome Landscape of Burkitt
845
-Lymphoma Subtypes.” *Blood*. <https://doi.org/10.1182/blood.2019001880>.
846
-
847
-</div>
848
-
849
-<div id="ref-pararajalingamCodingNoncodingDrivers2020"
850
-class="csl-entry">
851
-
852
-Pararajalingam, Prasath, Krysta M. Coyle, Sarah E. Arthur, Nicole
853
-Thomas, Miguel Alcaide, Barbara Meissner, Merrill Boyle, et al. 2020.
854
-“Coding and Noncoding Drivers of Mantle Cell Lymphoma Identified Through
855
-Exome and Genome Sequencing.” *Blood* 136 5: 572–84.
856
-<https://doi.org/10.1182/blood.2019002385>.
857
-
858
-</div>
859
-
860
-<div id="ref-parryWholeExomeSequencing2013" class="csl-entry">
861
-
862
-Parry, Marina, Matthew J. J. Rose-Zerilli, Jane Gibson, Sarah Ennis,
863
-Renata Walewska, Jade Forster, Helen Parker, et al. 2013. “Whole Exome
864
-Sequencing Identifies Novel Recurrently Mutated Genes in Patients with
865
-Splenic Marginal Zone Lymphoma.” *PloS One* 8 12: e83244.
866
-<https://doi.org/10.1371/journal.pone.0083244>.
867
-
868
-</div>
869
-
870
-<div id="ref-pasqualucciInactivationPRDM1BLIMP12006a" class="csl-entry">
871
-
872
-Pasqualucci, Laura, Mara Compagno, Jane Houldsworth, Stefano Monti,
873
-Adina Grunn, Subhadra V Nandula, Jon C Aster, Vundavally V Murty,
874
-Margaret A Shipp, and Riccardo Dalla-Favera. 2006. “Inactivation of the
875
-PRDM1/BLIMP1 Gene in Diffuse Large B Cell Lymphoma.” *J Exp Med* 203
876
-2: 311–17.
877
-
878
-</div>
879
-
880
-<div id="ref-pasqualucciInactivatingMutationsAcetyltransferase2011a"
881
-class="csl-entry">
882
-
883
-Pasqualucci, Laura, David Dominguez-Sola, Annalisa Chiarenza, Giulia
884
-Fabbri, Adina Grunn, Vladimir Trifonov, Lawryn H. Kasper, et al. 2011.
885
-“Inactivating Mutations of Acetyltransferase Genes in <span
886
-class="nocase">B-cell</span> Lymphoma.” *Nature* 471 7337: 189–95.
887
-<https://doi.org/10.1038/nature09730>.
888
-
889
-</div>
890
-
891
-<div id="ref-pasqualucciAnalysisCodingGenome2011" class="csl-entry">
892
-
893
-Pasqualucci, Laura, Vladimir Trifonov, Giulia Fabbri, Jing Ma, Davide
894
-Rossi, Annalisa Chiarenza, Victoria A. Wells, et al. 2011. “Analysis of
895
-the Coding Genome of Diffuse Large <span class="nocase">B-cell</span>
896
-Lymphoma.” *Nature Genetics* 43 9: 830–37.
897
-<https://doi.org/10.1038/ng.892>.
898
-
899
-</div>
900
-
901
-<div id="ref-pasqualucciHypermutationMultipleProtooncogenes2001a"
902
-class="csl-entry">
903
-
904
-Pasqualucci, L., P. Neumeister, T. Goossens, G. Nanjangud, R. S.
905
-Chaganti, R. Küppers, and R. Dalla-Favera. 2001. “Hypermutation of
906
-Multiple Proto-Oncogenes in <span class="nocase">B-cell</span> Diffuse
907
-Large-Cell Lymphomas.” *Nature* 412 6844: 341–46.
908
-<https://doi.org/10.1038/35085588>.
909
-
910
-</div>
911
-
912
-<div id="ref-reddyGeneticFunctionalDrivers2017" class="csl-entry">
913
-
914
-Reddy, Anupama, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt,
915
-Cassandra L Love, Alexander Waldrop, Sirpa Leppa, et al. 2017. “Genetic
916
-and Functional Drivers of Diffuse Large B Cell Lymphoma.” *Cell* 171
917
-2: 481–494.e15.
918
-
919
-</div>
920
-
921
-<div id="ref-reichelFlowSortingExome2015a" class="csl-entry">
922
-
923
-Reichel, Jonathan, Amy Chadburn, Paul G. Rubinstein, Lisa Giulino-Roth,
924
-Wayne Tam, Yifang Liu, Rafael Gaiolla, et al. 2015. “Flow Sorting and
925
-Exome Sequencing Reveal the Oncogenome of Primary Hodgkin and
926
-Reed-Sternberg Cells.” *Blood* 125 7: 1061–72.
927
-<https://doi.org/10.1182/blood-2014-11-610436>.
928
-
929
-</div>
930
-
931
-<div id="ref-richterRecurrentMutationID32012a" class="csl-entry">
932
-
933
-Richter, Julia, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen
934
-Leich, Birgit Burkhardt, Maciej Rosolowski, et al. 2012. “Recurrent
935
-Mutation of the ID3 Gene in Burkitt Lymphoma Identified by Integrated
936
-Genome, Exome and Transcriptome Sequencing.” *Nature Genetics* 44 12:
937
-1316–20. <https://doi.org/10.1038/ng.2469>.
938
-
939
-</div>
940
-
941
-<div id="ref-ritzRecurrentMutationsSTAT62009a" class="csl-entry">
942
-
943
-Ritz, Olga, Chrystelle Guiter, Flavia Castellano, Karola Dorsch, Julia
944
-Melzner, Jean-Philippe Jais, Gwendoline Dubois, Philippe Gaulard, Peter
945
-Möller, and Karen Leroy. 2009. “Recurrent Mutations of the STAT6 DNA
946
-Binding Domain in Primary Mediastinal <span class="nocase">B-cell</span>
947
-Lymphoma.” *Blood* 114 6: 1236–42.
948
-<https://doi.org/10.1182/blood-2009-03-209759>.
949
-
950
-</div>
951
-
952
-<div id="ref-rossiAlterationBIRC3Multiple2011a" class="csl-entry">
953
-
954
-Rossi, Davide, Silvia Deaglio, David Dominguez-Sola, Silvia Rasi,
955
-Tiziana Vaisitti, Claudio Agostinelli, Valeria Spina, et al. 2011.
956
-“Alteration of BIRC3 and Multiple Other <span
957
-class="nocase">NF-κB</span> Pathway Genes in Splenic Marginal Zone
958
-Lymphoma.” *Blood* 118 18: 4930–34.
959
-<https://doi.org/10.1182/blood-2011-06-359166>.
960
-
961
-</div>
962
-
963
-<div id="ref-rossiCodingGenomeSplenic2012c" class="csl-entry">
964
-
965
-Rossi, Davide, Vladimir Trifonov, Marco Fangazio, Alessio Bruscaggin,
966
-Silvia Rasi, Valeria Spina, Sara Monti, et al. 2012. “The Coding Genome
967
-of Splenic Marginal Zone Lymphoma: Activation of NOTCH2 and Other
968
-Pathways Regulating Marginal Zone Development.” *The Journal of
969
-Experimental Medicine* 209 9: 1537–51.
970
-<https://doi.org/10.1084/jem.20120904>.
971
-
972
-</div>
973
-
974
-<div id="ref-rushtonGeneticEvolutionaryPatterns2020" class="csl-entry">
975
-
976
-Rushton, Christopher K., Sarah E. Arthur, Miguel Alcaide, Matthew
977
-Cheung, Aixiang Jiang, Krysta M. Coyle, Kirstie L. S. Cleary, et al.
978
-2020. “Genetic and Evolutionary Patterns of Treatment Resistance in
979
-Relapsed <span class="nocase">B-cell</span> Lymphoma.” *Blood Advances*
980
-4 13: 2886–98. <https://doi.org/10.1182/bloodadvances.2020001696>.
981
-
982
-</div>
983
-
984
-<div id="ref-russler-germainMutationsAssociatedProgression2023b"
985
-class="csl-entry">
986
-
987
-Russler-Germain, David A., Kilannin Krysiak, Cody A. Ramirez, Matthew
988
-Mosior, Marcus P. Watkins, Felicia Gomez, Zachary L. Skidmore, et al.
989
-2023. “Mutations Associated with Progression in Follicular Lymphoma
990
-Predict Inferior Outcomes at Diagnosis: Alliance A151303.” *Blood
991
-Advances* 7: 5524–39.
992
-<https://doi.org/10.1182/bloodadvances.2023010779>.
993
-
994
-</div>
995
-
996
-<div id="ref-sarkozyMutationalLandscapeGray2021a" class="csl-entry">
997
-
998
-Sarkozy, Clémentine, Stacy S. Hung, Elizabeth A. Chavez, Gerben Duns,
999
-Katsuyoshi Takata, Lauren C. Chong, Tomohiro Aoki, et al. 2021.
1000
-“Mutational Landscape of Gray Zone Lymphoma.” *Blood* 137 13: 1765–76.
1001
-<https://doi.org/10.1182/blood.2020007507>.
1002
-
1003
-</div>
1004
-
1005
-<div id="ref-schmitzTNFAIP3A20Tumor2009a" class="csl-entry">
1006
-
1007
-Schmitz, Roland, Martin-Leo Hansmann, Verena Bohle, Jose Ignacio
1008
-Martin-Subero, Sylvia Hartmann, Gunhild Mechtersheimer, Wolfram Klapper,
1009
-et al. 2009. “TNFAIP3 A20 Is a Tumor Suppressor Gene in Hodgkin
1010
-Lymphoma and Primary Mediastinal B Cell Lymphoma.” *The Journal of
1011
-Experimental Medicine* 206 5: 981–89.
1012
-<https://doi.org/10.1084/jem.20090528>.
1013
-
1014
-</div>
1015
-
1016
-<div id="ref-schmitzGeneticsPathogenesisDiffuse2018a" class="csl-entry">
1017
-
1018
-Schmitz, Roland, George W. Wright, Da Wei Huang, Calvin A. Johnson,
1019
-James D. Phelan, James Q. Wang, Sandrine Roulland, et al. 2018.
1020
-“Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.” *The New
1021
-England Journal of Medicine* 378 15: 1396–1407.
1022
-<https://doi.org/10.1056/NEJMoa1801445>.
1023
-
1024
-</div>
1025
-
1026
-<div id="ref-schmitzBurkittLymphomaPathogenesis2012" class="csl-entry">
1027
-
1028
-Schmitz, Roland, Ryan M. Young, Michele Ceribelli, Sameer Jhavar,
1029
-Wenming Xiao, Meili Zhang, George Wright, et al. 2012. “Burkitt Lymphoma
1030
-Pathogenesis and Therapeutic Targets from Structural and Functional
1031
-Genomics.” *Nature* 490 7418: 116–20.
1032
-<https://doi.org/10.1038/nature11378>.
1033
-
1034
-</div>
1035
-
1036
-<div id="ref-schneiderAlterationsCD58Gene2015a" class="csl-entry">
1037
-
1038
-Schneider, Markus, Stefanie Schneider, Reina Zühlke-Jenisch, Wolfram
1039
-Klapper, Christer Sundström, Sylvia Hartmann, Martin-Leo Hansmann,
1040
-Reiner Siebert, Ralf Küppers, and Maciej Giefing. 2015. “Alterations of
1041
-the CD58 Gene in Classical Hodgkin Lymphoma.” *Genes, Chromosomes &
1042
-Cancer* 54 10: 638–45. <https://doi.org/10.1002/gcc.22276>.
1043
-
1044
-</div>
1045
-
1046
-<div id="ref-schollMutationsRegionFAS2007" class="csl-entry">
1047
-
1048
-Scholl, Vanesa, Claudio Gustavo Stefanoff, Rocio Hassan, Nelson Spector,
1049
-and Ilana Zalcberg Renault. 2007. “Mutations Within the 5’ Region of
1050
-FAS/CD95 Gene in Nodal Diffuse Large <span class="nocase">B-cell</span>
1051
-Lymphoma.” *Leukemia & Lymphoma* 48 5: 957–63.
1052
-<https://doi.org/10.1080/10428190701230858>.
1053
-
1054
-</div>
1055
-
1056
-<div id="ref-shinBRAFV600EMAP2K12015" class="csl-entry">
1057
-
1058
-Shin, Sang-Yong, Seung-Tae Lee, Hee-Jin Kim, Chang-Seok Ki, Chul Won
1059
-Jung, Jong-Won Kim, and Sun-Hee Kim. 2015. “BRAF V600E and MAP2K1
1060
-Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma
1061
-Cases.” *Annals of Laboratory Medicine* 35 2: 257–59.
1062
-<https://doi.org/10.3343/alm.2015.35.2.257>.
1063
-
1064
-</div>
1065
-
1066
-<div id="ref-spinaGeneticsNodalMarginal2016b" class="csl-entry">
1067
-
1068
-Spina, Valeria, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano
1069
-Cascione, Alessio Bruscaggin, Elisa Spaccarotella, et al. 2016. “The
1070
-Genetics of Nodal Marginal Zone Lymphoma.” *Blood* 128 10: 1362–73.
1071
-<https://doi.org/10.1182/blood-2016-02-696757>.
1072
-
1073
-</div>
1074
-
1075
-<div id="ref-tanakaFrequentIncidenceSomatic1992" class="csl-entry">
1076
-
1077
-Tanaka, S., D. C. Louie, J. A. Kant, and J. C. Reed. 1992. “Frequent
1078
-Incidence of Somatic Mutations in Translocated BCL2 Oncogenes of
1079
-Non-Hodgkin’s Lymphomas.” *Blood* 79 1: 229–37.
1080
-
1081
-</div>
1082
-
1083
-<div id="ref-thomasGeneticSubgroupsInform2023" class="csl-entry">
1084
-
1085
-Thomas, Nicole, Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton,
1086
-Jeremy S. Abramson, Richard F. Ambinder, Stefan Barta, et al. 2023.
1087
-“Genetic Subgroups Inform on Pathobiology in Adult and Pediatric Burkitt
1088
-Lymphoma.” *Blood* 141 8: 904–16.
1089
-<https://doi.org/10.1182/blood.2022016534>.
1090
-
1091
-</div>
1092
-
1093
-<div id="ref-tiacciPervasiveMutationsJAKSTAT2018b" class="csl-entry">
1094
-
1095
-Tiacci, Enrico, Erik Ladewig, Gianluca Schiavoni, Alex Penson,
1096
-Elisabetta Fortini, Valentina Pettirossi, Yuchun Wang, et al. 2018.
1097
-“Pervasive Mutations of JAK-STAT Pathway Genes in Classical Hodgkin
1098
-Lymphoma.” *Blood* 131 22: 2454–65.
1099
-<https://doi.org/10.1182/blood-2017-11-814913>.
1100
-
1101
-</div>
1102
-
1103
-<div id="ref-tiacciBRAFMutationsHairycell2011a" class="csl-entry">
1104
-
1105
-Tiacci, Enrico, Vladimir Trifonov, Gianluca Schiavoni, Antony Holmes,
1106
-Wolfgang Kern, Maria Paola Martelli, Alessandra Pucciarini, et al. 2011.
1107
-“BRAF Mutations in Hairy-Cell Leukemia.” *The New England Journal of
1108
-Medicine* 364 24: 2305–15. <https://doi.org/10.1056/NEJMoa1014209>.
1109
-
1110
-</div>
1111
-
1112
-<div id="ref-troenNOTCH2MutationsMarginal2008" class="csl-entry">
1113
-
1114
-Trøen, Gunhild, Iwona Wlodarska, Abdirashid Warsame, Silvia Hernández
1115
-Llodrà, Christiane De Wolf-Peeters, and Jan Delabie. 2008. “NOTCH2
1116
-Mutations in Marginal Zone Lymphoma.” *Haematologica* 93 7: 1107–9.
1117
-<https://doi.org/10.3324/haematol.11635>.
1118
-
1119
-</div>
1120
-
1121
-<div id="ref-viganoSomaticIL4RMutations2018b" class="csl-entry">
1122
-
1123
-Viganò, Elena, Jay Gunawardana, Anja Mottok, Tessa Van Tol, Katina Mak,
1124
-Fong Chun Chan, Lauren Chong, et al. 2018. “Somatic IL4R Mutations in
1125
-Primary Mediastinal Large <span class="nocase">B-cell</span> Lymphoma
1126
-Lead to Constitutive JAK-STAT Signaling Activation.” *Blood* 131 18:
1127
-2036–46. <https://doi.org/10.1182/blood-2017-09-808907>.
1128
-
1129
-</div>
1130
-
1131
-<div id="ref-wenigerMutationsTumorSuppressor2006a" class="csl-entry">
1132
-
1133
-Weniger, M. A., I. Melzner, C. K. Menz, S. Wegener, A. J. Bucur, K.
1134
-Dorsch, T. Mattfeldt, T. F. E. Barth, and P. Möller. 2006. “Mutations of
1135
-the Tumor Suppressor Gene SOCS-1 in Classical Hodgkin Lymphoma Are
1136
-Frequent and Associated with Nuclear Phospho-STAT5 Accumulation.”
1137
-*Oncogene* 25 18: 2679–84. <https://doi.org/10.1038/sj.onc.1209151>.
1138
-
1139
-</div>
1140
-
1141
-<div id="ref-wienandGenomicAnalysesFlowsorted2019b" class="csl-entry">
1142
-
1143
-Wienand, Kirsty, Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, David
1144
-Wu, Jaegil Kim, Atanas Kamburov, et al. 2019. “Genomic Analyses of
1145
-Flow-Sorted Hodgkin Reed-Sternberg Cells Reveal Complementary Mechanisms
1146
-of Immune Evasion.” *Blood Advances* 3 23: 4065–80.
1147
-<https://doi.org/10.1182/bloodadvances.2019001012>.
1148
-
1149
-</div>
1150
-
1151
-<div id="ref-wildaInactivationARFMDM2p53Pathway2004" class="csl-entry">
1152
-
1153
-Wilda, M., J. Bruch, L. Harder, D. Rawer, A. Reiter, A. Borkhardt, and
1154
-W. Woessmann. 2004. “Inactivation of the <span
1155
-class="nocase">ARF-MDM-2-p53</span> Pathway in Sporadic Burkitt’s
1156
-Lymphoma in Children.” *Leukemia* 18 3: 584–88.
1157
-<https://doi.org/10.1038/sj.leu.2403254>.
1158
-
1159
-</div>
1160
-
1161
-<div id="ref-wuGeneticHeterogeneityPrimary2016" class="csl-entry">
1162
-
1163
-Wu, Chenglin, Noel Fcc de Miranda, Longyun Chen, Agata M. Wasik, Larry
1164
-Mansouri, Wojciech Jurczak, Krystyna Galazka, et al. 2016. “Genetic
1165
-Heterogeneity in Primary and Relapsed Mantle Cell Lymphomas: Impact of
1166
-Recurrent CARD11 Mutations.” *Oncotarget* 7 25: 38180–90.
1167
-<https://doi.org/10.18632/oncotarget.9500>.
1168
-
1169
-</div>
1170
-
1171
-<div id="ref-yanBCRTLRSignaling2012a" class="csl-entry">
1172
-
1173
-Yan, Qingguo, Yuanxue Huang, A. James Watkins, Sylvia Kocialkowski,
1174
-Naiyan Zeng, Rifat A. Hamoudi, Peter G. Isaacson, Laurence de Leval,
1175
-Andrew Wotherspoon, and Ming-Qing Du. 2012. “BCR and TLR Signaling
1176
-Pathways Are Recurrently Targeted by Genetic Changes in Splenic Marginal
1177
-Zone Lymphomas.” *Haematologica* 97 4: 595–98.
1178
-<https://doi.org/10.3324/haematol.2011.054080>.
1179
-
1180
-</div>
1181
-
1182
-<div id="ref-yildizActivatingSTAT6Mutations2015c" class="csl-entry">
1183
-
1184
-Yildiz, Mehmet, Hongxiu Li, Denzil Bernard, Nisar A. Amin, Peter
1185
-Ouillette, Siân Jones, Kamlai Saiya-Cork, et al. 2015. “Activating STAT6
1186
-Mutations in Follicular Lymphoma.” *Blood* 125 4: 668–79.
1187
-<https://doi.org/10.1182/blood-2014-06-582650>.
1188
-
1189
-</div>
1190
-
1191
-<div id="ref-zhangGeneticHeterogeneityDiffuse2013" class="csl-entry">
1192
-
1193
-Zhang, Jenny, Vladimir Grubor, Cassandra L Love, Anjishnu Banerjee,
1194
-Kristy L Richards, Piotr A Mieczkowski, Cherie Dunphy, et al. 2013.
1195
-“Genetic Heterogeneity of Diffuse Large <span
1196
-class="nocase">B-cell</span> Lymphoma.” January.
1197
-
1198
-</div>
1199
-
1200
-<div id="ref-zhangGenomicLandscapeMantle2014" class="csl-entry">
1201
-
1202
-Zhang, Jenny, Dereje Jima, Andrea B. Moffitt, Qingquan Liu, Magdalena
1203
-Czader, Eric D. Hsi, Yuri Fedoriw, et al. 2014. “The Genomic Landscape
1204
-of Mantle Cell Lymphoma Is Related to the Epigenetically Determined
1205
-Chromatin State of Normal B Cells.” *Blood* 123 19: 2988–96.
1206
-<https://doi.org/10.1182/blood-2013-07-517177>.
1207
-
1208
-</div>
1209
-
1210
-<div id="ref-zhouSporadicEndemicBurkitt2019" class="csl-entry">
1211
-
1212
-Zhou, Peixun, Alex E. Blain, Alexander M. Newman, Masood Zaka, George
1213
-Chagaluka, Filbert R. Adlar, Ugonna T. Offor, et al. 2019. “Sporadic and
1214
-Endemic Burkitt Lymphoma Have Frequent FOXO1 Mutations but Distinct
1215
-Hotspots in the AKT Recognition Motif.” *Blood Advances* 3 14:
1216
-2118–27. <https://doi.org/10.1182/bloodadvances.2018029546>.
1217
-
1218
-</div>
1219
-
1220
-</div>
353
+# References
MCL_genes.md
... ...
@@ -1,467 +1,96 @@
1
-# MCL genes
2
-
3
-## Origins of MCL genes
4
-```mermaid
5 1
---
6
-config:
7
- sankey:
8
- showValues: false
9
- linkColor: target
10
- width: 800
11
- height: 1000
12
- nodeAlignment: right
2
+title: 'MCL genes'
3
+bibliography: 'morinlab.bib'
4
+csl: 'NLM.csl'
5
+link-citations: true
13 6
---
14
-sankey-beta
15
-Zhang 2014, MCL Tier 1, 2
16
-Zhang 2014, MCL Tier 2, 26
17
-Nadeu 2020, MCL Tier 1, 3
18
-Nadeu 2020, MCL Tier 2, 2
19
-Pararajalingam 2020, MCL Tier 1, 6
20
-Pararajalingam 2020, MCL Tier 2, 1
21
-Bea 2013, MCL Tier 1, 11
22
-Bea 2013, MCL Tier 2, 16
23
-MCL, exome, 28
24
-exome, Zhang 2014, 28
25
-MCL, WGS/exome, 7
26
-WGS/exome, Pararajalingam 2020, 7
27
-MCL, WGS, 5
28
-WGS, Nadeu 2020, 5
29
-MCL, WGS/exome, 27
30
-WGS/exome, Bea 2013, 27
31
-```
7
+
8
+## Origins of MCL genes
9
+
10
+![](MCL_sankey-1.svg)
32 11
33 12
## Tier 1 MCL genes
34 13
35 14
### *23 total*
36 15
37
-| Gene | Tier | Relevant references |
38
-|:------------------:|:------------:|:-----------------------------------------------------------------------------------------------|
39
-| [ATM](ATM) | 1 | Beà et al. 2013; Braggio et al. 2012; Reddy et al. 2017 |
40
-| [BIRC3](BIRC3) | 1 | Duns et al. 2021; Rossi et al. 2011; Arthur et al. 2018; Beà et al. 2013 |
41
-| [CARD11](CARD11) | 1 | Wu et al. 2016; Panea et al. 2019; Morin et al. 2011; Yan et al. 2012; Lenz et al. 2008 |
42
-| [CCND1](CCND1) | 1, aSHM | Beà et al. 2013 |
43
-| [DAZAP1](DAZAP1) | 1 | Pararajalingam et al. 2020 |
44
-| [EWSR1](EWSR1) | 1 | Pararajalingam et al. 2020 |
45
-| [HNRNPH1](HNRNPH1) | 1, noncoding | Pararajalingam et al. 2020 |
46
-| [KMT2D](KMT2D) | 1 | Grande et al. 2019; Beà et al. 2013; Morin et al. 2011; Desch et al. 2020; Rossi et al. 2012 |
47
-| [MEF2B](MEF2B) | 1 | Beà et al. 2013; Morin et al. 2011 |
48
-| [NFKBIE](NFKBIE) | 1 | Mansouri et al. 2016; Pararajalingam et al. 2020; Morin et al. 2016 |
49
-| [NOTCH1](NOTCH1) | 1 | Rossi et al. 2012; Love et al. 2012; Pasqualucci et al. 2011; Beà et al. 2013 |
50
-| [NOTCH2](NOTCH2) | 1 | Trøen et al. 2008; Beà et al. 2013; Rossi et al. 2012; Panea et al. 2019 |
51
-| [NSD2](NSD2) | 1 | Beà et al. 2013 |
52
-| [POT1](POT1) | 1 | Zhang et al. 2014 |
53
-| [RB1](RB1) | 1 | Zhang et al. 2014; Morin et al. 2013 |
54
-| [S1PR1](S1PR1) | 1 | Pararajalingam et al. 2020 |
55
-| [SMARCA4](SMARCA4) | 1 | Nadeu et al. 2020; Zhang et al. 2013; Krysiak et al. 2017; Richter et al. 2012 |
56
-| [SP140](SP140) | 1 | Beà et al. 2013 |
57
-| [SYNE1](SYNE1) | 1 | Nadeu et al. 2020 |
58
-| [TERT](TERT) | 1, noncoding | Nadeu et al. 2020 |
59
-| [TLR2](TLR2) | 1 | Chapuy et al. 2018; Beà et al. 2013 |
60
-| [TP53](TP53) | 1 | Rossi et al. 2012; Wilda et al. 2004; Morin et al. 2011; Tiacci et al. 2018; Beà et al. 2013 |
61
-| [UBR5](UBR5) | 1 | Pararajalingam et al. 2020; Zhang et al. 2013 |
16
+|Gene|Tier| Relevant references|
17
+|:-:|:-:|:-|
18
+|[ATM](ATM)|1|[@reddyGeneticFunctionalDrivers2017; @braggioGenomicAnalysisMarginal2012; @beaLandscapeSomaticMutations2013]|
19
+|[BIRC3](BIRC3)|1|[@rossiAlterationBIRC3Multiple2011a; @beaLandscapeSomaticMutations2013; @arthurGenomewideDiscoverySomatic2018; @dunsCharacterizationDLBCLPMBL2021b]|
20
+|[CARD11](CARD11)|1|[@yanBCRTLRSignaling2012a; @lenzOncogenicCARD11Mutations2008; @morinFrequentMutationHistonemodifying2011; @wuGeneticHeterogeneityPrimary2016; @paneaWholeGenomeLandscape2019]|
21
+|[CCND1](CCND1)|1, aSHM|[@beaLandscapeSomaticMutations2013]|
22
+|[DAZAP1](DAZAP1)|1|[@pararajalingamCodingNoncodingDrivers2020]|
23
+|[EWSR1](EWSR1)|1|[@pararajalingamCodingNoncodingDrivers2020]|
24
+|[HNRNPH1](HNRNPH1)|1, noncoding|[@pararajalingamCodingNoncodingDrivers2020]|
25
+|[KMT2D](KMT2D)|1|[@rossiCodingGenomeSplenic2012c; @morinFrequentMutationHistonemodifying2011; @beaLandscapeSomaticMutations2013; @grandeGenomewideDiscoverySomatic2019; @deschGenotypingCirculatingTumor2020]|
26
+|[MEF2B](MEF2B)|1|[@beaLandscapeSomaticMutations2013; @morinFrequentMutationHistonemodifying2011]|
27
+|[NFKBIE](NFKBIE)|1|[@pararajalingamCodingNoncodingDrivers2020; @mansouriFrequentNFKBIEDeletions2016; @morinGeneticLandscapesRelapsed2016]|
28
+|[NOTCH1](NOTCH1)|1|[@rossiCodingGenomeSplenic2012c; @loveGeneticLandscapeMutations2012; @beaLandscapeSomaticMutations2013; @pasqualucciAnalysisCodingGenome2011]|
29
+|[NOTCH2](NOTCH2)|1|[@troenNOTCH2MutationsMarginal2008; @paneaWholeGenomeLandscape2019; @rossiCodingGenomeSplenic2012c; @beaLandscapeSomaticMutations2013]|
30
+|[NSD2](NSD2)|1|[@beaLandscapeSomaticMutations2013]|
31
+|[POT1](POT1)|1|[@zhangGenomicLandscapeMantle2014]|
32
+|[RB1](RB1)|1|[@morinMutationalStructuralAnalysis2013; @zhangGenomicLandscapeMantle2014]|
33
+|[S1PR1](S1PR1)|1|[@pararajalingamCodingNoncodingDrivers2020]|
34
+|[SMARCA4](SMARCA4)|1|[@richterRecurrentMutationID32012a; @nadeuGenomicEpigenomicInsights2020b; @zhangGeneticHeterogeneityDiffuse2013; @krysiakRecurrentSomaticMutations2017b]|
35
+|[SP140](SP140)|1|[@beaLandscapeSomaticMutations2013]|
36
+|[SYNE1](SYNE1)|1|[@nadeuGenomicEpigenomicInsights2020b]|
37
+|[TERT](TERT)|1, noncoding|[@nadeuGenomicEpigenomicInsights2020b]|
38
+|[TLR2](TLR2)|1|[@chapuyMolecularSubtypesDiffuse2018b; @beaLandscapeSomaticMutations2013]|
39
+|[TP53](TP53)|1|[@beaLandscapeSomaticMutations2013; @wildaInactivationARFMDM2p53Pathway2004; @tiacciPervasiveMutationsJAKSTAT2018b; @morinFrequentMutationHistonemodifying2011; @rossiCodingGenomeSplenic2012c]|
40
+|[UBR5](UBR5)|1|[@zhangGeneticHeterogeneityDiffuse2013; @pararajalingamCodingNoncodingDrivers2020]|
62 41
63 42
## Tier 2 MCL genes
64 43
65 44
### *46 total*
66 45
67
-| Gene | Tier | Relevant references |
68
-|:--------------------:|:----:|:------------------------------------------------------------------------------|
69
-| [ABCA3](ABCA3) | 2 | Beà et al. 2013 |
70
-| [ABCC9](ABCC9) | 2 | Beà et al. 2013 |
71
-| [ANK2](ANK2) | 2 | Zhang et al. 2014 |
72
-| [ARID1B](ARID1B) | 2 | Reddy et al. 2017 |
73
-| [ATP11C](ATP11C) | 2 | Zhang et al. 2014 |
74
-| [B2M](B2M) | 2 | Pararajalingam et al. 2020; Reichel et al. 2015; Morin et al. 2011 |
75
-| [BCOR](BCOR) | 2 | Nadeu et al. 2020; Jallades et al. 2017 |
76
-| [CDH8](CDH8) | 2 | Zhang et al. 2014 |
77
-| [CHMP4C](CHMP4C) | 2 | Beà et al. 2013 |
78
-| [COL11A1](COL11A1) | 2 | Zhang et al. 2014 |
79
-| [COL16A1](COL16A1) | 2 | Zhang et al. 2014 |
80
-| [CRYBG3](CRYBG3) | 2 | Beà et al. 2013 |
81
-| [CTNNA2](CTNNA2) | 2 | Zhang et al. 2014 |
82
-| [DCP1B](DCP1B) | 2 | Beà et al. 2013 |
83
-| [DHDH](DHDH) | 2 | Zhang et al. 2014 |
84
-| [DLC1](DLC1) | 2 | Zhang et al. 2014 |
85
-| [DLGAP2](DLGAP2) | 2 | Beà et al. 2013 |
86
-| [DNAJC6](DNAJC6) | 2 | Beà et al. 2013 |
87
-| [EIF2AK4](EIF2AK4) | 2 | Zhang et al. 2014 |
88
-| [ESX1](ESX1) | 2 | Zhang et al. 2014 |
89
-| [FAT4](FAT4) | 2 | Parry et al. 2013; Zhang et al. 2014; Morin et al. 2013 |
90
-| [GRIN2A](GRIN2A) | 2 | Zhang et al. 2014 |
91
-| [HEPH](HEPH) | 2 | Zhang et al. 2014 |
92
-| [KCNC2](KCNC2) | 2 | Beà et al. 2013 |
93
-| [KIAA1671](KIAA1671) | 2 | Beà et al. 2013 |
94
-| [KMT2C](KMT2C) | 2 | Sarkozy et al. 2021; Zhang et al. 2014; Zhang et al. 2013; Zhou et al. 2019 |
95
-| [LUZP4](LUZP4) | 2 | Beà et al. 2013 |
96
-| [MRGPRF](MRGPRF) | 2 | Zhang et al. 2014 |
97
-| [NIN](NIN) | 2 | Zhang et al. 2014 |
98
-| [OGDHL](OGDHL) | 2 | Zhang et al. 2014 |
99
-| [PCDHB2](PCDHB2) | 2 | Zhang et al. 2014 |
100
-| [PCSK2](PCSK2) | 2 | Beà et al. 2013 |
101
-| [PDLIM3](PDLIM3) | 2 | Beà et al. 2013 |
102
-| [PLXNB3](PLXNB3) | 2 | Spina et al. 2016; Zhang et al. 2014 |
103
-| [RGS4](RGS4) | 2 | Beà et al. 2013 |
104
-| [ROBO2](ROBO2) | 2 | Zhang et al. 2014 |
105
-| [SALL3](SALL3) | 2 | Love et al. 2012; Zhang et al. 2014 |
106
-| [SI](SI) | 2 | Zhang et al. 2014 |
107
-| [SLC17A6](SLC17A6) | 2 | Beà et al. 2013 |
108
-| [SMARCB1](SMARCB1) | 2 | Nadeu et al. 2020 |
109
-| [SMC1A](SMC1A) | 2 | Zhang et al. 2014 |
110
-| [TBC1D26](TBC1D26) | 2 | Zhang et al. 2014 |
111
-| [TNRC6B](TNRC6B) | 2 | Beà et al. 2013 |
112
-| [TRPM6](TRPM6) | 2 | Beà et al. 2013 |
113
-| [ZNF117](ZNF117) | 2 | Zhang et al. 2014 |
114
-| [ZNF296](ZNF296) | 2 | Zhang et al. 2014 |
115
-
116
-# References
117
-
118
-<div id="refs" class="references csl-bib-body hanging-indent">
119
-
120
-<div id="ref-arthurGenomewideDiscoverySomatic2018" class="csl-entry">
121
-
122
-Arthur, Sarah E., Aixiang Jiang, Bruno M. Grande, Miguel Alcaide, Razvan
123
-Cojocaru, Christopher K. Rushton, Anja Mottok, et al. 2018. “Genome-Wide
124
-Discovery of Somatic Regulatory Variants in Diffuse Large <span
125
-class="nocase">B-cell</span> Lymphoma.” *Nature Communications* 9 1:
126
-4001. <https://doi.org/10.1038/s41467-018-06354-3>.
127
-
128
-</div>
129
-
130
-<div id="ref-beaLandscapeSomaticMutations2013" class="csl-entry">
131
-
132
-Beà, Sílvia, Rafael Valdés-Mas, Alba Navarro, Itziar Salaverria, David
133
-Martín-Garcia, Pedro Jares, Eva Giné, et al. 2013. “Landscape of Somatic
134
-Mutations and Clonal Evolution in Mantle Cell Lymphoma.” *Proceedings of
135
-the National Academy of Sciences* 110 45: 18250–55.
136
-<https://doi.org/10.1073/pnas.1314608110>.
137
-
138
-</div>
139
-
140
-<div id="ref-braggioGenomicAnalysisMarginal2012" class="csl-entry">
141
-
142
-Braggio, Esteban, Ahmet Dogan, Jonathan J. Keats, Wee J. Chng, Gaofeng
143
-Huang, Julie M. Matthews, Matthew J. Maurer, et al. 2012. “Genomic
144
-Analysis of Marginal Zone and Lymphoplasmacytic Lymphomas Identified
145
-Common and Disease-Specific Abnormalities.” *Modern Pathology: An
146
-Official Journal of the United States and Canadian Academy of Pathology,
147
-Inc* 25 5: 651–60. <https://doi.org/10.1038/modpathol.2011.213>.
148
-
149
-</div>
150
-
151
-<div id="ref-chapuyMolecularSubtypesDiffuse2018b" class="csl-entry">
152
-
153
-Chapuy, Bjoern, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Atanas
154
-Kamburov, Robert A. Redd, Mike S. Lawrence, et al. 2018. “Molecular
155
-Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct
156
-Pathogenic Mechanisms and Outcomes.” *Nature Medicine* 24 5: 679–90.
157
-<https://doi.org/10.1038/s41591-018-0016-8>.
158
-
159
-</div>
160
-
161
-<div id="ref-deschGenotypingCirculatingTumor2020" class="csl-entry">
162
-
163
-Desch, Ann-Kathrin, Kristin Hartung, Ante Botzen, Alexander Brobeil,
164
-Mathias Rummel, Lars Kurch, Thomas Georgi, et al. 2020. “Genotyping
165
-Circulating Tumor DNA of Pediatric Hodgkin Lymphoma.” *Leukemia* 34 1:
166
-151–66. <https://doi.org/10.1038/s41375-019-0541-6>.
167
-
168
-</div>
169
-
170
-<div id="ref-dunsCharacterizationDLBCLPMBL2021b" class="csl-entry">
171
-
172
-Duns, Gerben, Elena Viganò, Daisuke Ennishi, Clementine Sarkozy, Stacy
173
-S. Hung, Elizabeth Chavez, Katsuyoshi Takata, et al. 2021.
174
-“Characterization of DLBCL with a PMBL Gene Expression Signature.”
175
-*Blood* 138 2: 136–48. <https://doi.org/10.1182/blood.2020007683>.
176
-
177
-</div>
178
-
179
-<div id="ref-grandeGenomewideDiscoverySomatic2019" class="csl-entry">
180
-
181
-Grande, Bruno M., Daniela S. Gerhard, Aixiang Jiang, Nicholas B. Griner,
182
-Jeremy S. Abramson, Thomas B. Alexander, Hilary Allen, et al. 2019.
183
-“Genome-Wide Discovery of Somatic Coding and Noncoding Mutations in
184
-Pediatric Endemic and Sporadic Burkitt Lymphoma.” *Blood* 133 12:
185
-1313–24. <https://doi.org/10.1182/blood-2018-09-871418>.
186
-
187
-</div>
188
-
189
-<div id="ref-jalladesExomeSequencingIdentifies2017" class="csl-entry">
190
-
191
-Jallades, Laurent, Lucile Baseggio, Pierre Sujobert, Sarah Huet, Kaddour
192
-Chabane, Evelyne Callet-Bauchu, Aurélie Verney, et al. 2017. “Exome
193
-Sequencing Identifies Recurrent BCOR Alterations and the Absence of
194
-KLF2, TNFAIP3 and MYD88 Mutations in Splenic Diffuse Red Pulp Small
195
-<span class="nocase">B-cell</span> Lymphoma.” *Haematologica* 102 10:
196
-1758–66. <https://doi.org/10.3324/haematol.2016.160192>.
197
-
198
-</div>
199
-
200
-<div id="ref-krysiakRecurrentSomaticMutations2017b" class="csl-entry">
201
-
202
-Krysiak, Kilannin, Felicia Gomez, Brian S. White, Matthew Matlock,
203
-Christopher A. Miller, Lee Trani, Catrina C. Fronick, et al. 2017.
204
-“Recurrent Somatic Mutations Affecting <span
205
-class="nocase">B-cell</span> Receptor Signaling Pathway Genes in
206
-Follicular Lymphoma.” *Blood* 129 4: 473–83.
207
-<https://doi.org/10.1182/blood-2016-07-729954>.
208
-
209
-</div>
210
-
211
-<div id="ref-lenzOncogenicCARD11Mutations2008" class="csl-entry">
212
-
213
-Lenz, Georg, R Eric Davis, Vu N Ngo, Lloyd Lam, Thaddeus C George,
214
-George W Wright, Sandeep S Dave, et al. 2008. “Oncogenic CARD11
215
-Mutations in Human Diffuse Large B Cell Lymphoma.” *Science* 319 5870:
216
-1676–79.
217
-
218
-</div>
219
-
220
-<div id="ref-loveGeneticLandscapeMutations2012" class="csl-entry">
221
-
222
-Love, Cassandra, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney
223
-Miles, Kristy L. Richards, et al. 2012. “The Genetic Landscape of
224
-Mutations in Burkitt Lymphoma.” *Nature Genetics* 44 12: 1321–25.
225
-<https://doi.org/10.1038/ng.2468>.
226
-
227
-</div>
228
-
229
-<div id="ref-mansouriFrequentNFKBIEDeletions2016" class="csl-entry">
230
-
231
-Mansouri, Larry, Daniel Noerenberg, Emma Young, Elena Mylonas, Maysaa
232
-Abdulla, Mareike Frick, Fazila Asmar, et al. 2016. “Frequent NFKBIE
233
-Deletions Are Associated with Poor Outcome in Primary Mediastinal <span
234
-class="nocase">B-cell</span> Lymphoma.” *Blood* 128 23: 2666–70.
235
-<https://doi.org/10.1182/blood-2016-03-704528>.
236
-
237
-</div>
238
-
239
-<div id="ref-morinGeneticLandscapesRelapsed2016" class="csl-entry">
240
-
241
-Morin, Ryan D., Sarit Assouline, Miguel Alcaide, Arezoo Mohajeri,
242
-Rebecca L. Johnston, Lauren Chong, Jasleen Grewal, et al. 2016. “Genetic
243
-Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.”
244
-*Clinical Cancer Research: An Official Journal of the American
245
-Association for Cancer Research* 22 9: 2290–300.
246
-<https://doi.org/10.1158/1078-0432.CCR-15-2123>.
247
-
248
-</div>
249
-
250
-<div id="ref-morinFrequentMutationHistonemodifying2011"
251
-class="csl-entry">
252
-
253
-Morin, Ryan D., Maria Mendez-Lago, Andrew J. Mungall, Rodrigo Goya,
254
-Karen L. Mungall, Richard D. Corbett, Nathalie A. Johnson, et al. 2011.
255
-“Frequent Mutation of Histone-Modifying Genes in Non-Hodgkin Lymphoma.”
256
-*Nature* 476 7360: 298–303. <https://doi.org/10.1038/nature10351>.
257
-
258
-</div>
259
-
260
-<div id="ref-morinMutationalStructuralAnalysis2013" class="csl-entry">
261
-
262
-Morin, Ryan D., Karen Mungall, Erin Pleasance, Andrew J. Mungall,
263
-Rodrigo Goya, Ryan D. Huff, David W. Scott, et al. 2013. “Mutational and
264
-Structural Analysis of Diffuse Large <span class="nocase">B-cell</span>
265
-Lymphoma Using Whole-Genome Sequencing.” *Blood* 122 7: 1256–65.
266
-<https://doi.org/10.1182/blood-2013-02-483727>.
267
-
268
-</div>
269
-
270
-<div id="ref-nadeuGenomicEpigenomicInsights2020b" class="csl-entry">
271
-
272
-Nadeu, F., D. Martín-García, G. Clot, A. Díaz-Navarro, M. Duran-Ferrer,
273
-A. Navarro, Roser Vilarrasa-Blasi, et al. 2020. “Genomic and Epigenomic
274
-Insights into the Origin, Pathogenesis and Clinical Behavior of Mantle
275
-Cell Lymphoma Subtypes.” *Blood*.
276
-<https://doi.org/10.1182/blood.2020005289>.
277
-
278
-</div>
279
-
280
-<div id="ref-paneaWholeGenomeLandscape2019" class="csl-entry">
46
+|Gene|Tier| Relevant references|
47
+|:-:|:-:|:-|
48
+|[ABCA3](ABCA3)|2|[@beaLandscapeSomaticMutations2013]|
49
+|[ABCC9](ABCC9)|2|[@beaLandscapeSomaticMutations2013]|
50
+|[ANK2](ANK2)|2|[@zhangGenomicLandscapeMantle2014]|
51
+|[ARID1B](ARID1B)|2|[@reddyGeneticFunctionalDrivers2017]|
52
+|[ATP11C](ATP11C)|2|[@zhangGenomicLandscapeMantle2014]|
53
+|[B2M](B2M)|2|[@pararajalingamCodingNoncodingDrivers2020; @reichelFlowSortingExome2015a; @morinFrequentMutationHistonemodifying2011]|
54
+|[BCOR](BCOR)|2|[@jalladesExomeSequencingIdentifies2017; @nadeuGenomicEpigenomicInsights2020b]|
55
+|[CDH8](CDH8)|2|[@zhangGenomicLandscapeMantle2014]|
56
+|[CHMP4C](CHMP4C)|2|[@beaLandscapeSomaticMutations2013]|
57
+|[COL11A1](COL11A1)|2|[@zhangGenomicLandscapeMantle2014]|
58
+|[COL16A1](COL16A1)|2|[@zhangGenomicLandscapeMantle2014]|
59
+|[CRYBG3](CRYBG3)|2|[@beaLandscapeSomaticMutations2013]|
60
+|[CTNNA2](CTNNA2)|2|[@zhangGenomicLandscapeMantle2014]|
61
+|[DCP1B](DCP1B)|2|[@beaLandscapeSomaticMutations2013]|
62
+|[DHDH](DHDH)|2|[@zhangGenomicLandscapeMantle2014]|
63
+|[DLC1](DLC1)|2|[@zhangGenomicLandscapeMantle2014]|
64
+|[DLGAP2](DLGAP2)|2|[@beaLandscapeSomaticMutations2013]|
65
+|[DNAJC6](DNAJC6)|2|[@beaLandscapeSomaticMutations2013]|
66
+|[EIF2AK4](EIF2AK4)|2|[@zhangGenomicLandscapeMantle2014]|
67
+|[ESX1](ESX1)|2|[@zhangGenomicLandscapeMantle2014]|
68
+|[FAT4](FAT4)|2|[@parryWholeExomeSequencing2013; @zhangGenomicLandscapeMantle2014; @morinMutationalStructuralAnalysis2013]|
69
+|[GRIN2A](GRIN2A)|2|[@zhangGenomicLandscapeMantle2014]|
70
+|[HEPH](HEPH)|2|[@zhangGenomicLandscapeMantle2014]|
71
+|[KCNC2](KCNC2)|2|[@beaLandscapeSomaticMutations2013]|
72
+|[KIAA1671](KIAA1671)|2|[@beaLandscapeSomaticMutations2013]|
73
+|[KMT2C](KMT2C)|2|[@sarkozyMutationalLandscapeGray2021a; @zhangGeneticHeterogeneityDiffuse2013; @zhangGenomicLandscapeMantle2014; @zhouSporadicEndemicBurkitt2019]|
74
+|[LUZP4](LUZP4)|2|[@beaLandscapeSomaticMutations2013]|
75
+|[MRGPRF](MRGPRF)|2|[@zhangGenomicLandscapeMantle2014]|
76
+|[NIN](NIN)|2|[@zhangGenomicLandscapeMantle2014]|
77
+|[OGDHL](OGDHL)|2|[@zhangGenomicLandscapeMantle2014]|
78
+|[PCDHB2](PCDHB2)|2|[@zhangGenomicLandscapeMantle2014]|
79
+|[PCSK2](PCSK2)|2|[@beaLandscapeSomaticMutations2013]|
80
+|[PDLIM3](PDLIM3)|2|[@beaLandscapeSomaticMutations2013]|
81
+|[PLXNB3](PLXNB3)|2|[@zhangGenomicLandscapeMantle2014; @spinaGeneticsNodalMarginal2016b]|
82
+|[RGS4](RGS4)|2|[@beaLandscapeSomaticMutations2013]|
83
+|[ROBO2](ROBO2)|2|[@zhangGenomicLandscapeMantle2014]|
84
+|[SALL3](SALL3)|2|[@loveGeneticLandscapeMutations2012; @zhangGenomicLandscapeMantle2014]|
85
+|[SI](SI)|2|[@zhangGenomicLandscapeMantle2014]|
86
+|[SLC17A6](SLC17A6)|2|[@beaLandscapeSomaticMutations2013]|
87
+|[SMARCB1](SMARCB1)|2|[@nadeuGenomicEpigenomicInsights2020b]|
88
+|[SMC1A](SMC1A)|2|[@zhangGenomicLandscapeMantle2014]|
89
+|[TBC1D26](TBC1D26)|2|[@zhangGenomicLandscapeMantle2014]|
90
+|[TNRC6B](TNRC6B)|2|[@beaLandscapeSomaticMutations2013]|
91
+|[TRPM6](TRPM6)|2|[@beaLandscapeSomaticMutations2013]|
92
+|[ZNF117](ZNF117)|2|[@zhangGenomicLandscapeMantle2014]|
93
+|[ZNF296](ZNF296)|2|[@zhangGenomicLandscapeMantle2014]|
281 94
282
-Panea, R., C. Love, Jennifer R. Shingleton, Anupama Reddy, J. Bailey, A.
283
-Moormann, J. Otieno, et al. 2019. “The Whole Genome Landscape of Burkitt
284
-Lymphoma Subtypes.” *Blood*. <https://doi.org/10.1182/blood.2019001880>.
285 95
286
-</div>
287
-
288
-<div id="ref-pararajalingamCodingNoncodingDrivers2020"
289
-class="csl-entry">
290
-
291
-Pararajalingam, Prasath, Krysta M. Coyle, Sarah E. Arthur, Nicole
292
-Thomas, Miguel Alcaide, Barbara Meissner, Merrill Boyle, et al. 2020.
293
-“Coding and Noncoding Drivers of Mantle Cell Lymphoma Identified Through
294
-Exome and Genome Sequencing.” *Blood* 136 5: 572–84.
295
-<https://doi.org/10.1182/blood.2019002385>.
296
-
297
-</div>
298
-
299
-<div id="ref-parryWholeExomeSequencing2013" class="csl-entry">
300
-
301
-Parry, Marina, Matthew J. J. Rose-Zerilli, Jane Gibson, Sarah Ennis,
302
-Renata Walewska, Jade Forster, Helen Parker, et al. 2013. “Whole Exome
303
-Sequencing Identifies Novel Recurrently Mutated Genes in Patients with
304
-Splenic Marginal Zone Lymphoma.” *PloS One* 8 12: e83244.
305
-<https://doi.org/10.1371/journal.pone.0083244>.
306
-
307
-</div>
308
-
309
-<div id="ref-pasqualucciAnalysisCodingGenome2011" class="csl-entry">
310
-
311
-Pasqualucci, Laura, Vladimir Trifonov, Giulia Fabbri, Jing Ma, Davide
312
-Rossi, Annalisa Chiarenza, Victoria A. Wells, et al. 2011. “Analysis of
313
-the Coding Genome of Diffuse Large <span class="nocase">B-cell</span>
314
-Lymphoma.” *Nature Genetics* 43 9: 830–37.
315
-<https://doi.org/10.1038/ng.892>.
316
-
317
-</div>
318
-
319
-<div id="ref-reddyGeneticFunctionalDrivers2017" class="csl-entry">
320
-
321
-Reddy, Anupama, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt,
322
-Cassandra L Love, Alexander Waldrop, Sirpa Leppa, et al. 2017. “Genetic
323
-and Functional Drivers of Diffuse Large B Cell Lymphoma.” *Cell* 171
324
-2: 481–494.e15.
325
-
326
-</div>
327
-
328
-<div id="ref-reichelFlowSortingExome2015a" class="csl-entry">
329
-
330
-Reichel, Jonathan, Amy Chadburn, Paul G. Rubinstein, Lisa Giulino-Roth,
331
-Wayne Tam, Yifang Liu, Rafael Gaiolla, et al. 2015. “Flow Sorting and
332
-Exome Sequencing Reveal the Oncogenome of Primary Hodgkin and
333
-Reed-Sternberg Cells.” *Blood* 125 7: 1061–72.
334
-<https://doi.org/10.1182/blood-2014-11-610436>.
335
-
336
-</div>
337
-
338
-<div id="ref-richterRecurrentMutationID32012a" class="csl-entry">
339
-
340
-Richter, Julia, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen
341
-Leich, Birgit Burkhardt, Maciej Rosolowski, et al. 2012. “Recurrent
342
-Mutation of the ID3 Gene in Burkitt Lymphoma Identified by Integrated
343
-Genome, Exome and Transcriptome Sequencing.” *Nature Genetics* 44 12:
344
-1316–20. <https://doi.org/10.1038/ng.2469>.
345
-
346
-</div>
347
-
348
-<div id="ref-rossiAlterationBIRC3Multiple2011a" class="csl-entry">
349
-
350
-Rossi, Davide, Silvia Deaglio, David Dominguez-Sola, Silvia Rasi,
351
-Tiziana Vaisitti, Claudio Agostinelli, Valeria Spina, et al. 2011.
352
-“Alteration of BIRC3 and Multiple Other <span
353
-class="nocase">NF-κB</span> Pathway Genes in Splenic Marginal Zone
354
-Lymphoma.” *Blood* 118 18: 4930–34.
355
-<https://doi.org/10.1182/blood-2011-06-359166>.
356
-
357
-</div>
358
-
359
-<div id="ref-rossiCodingGenomeSplenic2012c" class="csl-entry">
360
-
361
-Rossi, Davide, Vladimir Trifonov, Marco Fangazio, Alessio Bruscaggin,
362
-Silvia Rasi, Valeria Spina, Sara Monti, et al. 2012. “The Coding Genome
363
-of Splenic Marginal Zone Lymphoma: Activation of NOTCH2 and Other
364
-Pathways Regulating Marginal Zone Development.” *The Journal of
365
-Experimental Medicine* 209 9: 1537–51.
366
-<https://doi.org/10.1084/jem.20120904>.
367
-
368
-</div>
369
-
370
-<div id="ref-sarkozyMutationalLandscapeGray2021a" class="csl-entry">
371
-
372
-Sarkozy, Clémentine, Stacy S. Hung, Elizabeth A. Chavez, Gerben Duns,
373
-Katsuyoshi Takata, Lauren C. Chong, Tomohiro Aoki, et al. 2021.
374
-“Mutational Landscape of Gray Zone Lymphoma.” *Blood* 137 13: 1765–76.
375
-<https://doi.org/10.1182/blood.2020007507>.
376
-
377
-</div>
378
-
379
-<div id="ref-spinaGeneticsNodalMarginal2016b" class="csl-entry">
380
-
381
-Spina, Valeria, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano
382
-Cascione, Alessio Bruscaggin, Elisa Spaccarotella, et al. 2016. “The
383
-Genetics of Nodal Marginal Zone Lymphoma.” *Blood* 128 10: 1362–73.
384
-<https://doi.org/10.1182/blood-2016-02-696757>.
385
-
386
-</div>
387
-
388
-<div id="ref-tiacciPervasiveMutationsJAKSTAT2018b" class="csl-entry">
389
-
390
-Tiacci, Enrico, Erik Ladewig, Gianluca Schiavoni, Alex Penson,
391
-Elisabetta Fortini, Valentina Pettirossi, Yuchun Wang, et al. 2018.
392
-“Pervasive Mutations of JAK-STAT Pathway Genes in Classical Hodgkin
393
-Lymphoma.” *Blood* 131 22: 2454–65.
394
-<https://doi.org/10.1182/blood-2017-11-814913>.
395
-
396
-</div>
397
-
398
-<div id="ref-troenNOTCH2MutationsMarginal2008" class="csl-entry">
399
-
400
-Trøen, Gunhild, Iwona Wlodarska, Abdirashid Warsame, Silvia Hernández
401
-Llodrà, Christiane De Wolf-Peeters, and Jan Delabie. 2008. “NOTCH2
402
-Mutations in Marginal Zone Lymphoma.” *Haematologica* 93 7: 1107–9.
403
-<https://doi.org/10.3324/haematol.11635>.
404
-
405
-</div>
406
-
407
-<div id="ref-wildaInactivationARFMDM2p53Pathway2004" class="csl-entry">
408
-
409
-Wilda, M., J. Bruch, L. Harder, D. Rawer, A. Reiter, A. Borkhardt, and
410
-W. Woessmann. 2004. “Inactivation of the <span
411
-class="nocase">ARF-MDM-2-p53</span> Pathway in Sporadic Burkitt’s
412
-Lymphoma in Children.” *Leukemia* 18 3: 584–88.
413
-<https://doi.org/10.1038/sj.leu.2403254>.
414
-
415
-</div>
416
-
417
-<div id="ref-wuGeneticHeterogeneityPrimary2016" class="csl-entry">
418
-
419
-Wu, Chenglin, Noel Fcc de Miranda, Longyun Chen, Agata M. Wasik, Larry
420
-Mansouri, Wojciech Jurczak, Krystyna Galazka, et al. 2016. “Genetic
421
-Heterogeneity in Primary and Relapsed Mantle Cell Lymphomas: Impact of
422
-Recurrent CARD11 Mutations.” *Oncotarget* 7 25: 38180–90.
423
-<https://doi.org/10.18632/oncotarget.9500>.
424
-
425
-</div>
426
-
427
-<div id="ref-yanBCRTLRSignaling2012a" class="csl-entry">
428
-
429
-Yan, Qingguo, Yuanxue Huang, A. James Watkins, Sylvia Kocialkowski,
430
-Naiyan Zeng, Rifat A. Hamoudi, Peter G. Isaacson, Laurence de Leval,
431
-Andrew Wotherspoon, and Ming-Qing Du. 2012. “BCR and TLR Signaling
432
-Pathways Are Recurrently Targeted by Genetic Changes in Splenic Marginal
433
-Zone Lymphomas.” *Haematologica* 97 4: 595–98.
434
-<https://doi.org/10.3324/haematol.2011.054080>.
435
-
436
-</div>
437
-
438
-<div id="ref-zhangGeneticHeterogeneityDiffuse2013" class="csl-entry">
439
-
440
-Zhang, Jenny, Vladimir Grubor, Cassandra L Love, Anjishnu Banerjee,
441
-Kristy L Richards, Piotr A Mieczkowski, Cherie Dunphy, et al. 2013.
442
-“Genetic Heterogeneity of Diffuse Large <span
443
-class="nocase">B-cell</span> Lymphoma.” January.
444
-
445
-</div>
446
-
447
-<div id="ref-zhangGenomicLandscapeMantle2014" class="csl-entry">
448
-
449
-Zhang, Jenny, Dereje Jima, Andrea B. Moffitt, Qingquan Liu, Magdalena
450
-Czader, Eric D. Hsi, Yuri Fedoriw, et al. 2014. “The Genomic Landscape
451
-of Mantle Cell Lymphoma Is Related to the Epigenetically Determined
452
-Chromatin State of Normal B Cells.” *Blood* 123 19: 2988–96.
453
-<https://doi.org/10.1182/blood-2013-07-517177>.
454
-
455
-</div>
456
-
457
-<div id="ref-zhouSporadicEndemicBurkitt2019" class="csl-entry">
458
-
459
-Zhou, Peixun, Alex E. Blain, Alexander M. Newman, Masood Zaka, George
460
-Chagaluka, Filbert R. Adlar, Ugonna T. Offor, et al. 2019. “Sporadic and
461
-Endemic Burkitt Lymphoma Have Frequent FOXO1 Mutations but Distinct
462
-Hotspots in the AKT Recognition Motif.” *Blood Advances* 3 14:
463
-2118–27. <https://doi.org/10.1182/bloodadvances.2018029546>.
464
-
465
-</div>
466
-
467
-</div>
96
+# References
MZL_genes.md
... ...
@@ -0,0 +1,143 @@
1
+---
2
+title: 'MZL genes'
3
+bibliography: 'morinlab.bib'
4
+csl: 'NLM.csl'
5
+link-citations: true
6
+---
7
+
8
+## Origins of MZL genes
9
+
10
+![](MZL_sankey-1.svg)
11
+
12
+## Tier 1 MZL genes
13
+
14
+### *42 total*
15
+
16
+|Gene|Tier| Relevant references|
17
+|:-:|:-:|:-|
18
+|[ACTB](ACTB)|1|[@lohrDiscoveryPrioritizationSomatic2012a; @wienandGenomicAnalysesFlowsorted2019b]|
19
+|[ARID1A](ARID1A)|1|[@krysiakRecurrentSomaticMutations2017b; @rossiCodingGenomeSplenic2012c; @zhangGeneticHeterogeneityDiffuse2013; @wienandGenomicAnalysesFlowsorted2019b; @loveGeneticLandscapeMutations2012]|
20
+|[ATM](ATM)|1|[@beaLandscapeSomaticMutations2013; @reddyGeneticFunctionalDrivers2017; @braggioGenomicAnalysisMarginal2012]|
21
+|[BCL10](BCL10)|1|[@spinaGeneticsNodalMarginal2016b; @russler-germainMutationsAssociatedProgression2023b; @morinFrequentMutationHistonemodifying2011]|
22
+|[BCL7A](BCL7A)|1|[@reichelFlowSortingExome2015a; @grandeGenomewideDiscoverySomatic2019; @arthurGenomewideDiscoverySomatic2018; @krysiakRecurrentSomaticMutations2017b]|
23
+|[BIRC3](BIRC3)|1|[@rossiAlterationBIRC3Multiple2011a; @beaLandscapeSomaticMutations2013; @arthurGenomewideDiscoverySomatic2018; @dunsCharacterizationDLBCLPMBL2021b]|
24
+|[BRAF](BRAF)|1|[@loveGeneticLandscapeMutations2012; @tiacciBRAFMutationsHairycell2011a]|
25
+|[BTG1](BTG1)|1|[@burkhardtClinicalRelevanceMolecular2022b; @sarkozyMutationalLandscapeGray2021a; @morinFrequentMutationHistonemodifying2011]|
26
+|[CARD11](CARD11)|1|[@lenzOncogenicCARD11Mutations2008; @wuGeneticHeterogeneityPrimary2016; @morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019; @yanBCRTLRSignaling2012a]|
27
+|[CCND3](CCND3)|1|[@jalladesExomeSequencingIdentifies2017; @morinFrequentMutationHistonemodifying2011; @deschGenotypingCirculatingTumor2020; @richterRecurrentMutationID32012a]|
28
+|[CXCR4](CXCR4)|1|[@krysiakRecurrentSomaticMutations2017b; @paneaWholeGenomeLandscape2019; @khodabakhshiRecurrentTargetsAberrant2012]|
29
+|[DTX1](DTX1)|1|[@gomezUltraDeepSequencingReveals2023; @schmitzGeneticsPathogenesisDiffuse2018a; @paneaWholeGenomeLandscape2019; @rossiCodingGenomeSplenic2012c]|
30
+|[EP300](EP300)|1|[@pasqualucciInactivatingMutationsAcetyltransferase2011a; @rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019]|
31
+|[EZH2](EZH2)|1|[@loveGeneticLandscapeMutations2012; @mottokIntegrativeGenomicAnalysis2019b; @morinSomaticMutationsAltering2010a]|
32
+|[FAS](FAS)|1|[@spinaGeneticsNodalMarginal2016b; @schollMutationsRegionFAS2007]|
33
+|[FAT1](FAT1)|1|[@spinaGeneticsNodalMarginal2016b]|
34
+|[FOXO1](FOXO1)|1|[@schmitzBurkittLymphomaPathogenesis2012; @morinFrequentMutationHistonemodifying2011; @dunsCharacterizationDLBCLPMBL2021b]|
35
+|[H1-4](H1-4)|1||
36
+|[H1-5](H1-5)|1||
37
+|[ID3](ID3)|1|[@richterRecurrentMutationID32012a; @spinaGeneticsNodalMarginal2016b; @schmitzBurkittLymphomaPathogenesis2012]|
38
+|[KLF2](KLF2)|1|[@jalladesExomeSequencingIdentifies2017; @pasqualucciAnalysisCodingGenome2011; @deschGenotypingCirculatingTumor2020]|
39
+|[KLHL6](KLHL6)|1|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011; @ganapathiGeneticLandscapeDural2016]|
40
+|[KMT2D](KMT2D)|1|[@beaLandscapeSomaticMutations2013; @grandeGenomewideDiscoverySomatic2019; @deschGenotypingCirculatingTumor2020; @rossiCodingGenomeSplenic2012c; @morinFrequentMutationHistonemodifying2011]|
41
+|[MAP3K14](MAP3K14)|1|[@rossiAlterationBIRC3Multiple2011a; @ottoGeneticLesionsTRAF32012a]|
42
+|[MPEG1](MPEG1)|1|[@morinMutationalStructuralAnalysis2013]|
43
+|[MYD88](MYD88)|1|[@ngoOncogenicallyActiveMYD882011a; @yanBCRTLRSignaling2012a]|
44
+|[NCOR2](NCOR2)|1|[@sarkozyMutationalLandscapeGray2021a; @schmitzBurkittLymphomaPathogenesis2012; @spinaGeneticsNodalMarginal2016b]|
45
+|[NOL9](NOL9)|1|[@spinaGeneticsNodalMarginal2016b; @schmitzGeneticsPathogenesisDiffuse2018a]|
46
+|[NOTCH1](NOTCH1)|1|[@rossiCodingGenomeSplenic2012c; @loveGeneticLandscapeMutations2012; @beaLandscapeSomaticMutations2013; @pasqualucciAnalysisCodingGenome2011]|
47
+|[NOTCH2](NOTCH2)|1|[@troenNOTCH2MutationsMarginal2008; @paneaWholeGenomeLandscape2019; @rossiCodingGenomeSplenic2012c; @beaLandscapeSomaticMutations2013]|
48
+|[PCLO](PCLO)|1|[@lohrDiscoveryPrioritizationSomatic2012a]|
49
+|[POU2AF1](POU2AF1)|1|[@krysiakRecurrentSomaticMutations2017b]|
50
+|[PTPRD](PTPRD)|1|[@spinaGeneticsNodalMarginal2016b]|
51
+|[SIN3A](SIN3A)|1|[@rossiCodingGenomeSplenic2012c; @grandeGenomewideDiscoverySomatic2019]|
52
+|[SOCS1](SOCS1)|1|[@morinFrequentMutationHistonemodifying2011; @wenigerMutationsTumorSuppressor2006a]|
53
+|[SPEN](SPEN)|1|[@rossiCodingGenomeSplenic2012c; @sarkozyMutationalLandscapeGray2021a]|
54
+|[STAT6](STAT6)|1|[@ritzRecurrentMutationsSTAT62009a; @yildizActivatingSTAT6Mutations2015c]|
55
+|[TBL1XR1](TBL1XR1)|1|[@mareschalWholeExomeSequencing2016; @rossiCodingGenomeSplenic2012c]|
56
+|[TNFAIP3](TNFAIP3)|1|[@compagnoMutationsMultipleGenes2009a; @rossiAlterationBIRC3Multiple2011a; @schmitzTNFAIP3A20Tumor2009a]|
57
+|[TNFRSF14](TNFRSF14)|1|[@spinaGeneticsNodalMarginal2016b; @cheungAcquiredTNFRSF14Mutations2010a]|
58
+|[TP53](TP53)|1|[@tiacciPervasiveMutationsJAKSTAT2018b; @morinFrequentMutationHistonemodifying2011; @rossiCodingGenomeSplenic2012c; @beaLandscapeSomaticMutations2013; @wildaInactivationARFMDM2p53Pathway2004]|
59
+|[TRAF3](TRAF3)|1|[@ottoGeneticLesionsTRAF32012a; @rossiAlterationBIRC3Multiple2011a; @pasqualucciAnalysisCodingGenome2011]|
60
+
61
+## Tier 2 MZL genes
62
+
63
+### *74 total*
64
+
65
+|Gene|Tier| Relevant references|
66
+|:-:|:-:|:-|
67
+|[ABCA13](ABCA13)|2|[@spinaGeneticsNodalMarginal2016b; @sarkozyMutationalLandscapeGray2021a]|
68
+|[ACTG1](ACTG1)|2|[@hubschmannMutationalMechanismsShaping2021b; @spinaGeneticsNodalMarginal2016b; @deschGenotypingCirculatingTumor2020]|
69
+|[ADD2](ADD2)|2|[@spinaGeneticsNodalMarginal2016b]|
70
+|[AMN](AMN)|2|[@spinaGeneticsNodalMarginal2016b]|
71
+|[AMOTL1](AMOTL1)|2|[@parryWholeExomeSequencing2013]|
72
+|[AOC2](AOC2)|2|[@spinaGeneticsNodalMarginal2016b]|
73
+|[ARHGAP20](ARHGAP20)|2|[@jalladesExomeSequencingIdentifies2017]|
74
+|[ARHGEF15](ARHGEF15)|2|[@jalladesExomeSequencingIdentifies2017]|
75
+|[ARHGEF17](ARHGEF17)|2|[@jalladesExomeSequencingIdentifies2017]|
76
+|[BCOR](BCOR)|2|[@jalladesExomeSequencingIdentifies2017; @nadeuGenomicEpigenomicInsights2020b]|
77
+|[C6orf103](C6orf103)|2|[@spinaGeneticsNodalMarginal2016b]|
78
+|[CBFA2T3](CBFA2T3)|2|[@parryWholeExomeSequencing2013]|
79
+|[CD79A](CD79A)|2|[@rossiCodingGenomeSplenic2012c; @burkhardtClinicalRelevanceMolecular2022b]|
80
+|[CD9B](CD9B)|2|[@vandenbrandRecurrentMutationsGenes2017]|
81
+|[CDC42BPB](CDC42BPB)|2|[@spinaGeneticsNodalMarginal2016b]|
82
+|[CDKN2A](CDKN2A)|2|[@grandeGenomewideDiscoverySomatic2019; @spinaGeneticsNodalMarginal2016b; @morinMutationalStructuralAnalysis2013]|
83
+|[CLGN](CLGN)|2|[@spinaGeneticsNodalMarginal2016b]|
84
+|[CNKSR2](CNKSR2)|2|[@spinaGeneticsNodalMarginal2016b]|
85
+|[CREBBP](CREBBP)|2|[@dunsCharacterizationDLBCLPMBL2021b; @parryWholeExomeSequencing2013; @loveGeneticLandscapeMutations2012; @pasqualucciInactivatingMutationsAcetyltransferase2011a]|
86
+|[DNAH5](DNAH5)|2|[@jalladesExomeSequencingIdentifies2017; @morinMutationalStructuralAnalysis2013]|
87
+|[DNAH7](DNAH7)|2|[@jalladesExomeSequencingIdentifies2017]|
88
+|[DNAI1](DNAI1)|2|[@jalladesExomeSequencingIdentifies2017]|
89
+|[DOCK6](DOCK6)|2|[@jalladesExomeSequencingIdentifies2017]|
90
+|[DSP](DSP)|2||
91
+|[DTNB](DTNB)|2||
92
+|[DTX3L](DTX3L)|2|[@jalladesExomeSequencingIdentifies2017]|
93
+|[EGR1](EGR1)|2|[@reichelFlowSortingExome2015a; @rossiCodingGenomeSplenic2012c; @krysiakRecurrentSomaticMutations2017b]|
94
+|[EGR2](EGR2)|2|[@rossiCodingGenomeSplenic2012c]|
95
+|[EZH1](EZH1)|2|[@jalladesExomeSequencingIdentifies2017]|
96
+|[FAT4](FAT4)|2|[@zhangGenomicLandscapeMantle2014; @morinMutationalStructuralAnalysis2013; @parryWholeExomeSequencing2013]|
97
+|[FBXO11](FBXO11)|2|[@hubschmannMutationalMechanismsShaping2021b; @richterRecurrentMutationID32012a; @parryWholeExomeSequencing2013]|
98
+|[GPR98](GPR98)|2|[@spinaGeneticsNodalMarginal2016b]|
99
+|[GPS2](GPS2)|2|[@rossiCodingGenomeSplenic2012c]|
100
+|[HIST1H1D](HIST1H1D)|2|[@morinMutationalStructuralAnalysis2013; @krysiakRecurrentSomaticMutations2017b; @jalladesExomeSequencingIdentifies2017]|
101
+|[HIST1H2AD](HIST1H2AD)|2|[@jalladesExomeSequencingIdentifies2017]|
102
+|[HIST1H2AG](HIST1H2AG)|2|[@morinMutationalStructuralAnalysis2013; @paneaWholeGenomeLandscape2019; @krysiakRecurrentSomaticMutations2017b; @rossiCodingGenomeSplenic2012c]|
103
+|[HIST1H2BK](HIST1H2BK)|2|[@paneaWholeGenomeLandscape2019; @rossiCodingGenomeSplenic2012c]|
104
+|[HIST4H4](HIST4H4)|2|[@jalladesExomeSequencingIdentifies2017]|
105
+|[HRAS](HRAS)|2|[@jalladesExomeSequencingIdentifies2017; @reddyGeneticFunctionalDrivers2017]|
106
+|[IKBKB](IKBKB)|2|[@rossiAlterationBIRC3Multiple2011a; @wienandGenomicAnalysesFlowsorted2019b; @reddyGeneticFunctionalDrivers2017]|
107
+|[KAT6A](KAT6A)|2|[@jalladesExomeSequencingIdentifies2017]|
108
+|[KDM6A](KDM6A)|2|[@jalladesExomeSequencingIdentifies2017]|
109
+|[KIF26A](KIF26A)|2|[@jalladesExomeSequencingIdentifies2017]|
110
+|[LRP1B](LRP1B)|2|[@spinaGeneticsNodalMarginal2016b]|
111
+|[MCRS1](MCRS1)|2|[@rossiCodingGenomeSplenic2012c]|
112
+|[MGA](MGA)|2|[@zhangGeneticHeterogeneityDiffuse2013; @jalladesExomeSequencingIdentifies2017]|
113
+|[MSL2](MSL2)|2|[@rossiCodingGenomeSplenic2012c]|
114
+|[MYC](MYC)|2|[@jalladesExomeSequencingIdentifies2017; @dunsCharacterizationDLBCLPMBL2021b; @johnstonCmycHypermutationBurkitt1992; @pasqualucciHypermutationMultipleProtooncogenes2001a]|
115
+|[MYLK](MYLK)|2|[@jalladesExomeSequencingIdentifies2017]|
116
+|[NCOA6](NCOA6)|2|[@jalladesExomeSequencingIdentifies2017]|
117
+|[NRAS](NRAS)|2|[@jalladesExomeSequencingIdentifies2017]|
118
+|[PACRG](PACRG)|2|[@spinaGeneticsNodalMarginal2016b]|
119
+|[PARK2](PARK2)|2|[@spinaGeneticsNodalMarginal2016b]|
120
+|[PLA2G4D](PLA2G4D)|2|[@parryWholeExomeSequencing2013]|
121
+|[PLXNB3](PLXNB3)|2|[@spinaGeneticsNodalMarginal2016b; @zhangGenomicLandscapeMantle2014]|
122
+|[RAF1](RAF1)|2|[@jalladesExomeSequencingIdentifies2017]|
123
+|[RAPGEF2](RAPGEF2)|2||
124
+|[RCOR1](RCOR1)|2|[@spinaGeneticsNodalMarginal2016b]|
125
+|[RFTN1](RFTN1)|2|[@arthurGenomewideDiscoverySomatic2018; @dunsCharacterizationDLBCLPMBL2021b]|
126
+|[ROCK1](ROCK1)|2|[@jalladesExomeSequencingIdentifies2017]|
127
+|[RPL1L](RPL1L)|2|[@spinaGeneticsNodalMarginal2016b]|
128
+|[SAMD5](SAMD5)|2|[@spinaGeneticsNodalMarginal2016b]|
129
+|[SCG3](SCG3)|2|[@spinaGeneticsNodalMarginal2016b]|
130
+|[STXBP5](STXBP5)|2|[@spinaGeneticsNodalMarginal2016b]|
131
+|[SWAP70](SWAP70)|2|[@rossiCodingGenomeSplenic2012c]|
132
+|[TAF1](TAF1)|2|[@morinMutationalStructuralAnalysis2013; @spinaGeneticsNodalMarginal2016b]|
133
+|[TBK1](TBK1)|2|[@jalladesExomeSequencingIdentifies2017]|
134
+|[TCTN2](TCTN2)|2|[@spinaGeneticsNodalMarginal2016b]|
135
+|[TNIP2](TNIP2)|2|[@vandenbrandRecurrentMutationsGenes2017]|
136
+|[TRRAP](TRRAP)|2|[@rossiCodingGenomeSplenic2012c; @parryWholeExomeSequencing2013]|
137
+|[USH2A](USH2A)|2|[@parryWholeExomeSequencing2013]|
138
+|[WAC](WAC)|2|[@reddyGeneticFunctionalDrivers2017; @rossiCodingGenomeSplenic2012c]|
139
+|[WNK1](WNK1)|2|[@jalladesExomeSequencingIdentifies2017; @thomasGeneticSubgroupsInform2023; @hubschmannMutationalMechanismsShaping2021b]|
140
+|[ZNF9](ZNF9)|2|[@spinaGeneticsNodalMarginal2016b]|
141
+
142
+
143
+# References
PMBL_genes.md
... ...
@@ -0,0 +1,185 @@
1
+---
2
+title: 'PMBL genes'
3
+bibliography: 'morinlab.bib'
4
+csl: 'NLM.csl'
5
+link-citations: true
6
+---
7
+
8
+## Origins of PMBL genes
9
+
10
+![](PMBL_sankey-1.svg)
11
+
12
+## Tier 1 PMBL genes
13
+
14
+### *76 total*
15
+
16
+|Gene|Tier| Relevant references|
17
+|:-:|:-:|:-|
18
+|[ACTB](ACTB)|1|[@lohrDiscoveryPrioritizationSomatic2012a; @wienandGenomicAnalysesFlowsorted2019b]|
19
+|[ARID1A](ARID1A)|1|[@rossiCodingGenomeSplenic2012c; @krysiakRecurrentSomaticMutations2017b; @zhangGeneticHeterogeneityDiffuse2013; @loveGeneticLandscapeMutations2012; @wienandGenomicAnalysesFlowsorted2019b]|
20
+|[ARID5B](ARID5B)|1|[@gomezUltraDeepSequencingReveals2023; @reddyGeneticFunctionalDrivers2017]|
21
+|[B2M](B2M)|1|[@pararajalingamCodingNoncodingDrivers2020; @reichelFlowSortingExome2015a; @morinFrequentMutationHistonemodifying2011]|
22
+|[BIRC6](BIRC6)|1|[@sarkozyMutationalLandscapeGray2021a; @reddyGeneticFunctionalDrivers2017]|
23
+|[BTG1](BTG1)|1|[@morinFrequentMutationHistonemodifying2011; @sarkozyMutationalLandscapeGray2021a; @burkhardtClinicalRelevanceMolecular2022b]|
24
+|[CD58](CD58)|1|[@morinFrequentMutationHistonemodifying2011; @schneiderAlterationsCD58Gene2015a]|
25
+|[CD83](CD83)|1|[@dunsCharacterizationDLBCLPMBL2021b; @paneaWholeGenomeLandscape2019; @russler-germainMutationsAssociatedProgression2023b; @morinMutationalStructuralAnalysis2013]|
26
+|[CDKN2A](CDKN2A)|1|[@grandeGenomewideDiscoverySomatic2019; @spinaGeneticsNodalMarginal2016b; @morinMutationalStructuralAnalysis2013]|
27
+|[CHD8](CHD8)|1|[@grandeGenomewideDiscoverySomatic2019; @reddyGeneticFunctionalDrivers2017]|
28
+|[CIITA](CIITA)|1|[@mottokGenomicAlterationsCIITA2015b; @morinFrequentMutationHistonemodifying2011]|
29
+|[CISH](CISH)|1|[@mottokIntegrativeGenomicAnalysis2019b]|
30
+|[CREBBP](CREBBP)|1|[@dunsCharacterizationDLBCLPMBL2021b; @parryWholeExomeSequencing2013; @loveGeneticLandscapeMutations2012; @pasqualucciInactivatingMutationsAcetyltransferase2011a]|
31
+|[CSF2RB](CSF2RB)|1|[@reichelFlowSortingExome2015a]|
32
+|[DDX3X](DDX3X)|1|[@schmitzGeneticsPathogenesisDiffuse2018a; @schmitzBurkittLymphomaPathogenesis2012; @mottokIntegrativeGenomicAnalysis2019b]|
33
+|[DTX1](DTX1)|1|[@rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019; @schmitzGeneticsPathogenesisDiffuse2018a; @gomezUltraDeepSequencingReveals2023]|
34
+|[DUSP2](DUSP2)|1|[@morinMutationalStructuralAnalysis2013; @dunsCharacterizationDLBCLPMBL2021b]|
35
+|[EBF1](EBF1)|1|[@reichelFlowSortingExome2015a; @thomasGeneticSubgroupsInform2023; @bohleRoleEarlyBcell2013]|
36
+|[EEF1A1](EEF1A1)|1|[@reichelFlowSortingExome2015a; @hubschmannMutationalMechanismsShaping2021b]|
37
+|[ETS1](ETS1)|1|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011]|
38
+|[EWSR1](EWSR1)|1|[@pararajalingamCodingNoncodingDrivers2020]|
39
+|[EZH2](EZH2)|1|[@mottokIntegrativeGenomicAnalysis2019b; @morinSomaticMutationsAltering2010a; @loveGeneticLandscapeMutations2012]|
40
+|[FAS](FAS)|1|[@schollMutationsRegionFAS2007; @spinaGeneticsNodalMarginal2016b]|
41
+|[FAT1](FAT1)|1|[@spinaGeneticsNodalMarginal2016b]|
42
+|[FAT4](FAT4)|1|[@parryWholeExomeSequencing2013; @zhangGenomicLandscapeMantle2014; @morinMutationalStructuralAnalysis2013]|
43
+|[GNA13](GNA13)|1|[@loveGeneticLandscapeMutations2012; @reichelFlowSortingExome2015a; @morinFrequentMutationHistonemodifying2011]|
44
+|[HIST1H1B](HIST1H1B)|1|[@krysiakRecurrentSomaticMutations2017b; @sarkozyMutationalLandscapeGray2021a; @chapuyMolecularSubtypesDiffuse2018b]|
45
+|[HIST1H1C](HIST1H1C)|1|[@morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019]|
46
+|[HIST1H1D](HIST1H1D)|1|[@krysiakRecurrentSomaticMutations2017b; @jalladesExomeSequencingIdentifies2017; @morinMutationalStructuralAnalysis2013]|
47
+|[HIST1H1E](HIST1H1E)|1|[@krysiakRecurrentSomaticMutations2017b; @grandeGenomewideDiscoverySomatic2019; @morinMutationalStructuralAnalysis2013; @reichelFlowSortingExome2015a]|
48
+|[HLA-B](HLA-B)|1|[@wienandGenomicAnalysesFlowsorted2019b]|
49
+|[IL4R](IL4R)|1|[@viganoSomaticIL4RMutations2018b; @dunsCharacterizationDLBCLPMBL2021b]|
50
+|[IRF8](IRF8)|1|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011; @mottokIntegrativeGenomicAnalysis2019b]|
51
+|[ITPKB](ITPKB)|1|[@schmitzGeneticsPathogenesisDiffuse2018a; @reichelFlowSortingExome2015a]|
52
+|[JAK1](JAK1)|1|[@mottokIntegrativeGenomicAnalysis2019b; @zhangGeneticHeterogeneityDiffuse2013]|
53
+|[KMT2C](KMT2C)|1|[@sarkozyMutationalLandscapeGray2021a; @zhangGeneticHeterogeneityDiffuse2013; @zhangGenomicLandscapeMantle2014; @zhouSporadicEndemicBurkitt2019]|
54
+|[LTB](LTB)|1|[@deschGenotypingCirculatingTumor2020; @chapuyMolecularSubtypesDiffuse2018b; @paneaWholeGenomeLandscape2019]|
55
+|[MAP3K14](MAP3K14)|1|[@rossiAlterationBIRC3Multiple2011a; @ottoGeneticLesionsTRAF32012a]|
56
+|[MS4A1](MS4A1)|1|[@mottokIntegrativeGenomicAnalysis2019b; @rushtonGeneticEvolutionaryPatterns2020]|
57
+|[NFKBIA](NFKBIA)|1|[@wienandGenomicAnalysesFlowsorted2019b; @lakeMutationsNFKBIAEncoding2009; @russler-germainMutationsAssociatedProgression2023b]|
58
+|[NFKBIE](NFKBIE)|1|[@mansouriFrequentNFKBIEDeletions2016; @morinGeneticLandscapesRelapsed2016; @pararajalingamCodingNoncodingDrivers2020]|
59
+|[OSBPL10](OSBPL10)|1|[@arthurGenomewideDiscoverySomatic2018]|
60
+|[P2RY8](P2RY8)|1|[@lohrDiscoveryPrioritizationSomatic2012a; @muppidiLossSignalingGa132014b]|
61
+|[PCLO](PCLO)|1|[@lohrDiscoveryPrioritizationSomatic2012a]|
62
+|[PHIP](PHIP)|1||
63
+|[PIM1](PIM1)|1|[@dunsCharacterizationDLBCLPMBL2021b; @pasqualucciHypermutationMultipleProtooncogenes2001a; @burkhardtClinicalRelevanceMolecular2022b]|
64
+|[PIM2](PIM2)|1|[@arthurGenomewideDiscoverySomatic2018; @reichelFlowSortingExome2015a]|
65
+|[PRKDC](PRKDC)|1|[@schmitzGeneticsPathogenesisDiffuse2018a; @hubschmannMutationalMechanismsShaping2021b]|
66
+|[PTPN1](PTPN1)|1|[@gunawardanaRecurrentSomaticMutations2014c]|
67
+|[PTPRD](PTPRD)|1|[@spinaGeneticsNodalMarginal2016b]|
68
+|[RHOA](RHOA)|1|[@richterRecurrentMutationID32012a]|
69
+|[S1PR2](S1PR2)|1|[@muppidiLossSignalingGa132014b; @morinFrequentMutationHistonemodifying2011]|
70
+|[SGK1](SGK1)|1|[@dunsCharacterizationDLBCLPMBL2021b; @morinFrequentMutationHistonemodifying2011]|
71
+|[SIN3A](SIN3A)|1|[@rossiCodingGenomeSplenic2012c; @grandeGenomewideDiscoverySomatic2019]|
72
+|[SMARCA2](SMARCA2)|1||
73
+|[SMARCA4](SMARCA4)|1|[@richterRecurrentMutationID32012a; @zhangGeneticHeterogeneityDiffuse2013; @krysiakRecurrentSomaticMutations2017b; @nadeuGenomicEpigenomicInsights2020b]|
74
+|[SOCS1](SOCS1)|1|[@wenigerMutationsTumorSuppressor2006a; @morinFrequentMutationHistonemodifying2011]|
75
+|[SPEN](SPEN)|1|[@rossiCodingGenomeSplenic2012c; @sarkozyMutationalLandscapeGray2021a]|
76
+|[STAT3](STAT3)|1|[@ohgamiSTAT3MutationsAre2014]|
77
+|[STAT6](STAT6)|1|[@ritzRecurrentMutationsSTAT62009a; @yildizActivatingSTAT6Mutations2015c]|
78
+|[TAP1](TAP1)|1|[@schmitzGeneticsPathogenesisDiffuse2018a]|
79
+|[TBL1XR1](TBL1XR1)|1|[@mareschalWholeExomeSequencing2016; @rossiCodingGenomeSplenic2012c]|
80
+|[TCF3](TCF3)|1|[@schmitzBurkittLymphomaPathogenesis2012]|
81
+|[TET3](TET3)|1||
82
+|[TMSB4X](TMSB4X)|1|[@albuquerqueEnhancingKnowledgeDiscovery2017a]|
83
+|[TNFAIP3](TNFAIP3)|1|[@compagnoMutationsMultipleGenes2009a; @rossiAlterationBIRC3Multiple2011a; @schmitzTNFAIP3A20Tumor2009a]|
84
+|[TNFRSF1B](TNFRSF1B)|1||
85
+|[TP53](TP53)|1|[@wildaInactivationARFMDM2p53Pathway2004; @beaLandscapeSomaticMutations2013; @tiacciPervasiveMutationsJAKSTAT2018b; @morinFrequentMutationHistonemodifying2011; @rossiCodingGenomeSplenic2012c]|
86
+|[TRAF3](TRAF3)|1|[@pasqualucciAnalysisCodingGenome2011; @rossiAlterationBIRC3Multiple2011a; @ottoGeneticLesionsTRAF32012a]|
87
+|[UBE2A](UBE2A)|1|[@reichelFlowSortingExome2015a; @reddyGeneticFunctionalDrivers2017]|
88
+|[UBR5](UBR5)|1|[@pararajalingamCodingNoncodingDrivers2020; @zhangGeneticHeterogeneityDiffuse2013]|
89
+|[UNC5C](UNC5C)|1||
90
+|[VPS13B](VPS13B)|1||
91
+|[WEE1](WEE1)|1|[@reichelFlowSortingExome2015a; @schmitzGeneticsPathogenesisDiffuse2018a]|
92
+|[XPO1](XPO1)|1|[@jardinRecurrentMutationsExportin2016a; @mareschalWholeExomeSequencing2016]|
93
+|[ZFP36L1](ZFP36L1)|1|[@morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019; @reichelFlowSortingExome2015a]|
94
+
95
+## Tier 2 PMBL genes
96
+
97
+### *82 total*
98
+
99
+|Gene|Tier| Relevant references|
100
+|:-:|:-:|:-|
101
+|[ABCA13](ABCA13)|2|[@sarkozyMutationalLandscapeGray2021a; @spinaGeneticsNodalMarginal2016b]|
102
+|[ACTG1](ACTG1)|2|[@hubschmannMutationalMechanismsShaping2021b; @spinaGeneticsNodalMarginal2016b; @deschGenotypingCirculatingTumor2020]|
103
+|[AKAP6](AKAP6)|2|[@tiacciPervasiveMutationsJAKSTAT2018b]|
104
+|[ARIH2](ARIH2)|2|[@reichelFlowSortingExome2015a]|
105
+|[AXDND1](AXDND1)|2|[@gomezUltraDeepSequencingReveals2023]|
106
+|[BCL2](BCL2)|2|[@burkhardtClinicalRelevanceMolecular2022b; @tanakaFrequentIncidenceSomatic1992; @morinFrequentMutationHistonemodifying2011; @sarkozyMutationalLandscapeGray2021a]|
107
+|[BCL7A](BCL7A)|2|[@grandeGenomewideDiscoverySomatic2019; @reichelFlowSortingExome2015a; @krysiakRecurrentSomaticMutations2017b; @arthurGenomewideDiscoverySomatic2018]|
108
+|[BIRC3](BIRC3)|2|[@rossiAlterationBIRC3Multiple2011a; @beaLandscapeSomaticMutations2013; @arthurGenomewideDiscoverySomatic2018; @dunsCharacterizationDLBCLPMBL2021b]|
109
+|[CCND3](CCND3)|2|[@jalladesExomeSequencingIdentifies2017; @morinFrequentMutationHistonemodifying2011; @deschGenotypingCirculatingTumor2020; @richterRecurrentMutationID32012a]|
110
+|[CDH2](CDH2)|2|[@deschGenotypingCirculatingTumor2020]|
111
+|[CDH5](CDH5)|2|[@gomezUltraDeepSequencingReveals2023]|
112
+|[CXCR5](CXCR5)|2|[@mottokIntegrativeGenomicAnalysis2019b; @schmitzGeneticsPathogenesisDiffuse2018a]|
113
+|[DGKB](DGKB)|2|[@tiacciPervasiveMutationsJAKSTAT2018b]|
114
+|[DMD](DMD)|2|[@reichelFlowSortingExome2015a]|
115
+|[DNAH12](DNAH12)|2|[@wienandGenomicAnalysesFlowsorted2019b]|
116
+|[EGR1](EGR1)|2|[@reichelFlowSortingExome2015a; @krysiakRecurrentSomaticMutations2017b; @rossiCodingGenomeSplenic2012c]|
117
+|[EPHA7](EPHA7)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
118
+|[EZR](EZR)|2|[@deschGenotypingCirculatingTumor2020]|
119
+|[FOXO1](FOXO1)|2|[@morinFrequentMutationHistonemodifying2011; @dunsCharacterizationDLBCLPMBL2021b; @schmitzBurkittLymphomaPathogenesis2012]|
120
+|[GCSAM](GCSAM)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
121
+|[GPR126](GPR126)|2|[@wenigerMutationsTumorSuppressor2006a]|
122
+|[HECW2](HECW2)|2|[@reichelFlowSortingExome2015a]|
123
+|[HELLS](HELLS)|2|[@reichelFlowSortingExome2015a]|
124
+|[HIST1H2BC](HIST1H2BC)|2|[@reddyGeneticFunctionalDrivers2017; @mottokIntegrativeGenomicAnalysis2019b; @krysiakRecurrentSomaticMutations2017b]|
125
+|[HIST1H3B](HIST1H3B)|2|[@zhangGeneticHeterogeneityDiffuse2013; @reichelFlowSortingExome2015a]|
126
+|[HIST1H4C](HIST1H4C)|2|[@reichelFlowSortingExome2015a]|
127
+|[HIST1H4E](HIST1H4E)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
128
+|[HIST1H4J](HIST1H4J)|2|[@paneaWholeGenomeLandscape2019; @mottokIntegrativeGenomicAnalysis2019b]|
129
+|[HLA-A](HLA-A)|2|[@deschGenotypingCirculatingTumor2020]|
130
+|[HLA-C](HLA-C)|2|[@gomezUltraDeepSequencingReveals2023]|
131
+|[HRNR](HRNR)|2|[@dunsCharacterizationDLBCLPMBL2021b]|
132
+|[IGLL5](IGLL5)|2|[@russler-germainMutationsAssociatedProgression2023b; @paneaWholeGenomeLandscape2019; @deschGenotypingCirculatingTumor2020]|
133
+|[IKBKB](IKBKB)|2|[@rossiAlterationBIRC3Multiple2011a; @wienandGenomicAnalysesFlowsorted2019b; @reddyGeneticFunctionalDrivers2017]|
134
+|[IL13RA1](IL13RA1)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
135
+|[IL1RAPL2](IL1RAPL2)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
136
+|[IRF2BP2](IRF2BP2)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
137
+|[IRF4](IRF4)|2|[@morinFrequentMutationHistonemodifying2011; @mottokIntegrativeGenomicAnalysis2019b]|
138
+|[ITGB2](ITGB2)|2||
139
+|[ITPR3](ITPR3)|2|[@tiacciPervasiveMutationsJAKSTAT2018b; @loveGeneticLandscapeMutations2012]|
140
+|[JUNB](JUNB)|2|[@reddyGeneticFunctionalDrivers2017; @mottokIntegrativeGenomicAnalysis2019b]|
141
+|[KLF2](KLF2)|2|[@pasqualucciAnalysisCodingGenome2011; @deschGenotypingCirculatingTumor2020; @jalladesExomeSequencingIdentifies2017]|
142
+|[KMT2D](KMT2D)|2|[@rossiCodingGenomeSplenic2012c; @morinFrequentMutationHistonemodifying2011; @beaLandscapeSomaticMutations2013; @grandeGenomewideDiscoverySomatic2019; @deschGenotypingCirculatingTumor2020]|
143
+|[LIMD2](LIMD2)|2|[@gomezUltraDeepSequencingReveals2023]|
144
+|[LPHN3](LPHN3)|2|[@dunsCharacterizationDLBCLPMBL2021b]|
145
+|[LRRN3](LRRN3)|2|[@morinMutationalStructuralAnalysis2013; @sarkozyMutationalLandscapeGray2021a]|
146
+|[MAGEC2](MAGEC2)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
147
+|[MCL1](MCL1)|2|[@reddyGeneticFunctionalDrivers2017; @dunsCharacterizationDLBCLPMBL2021b; @paneaWholeGenomeLandscape2019]|
148
+|[MFHAS1](MFHAS1)|2|[@sarkozyMutationalLandscapeGray2021a]|
149
+|[MPDZ](MPDZ)|2|[@reichelFlowSortingExome2015a; @morinMutationalStructuralAnalysis2013]|
150
+|[MYB](MYB)|2|[@deschGenotypingCirculatingTumor2020; @reddyGeneticFunctionalDrivers2017]|
151
+|[MYC](MYC)|2|[@pasqualucciHypermutationMultipleProtooncogenes2001a; @jalladesExomeSequencingIdentifies2017; @dunsCharacterizationDLBCLPMBL2021b; @johnstonCmycHypermutationBurkitt1992]|
152
+|[NCOR2](NCOR2)|2|[@spinaGeneticsNodalMarginal2016b; @schmitzBurkittLymphomaPathogenesis2012; @sarkozyMutationalLandscapeGray2021a]|
153
+|[NEK1](NEK1)|2|[@reichelFlowSortingExome2015a]|
154
+|[NFKB2](NFKB2)|2|[@mottokIntegrativeGenomicAnalysis2019b; @reddyGeneticFunctionalDrivers2017]|
155
+|[NSD2](NSD2)|2|[@beaLandscapeSomaticMutations2013]|
156
+|[NUP214](NUP214)|2|[@tiacciPervasiveMutationsJAKSTAT2018b]|
157
+|[OR13C2](OR13C2)|2|[@gomezUltraDeepSequencingReveals2023]|
158
+|[PCBP1](PCBP1)|2|[@schmitzBurkittLymphomaPathogenesis2012]|
159
+|[PCDH7](PCDH7)|2||
160
+|[PRUNE2](PRUNE2)|2|[@tiacciPervasiveMutationsJAKSTAT2018b]|
161
+|[RANBP2](RANBP2)|2|[@reichelFlowSortingExome2015a]|
162
+|[RBM38](RBM38)|2|[@wienandGenomicAnalysesFlowsorted2019b]|
163
+|[RDH12](RDH12)|2||
164
+|[RELN](RELN)|2|[@sarkozyMutationalLandscapeGray2021a]|
165
+|[RFTN1](RFTN1)|2|[@arthurGenomewideDiscoverySomatic2018; @dunsCharacterizationDLBCLPMBL2021b]|
166
+|[RGS1](RGS1)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
167
+|[SCN9A](SCN9A)|2||
168
+|[SENP7](SENP7)|2|[@reichelFlowSortingExome2015a]|
169
+|[SETD5](SETD5)|2|[@reddyGeneticFunctionalDrivers2017; @tiacciPervasiveMutationsJAKSTAT2018b]|
170
+|[SETDB1](SETDB1)|2|[@reichelFlowSortingExome2015a]|
171
+|[SIAH2](SIAH2)|2|[@hubschmannMutationalMechanismsShaping2021b; @reichelFlowSortingExome2015a]|
172
+|[SMAD3](SMAD3)|2||
173
+|[STAT5B](STAT5B)|2|[@zhangGeneticHeterogeneityDiffuse2013; @tiacciPervasiveMutationsJAKSTAT2018b]|
174
+|[STRAP](STRAP)|2||
175
+|[TBC1D15](TBC1D15)|2|[@reichelFlowSortingExome2015a]|
176
+|[TICRR](TICRR)|2|[@reichelFlowSortingExome2015a]|
177
+|[TNIP1](TNIP1)|2|[@tiacciPervasiveMutationsJAKSTAT2018b]|
178
+|[TRIP11](TRIP11)|2|[@reichelFlowSortingExome2015a]|
179
+|[VMP1](VMP1)|2|[@mottokIntegrativeGenomicAnalysis2019b]|
180
+|[WDR87](WDR87)|2|[@dunsCharacterizationDLBCLPMBL2021b]|
181
+|[ZCCHC11](ZCCHC11)|2|[@tiacciPervasiveMutationsJAKSTAT2018b]|
182
+|[ZNF217](ZNF217)|2|[@reichelFlowSortingExome2015a; @hubschmannMutationalMechanismsShaping2021b]|
183
+
184
+
185
+# References